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ABSTRACT 
 The number of individuals with neurodegenerative disorders, particularly Alzheimer’s 
disease (AD), is growing and is projected to continue increasing. Despite this reality, there are no 
available treatments for AD. Positron emission tomography (PET) imaging has been a valuable 
tool for drug discovery in the AD space, and has been used to improve our understanding of the 
pathology of AD. PET imaging strategies in AD have followed the biomarkers used in the drug 
discovery pipeline, with an early focus on misfolded proteins (amyloid-β (Aβ) and tau 
neurofibrillary tangles (NFTs)), neurotransmitters, and neuroinflammation. The focus of this 
thesis has been on using PET imaging to investigate novel aspects of AD pathology. The widely 
used tau ligand [18F]AV-1451 was investigated for its off-target binding effects to monoamine 
oxidase (MAO). MAO is also a marker of microgliosis, the activation of microglia, and we have 
investigated it as an imaging biomarker of neuroinflammation. We developed substrates for 
imaging MAO-B activity, using a trapped metabolite approach. Inspired by this principle, we 
used one of these substrates, [11C]AZ, to demonstrate that the feasibility of using an enzyme 
substrate for dual PET-magnetic resonance (MR) imaging. PET-MR with a single agent has 
typically been considered impossible because PET imaging would not work at the concentrations 
required for MRI (i.e. low specific activity). However, we demonstrated that MAO was not 
saturable in vivo at the necessary MR concentration, and that the PET whole brain time activity 
curves did not suffer. Finally, we evaluated ligands for the receptor for advanced glycation end-
products (RAGE), a potential new biomarker of neuroinflammation, using an extracellular and 
xiii 
 
intracellular approach. We evaluated RAGE as a biomarker using the standard 
lipopolysaccharide (LPS) murine model of neuroinflammation.  
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CHAPTER 1 
 Introduction 
 Neurodegenerative disorders encompass a broad group of diseases that describe 
individuals whom experience progressive loss of neurons and brain function deficits.1 These 
disorders include Alzheimer’s disease (AD), Parkinson’s disease (PD), Dementia with Lewy 
bodies (DLB), fronto-temporal lobar degeneration (FTD), amyotrophic lateral sclerosis (ALS), 
Huntington’s disease (HD), and multiple sclerosis (MS). Brain functions affected by neuronal 
loss are specific to certain brain regions. PD, HD, and ALS are characterized by the loss of 
movement and gait control, among other symptoms. In regards to prevalence, most sufferers of 
neurodegeneration fall into the ‘dementia’ umbrella of disorders, with AD and Lewy Body 
Disease (LBD; including pure autonomic failure, DLB, and Parkinson’s disease with dementia) 
being the top diseases in the United States. AD is the most common form of dementia, affecting 
5.7 million Americans and 10% of adults over 65 with over two thirds of those individuals being 
women (figure 1.1).2 These patients are mostly receiving unpaid care by family members, an 
estimated $232 billion worth of care per year. There is no cure for dementia of any type, nor are 
there any effective treatments to ameliorate the burden. Throughout this chapter, the current state 
of understanding, drug options, and imaging efforts will be reviewed for AD. The focus on 
protein aggregates (figure 1.2) has dominated the field of dementia and through trials and 
tribulations, it is apparent that an alternative strategy is necessary for understanding the process 
of neurodegeneration. Recently, neuroinflammation has been identified as a cause of neuronal 
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death in AD.3 The involvement of inflammation in the CNS will be explored throughout this 
chapter for its use in studying AD pathology.  
 
Figure 1.1. Dementia in the American population 65 and older.  
 
 
Figure 1.2. Protein aggregates shared between neurodegenerative diseases. AD is marked by the presence of Aβ 
plaques and tau NFTs. The main component of Lewy bodies is α- synuclein (αsyn), found in PD. Lewy body 
vascular AD (LBVAD) and DLB contain all three protein aggregates. FTD and progressive supranuclear palsy 
(PSP) only contain tau NFTs.   
 
Alzheimer’s disease and the Amyloid Hypothesis 
 AD has been characterized for over a century by the symptoms of impaired cognition and 
memory decline, in addition to the amyloid-beta (Aβ) plaques present extracellularly and 
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intracellular neurofibrillary tangles (NFTs) in the brain tissue.4 Definitive diagnosis of AD can 
only be given post-mortem based on the presence of protein aggregates. Symptomatically, AD 
can present similarly to other dementias, like vascular dementia or FTD, and diagnosis based on 
behavioral and psychological symptoms of dementia (BPSD) and cognitive testing is required.5 
BPSD represents the non-cognitive symptoms and behaviors associated with dementia subjects. 
For example, it has been shown that depression and anxiety symptoms are more frequent in 
vascular dementia than AD.5 Cognitive function is often measured by the mini-mental state 
examination (MMSE).6 MMSE and similar tests are frequently used as the primary outcome 
measure for cognition in clinical drug trials. Advances in diagnosis and treatment technology for 
AD rely on the continuing research efforts into the causes of AD and their relation to these 
symptoms. Much of the knowledge surrounding AD pathology has been focused on the 
extracellular Aβ plaques and their origin. 
 Aβ was first isolated in 1984 from fibrils,7 but cloning and gene mapping in 1987 
revealed that the peptide was synthesized from a larger protein then named β–amyloid precursor 
protein (APP).8 The amyloid hypothesis centers on the formation of Aβ fibrils from cleaving a 
peptide from APP (figure 1.3). This cleavage can occur by two different proteases and results in 
different outcomes. The non-amyloidogenic pathway is controlled by α-secretase which first 
cleaves and releases the extracellular amino-terminus of APP; then γ-secretase digests an 83- 
amino acid residue carboxy-terminal fragment. The amyloidogenic pathway combines the 
sequential actions of β- and γ-secretases, which generate Aβ peptides that can misfold and form 
extracellular fibrils.9 The amyloid hypothesis claims that the generation of Aβ peptides and the 
eventual formation of plaques is the cause of neuronal cell death.10 
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Figure 1.3. Pathway of Aβ plaque formation from amyloid precursor protein (APP). Filled arrows represent non-
amyloidogenic pathway of α-secretase cleavage being the primary step. Open arrows follow the amyloidogenic 
pathway beginning with β-secretase cleavage. This cleavage results in the Aβ peptide which can form protofibrils, 
fibrils, and plaques. 
 
Classic Approaches to Drugging Alzheimer’s Disease  
 γ- and β-secretase (BACE) were identified early as druggable enzyme targets for AD 
treatment because of their direct role in processing APP in the amyloidogenic pathway (figure 
1.3). Despite an abundance of work toward protease inhibitors for AD; this strategy has 
demonstrated little success clinically (structures in figure 1.4).11 γ secretase inhibitors (GSI) have 
been abandoned in clinical trials because of Notch-related toxicity. Notch is another substrate of 
gamma secretase. The GSI semagacestat (LY-450139) was well tolerated and appeared to have 
selection against Notch; however, it failed to show cognitive improvement and exhibited severe 
skin toxicity.12 In light of the GSI strategy failure and safety concerns, use of γ-secretase 
modulators (GSM) was also explored. Utilizing an allosteric binding site, these drugs were able 
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to avoid Notch-related toxicity and, in vitro, increase non-amyloidogenic peptide production. 
However, poor blood-brain barrier permeability and unpredicted eye side effects (cataracts) have 
halted this strategy.13 Inhibition of BACE1 has also proven difficult, with failures like 
LY2811376 and Verubecestat (MK-8931) (figure 1.4).14 For example, verubecestat was 
abandoned in a phase III clinical trial because of no improved cognition (primary end point) 
despite having improved Aβ peptide clearance in cerebral spinal fluid (CSF).15 
Figure 1.4 Structures of γ secretase inhibitor and BACE1 inhibitors. 
 
 The main non-secretase strategy has been antibodies and antibody drug fragments for the 
removal of peptide before fibrils (and plaques) can form. Humanized murine monoclonal 
antibodies which targeted linear epitopes of the primary Aβ monomer sequence advanced the 
furthest in clinical trial. Two versions, bapineuzumab (N-terminal region targeting)16 and 
solanezumab (central region targeting)17 have been evaluated through phase III clinical trial. 
Although amyloid burden was decreased, based on positron emission tomography (PET) 
imaging, both of these antibodies failed to meet their primary endpoint.18 The primary outcome 
measure was the AD assessment scale- cognition (ADAS-Cog).19 Aducanumab,20 another 
antibody being developed by Biogen is in phase III now and results of the trial have not been 
announced yet. The high profile failures of bapinuezumab and solanezumab are causing the AD 
community to consider the need to move away from the amyloid hypothesis. They demonstrated 
that although the amyloid burden was lowered, cognition did not improve. Independently of 
these clinical trials, prospective studies using amyloid PET imaging and magnetic resonance 
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imaging (MRI) have suggested that Aβ deposition is a slow process.21 It is likely that modifying 
the symptoms of AD will require a different strategy.  
 The other protein aggregate hallmark of AD, tau NFTs, are also a target of drug 
development; however, less is known about the formation of NFTs in comparison to Aβ plaques. 
NFTs are mainly composed of hyperphosphorylated tau protein. Six tau isoforms are expressed 
in the human brain, resulting from alternative splicing. Isoforms are typically described by the 
presence or absence of a 31-amino acid repeat from exon 10. Inclusion results in 4 repeats (4R) 
and absence in 3 repeats (3R); these repeated sections are used to bind to and promote 
microtubule assembly.22 Nonpathogenic tau protein is responsible for supporting microtubules 
and it has been shown that phosphorylation of tau negatively regulates this interaction.23 This is a 
stark difference between amyloid-precursor protein, whose nonpathogenic function is still 
unknown. It remains a question in the field if tau phosphorylation equates aggregation, yet this 
pathway has been considered as druggable (figure 1.5).24-25  
 Multiple kinases are capable of phosphorylating tau protein, though glycogen synthase 
kinase 3β (GSK3β) was first identified as a possible target. Inhibition of GSK3β has been 
considered in the effort to decrease tau phosphorylation and was shown to be efficacious in an 
AD animal model.26 However, tideglusib failed to meet its cognitive endpoint in phase II trial.27 
Other kinase inhibitors are being considered, but it should be noted that selectivity and 
specificity for kinases is difficult in drug design. Similar to amyloid targeting strategies, tau 
protein itself is considered a possible drug target. Tau stabilizing and phosphorylated tau (p-tau) 
clearing immunotherapies have begun entering phase II clinical trial, and it will be interesting to 
observe if these have significant effects on cognition.13 
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Figure 1.5. Proposed mechanism of tau hyperphosphorylation and deposition. Showing two possible kinases, GSK3 
and Cdk5. Filled arrows are known phenomenon, being that they’ve been reproducible in animal models. Both p-tau 
and NFTs are theorized to cause apoptosis. 
 
Neuroinflammation as an Alternative Pathway 
 The preliminary approaches in AD (the amyloid hypothesis) have not been clinically 
successful to date; however, they have greatly advanced the understanding of AD and opened up 
alternative pathways. The neuroinflammation hypothesis states that chronic inflammation 
precedes Aβ accumulation and tau deposition, and could play a role in the activation of these 
pathways. Inflammation in the CNS, like in the peripheral immune system, is a protective 
response that is carefully regulated. Innate immunity is the first line of defense against 
pathogens. In the periphery, innate immunity is mediated by phagocytes including macrophages 
and dendritic cells.28 The other branch of the immune system, acquired immunity, is later stage 
and relies on the generation of antigen-specific receptors on lymphocytes. In the discussion of 
neuroinflammation, the innate immune system is considered key as it is faster in response, and 
unless the blood-brain barrier (BBB) is severely damaged, the CNS is considered immune 
privileged and free of lymphocytes.28 
 The innate immune system recognizes microorganisms through pattern-recognition 
receptors (PRRs). In the CNS, the main mediator is the microglia, a cell type of the myeloid 
lineage and having macrophage character. Microglia is a cell population that constitutively 
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expresses PRRs, but is usually in its resting state.29 In response to injury, microglia become 
active, change phenotype, and alter their shape (figure 1.6). Reactive microgliosis is a self-
limiting function. In culture it has been shown that most reactive microglia undergo apoptosis 
afterwards. In addition to microglia, astrocytes also play a role in innate immunity. Astrocytes 
are the most abundant non-neuronal cell type and are critical for the homeostatic balance of the 
neurovascular unit (i.e.: uptake of neurotransmitters, production of neurotrophic factors, ion 
homeostasis, metabolic support of neurons, and BBB maintenance).30-31 Astrocytes also express 
PRRs and are capable of secreting soluble factors (such as chemokines) to activate neighboring 
microglial cells into their M1 state.30 
 
Figure 1.6. Microglial activation. Classical activation, or the M1 type, is pro-inflammatory and results in the 
expression of cytokines that will activate neighboring cells. Alternative activation, or the M2 type, releases IL-14, 
IL-10 and other anti-inflammatory cytokines that will damped a response from neighboring cells. It is theorized that 
activated microglia can transform in and out of these two states. 
  
 Evidence for innate immune responses in AD are rooted in the finding that Aβ peptide 
induces an inflammatory response in microglia.32 Furthermore a link between mutations in genes 
encoding triggering receptor expressed on myeloid cells 2 (TREM2) and AD confirmed an 
association between neurodegeneration and the immune system.33 TREM2 is expressed on 
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microglia cells and activates phagocytosis; however, the normal function is not well understood. 
It has been found that TREM2 signaling negatively regulates the PRR toll-like receptor (TLR) 
signaling pathways.34 The most common rs75932628 variant causes an R47H substitution,35 and 
is a functional variant that impairs the interaction of TREM2 with neurons and plaques during 
amyloid plaque accumulation; it is predicted to triple the risk of developing AD.33 
 Soluble immune factors, cytokines and chemokines, are known to distribute through the 
CSF and eventually be cleared through the blood system. A minimally invasive strategy to 
quantify immune response in the CNS is to quantify these biomarkers in the CSF or blood. 
However, because of the similar mechanism of innate immunity between the CNS and periphery, 
determining neuroinflammation independently of peripheral inflammation is challenging. It has 
so far been possible to quantify Aβ peptide and p-tau from the blood; however, their utility as 
diagnostic biomarkers has not been proven.36 Interpreting these soluble factors has been difficult 
because the mechanism, and time course, of clearance is unknown in this disease state. Instead of 
evaluating soluble factors in the CSF or blood, we aim to employ the molecular imaging 
technique, Positron Emission Tomography (PET). 
Positron Emission Tomography 
 PET is a non-invasive in vivo imaging technique that provides biochemical information. 
This form of nuclear imaging utilizes a bioactive molecule substituted with a positron emitting 
radioisotope; when the bioactive molecule interacts with its target in vivo, the positron decays are 
detected over time. This collection of decays per time and location allows researchers to observe 
biochemical processes in vivo (figure 1.7).37 In order to correlate this dynamic information with 
structural data, PET is often combined with a structural technique such as computed tomography 
(CT) or magnetic resonance (MR) imaging. Common PET isotopes are carbon-11, fluorine-18, 
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nitrogen-13, oxygen-15, and gallium-68.38 Due to half-life constraints and incorporation into 
small molecules, carbon-11 and fluorine-18 are used the most frequently (table 1.1). 
 
Figure 1.7. Bench to bedside process of PET imaging. Due to the short half-life of the radionuclide, production of 
the molecule occurs on site. After the cyclotron produced radioisotope is made, it is chemically incorporated into the 
molecule. After quality control testing, the radionuclide containing molecule can be injected into the patient. During 
the PET scan, the scanner detects the annihilation event from the decayed positron colliding with a neighboring 
electron. After the scan, the image can be reconstructed based on time, activity, and which detector recorded the 
incident. 
 
Table 1.1 Common PET Radioisotopes Half-lives 
Isotope Half-life (min) 
Carbon-11 20.4 
Nitrogen-13 9.98 
Oxygen-15 2.03 
Fluorine-18 109.8 
Gallium-68 67.71 
 
 
 
Amyloid and Tau PET 
 Molecular imaging agents were developed in tandem to many of the aforementioned drug 
targets in the amyloid and tau pathways (figure 1.8). The inspiration for Aβ imaging agents was 
based on fluorescent dyes, which were classically used by pathologists to label protein 
aggregates in post-mortem human brain tissue. [18F]FDDNP, based on 2-[1-[6-(dimethylamino)-
11 
 
2-naphthyl]ethylidene]malononitrile (DDNP), was developed by Huang and Barrio at UCLA.39 
In humans, [18F]FDDNP is extensively metabolized; polar radiometabolites were found to be 
BBB permeable.40 The presence of brain-penetrating metabolites has made this radioligand 
impossible to use in a human study without the inclusion of metabolite-corrected plasma input 
function. Furthermore the low signal to noise ratio was not ideal for use. Concurrent with these 
efforts, [11C]6-OH-BTA-1 ([11C]Pittsburgh Compound B; [11C]PiB) was developed, based on the 
fluorescent pigment, thioflavin T to be selective for Aβ plaques and be more brain penetrating.41  
[11C]PiB was widely adopted in human PET imaging and was used as the target engagement 
determinant for multiple clinical trials (figure 1.9); however, fluorine-18 ligands are often 
preferred for human use because of the flexibility in synthesis and scanning time. A closely 
related fluorine-18 analogue of [11C]PiB, [18F]flutemetamol has been proven similar in detecting 
Aβ deposition and discriminating AD from healthy control.42 Another ligand, [18F]NAV4694, is 
being widely used and has demonstrated enough sensitivity to distinguish mild cognitive 
impairment (MCI) from AD.43 From a different scaffold, [18F]florbetaben44 and [18F]florbetapir45 
have also been developed for human use; however, it has been suggested that these ligands also 
bind to tau, but not α-synuclein (the protein aggregate distinct of PD).46 Because of the similar β-
sheet structure, designing selectivity between Aβ plaque, NFTs, and α-synuclein inclusions has 
been challenging; however, the growing interest of the role of tau in AD inspired dedicated 
research in this area.  
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Figure 1.8. Aβ PET Radioligands. Florbetapir, florbetaben, and flutemetamol are FDA approved. 
 
 
Figure 1.9. Typical [11C]PiB PET scan. The color scale bar represents cortical voxel-to-cerebellar retention ratio. 
CN: cognitive normal. Low aMCI: low amyloid Mild Cognitive Impairment, high aMCI: high amyloid mild 
cognitive impairment. Reprinted with permission.47 
  
 Tau PET radioligands were developed more recently and seemingly were pushed through 
clinical translation at a faster pace than the amyloid ligands.48 The first generation tau tracers are 
considered to be [11C]PBB3, [18F]THK5351, and [18F]AV-1451 (figure 1.10). [11C]PBB3 was 
developed to bind both 3R and 4R tau inclusions,49 though it is not widely used because of 
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photoisomerization occurring during radiosynthesis50 and brain-penetrating metabolites in 
humans.51 Tohoku University developed a small library of compounds,52-53 [18F]THK5351 being 
the molecule with the highest brain uptake. This radioligand showed promising preliminary 
results in human PET imaging;54 however, the authors described significant off-target binding to 
monoamine oxidase-B (MAO-B) which limits the use of the ligand.55-56 [18F]Flortaucipir, 
discovered by Siemens57 and translated by Avid Radiopharmaceuticals/ Eli Lilly & Company, 
boasted a greater selectivity for tau over Aβ and has become the most widely used first 
generation tau tracer. Clinical trials have shown a significant correlation between tau burden and 
cognitive impairment as measured by [18F]flortaucipir (figure 1.11);58 however, there are similar 
concerns about off-target binding to MAO-B.59 The second generation tau radioligand, [18F]MK-
6240, was developed specifically with off-target binding in mind and does not share MAO-B as a 
binding partner.60 Additionally, the overall uptake of [18F]MK-6240 is significantly higher than 
[18F]flortaucipir which could make analysis of the images easier.61 [18F]MK-6240 is not without 
faults though- unexplained, nonspecific uptake in the meninges has been observed in some 
patients.62 There are many efforts to develop second generation tau PET imaging agents 
including [11C]RO6931643,[11C]RO6924963, [18F]RO695948,63 [18F]JNJ64349311,64 and 
[11C]N-methyl-lansporazole.65 Continued use of these agents will investigate NFTs’ relationship 
to cognition and serve as treatment monitoring agents in upcoming clinical trials for tau 
modulating drugs. 
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Figure 1.10. Tau PET ligands. 
 
 
Figure 1.11 [18F]AV-1451 PET Scan. Mean flortaucipir voxel-wise SUVr images for Aβ+ MCI and Alzheimer’s 
disease subjects <75 years and ≥75 years old. Figure reprinted under the terms of the Creative Commons Attribution 
Non-Commercial License.66 
 
Neuroinflammation imaging biomarkers 
 Developing PET imaging agents for new biomarkers of disease has been happening in 
tandem with drug discovery since the development of PET.67 The utility of small molecule 
radioligands to confirm in vivo target engagement for drug companies was immediately realized. 
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Molecular imaging has also been used to extend knowledge of disease states with this new 
window into physiology. Throughout this section, the most popular biomarkers will be discussed 
including their inflammatory biology and imaging efforts.  
Translocator protein (18 kDa) 
Translocator protein (18 kDa), TSPO, is responsible for cholesterol transport from the outer 
mitochondrial-membrane to the inner mitochondrial-membrane. Other endogenous ligands of 
TSPO include porphyrins and endozepines, a family of neuropeptides.68 Endozepines are 
synthesized in the peripheral nervous system by Schwann cells, in which production increases in 
response to local injury.69 TSPO expression is highest in adrenal, gonad, and brain tissue.70 
Researchers explained the high level of expression in these tissues by their importance in 
steroidogenesis and cholesterol use. TSPO has been identified to have many distinct 
physiological roles: steroidogenesis,71 apoptosis, and cell proliferation.72  
 The benzodiazepine, Ro 5-4864, was the first high affinity agonist for TSPO and through 
pharmacological studies, PK11195 was developed as an antagonist.73 PK11195 was utilized to 
biochemically characterize TSPO in cell lines,74 pharmacologically in rodent models,75 and 
autoradiographically (with the tritiated version) on tissue.76 Through these studies, TSPO was 
found to be expressed in fetal rat glial cultures77 and immature rat astrocytes;78 this was 
supported by rodent models of excitotoxic brain damage in vivo.75 This evidence was used to 
justify TSPO as a biomarker for neuroinflammation and develop PK11195 as a PET radioligand 
for human use. 
 [11C]N-methyl-PK11195 ([11C]PK11195) was first synthesized in 1984 (figure 1.12).79 
One of the most important [11C]PK11195 human studies was performed at the University of 
Michigan; eight patients with a clinical diagnosis of probable AD underwent PET scans and MRI 
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to compare the hemisphere structures.80 After quantitative analysis of the [11C]PK11195 PET 
scans, the authors determined that the radioligand does not detect the presence of microgliosis or 
cellular inflammation.80 The signal to noise ratio of [11C]PK11195 was poor and would not be 
easy to utilize in a meaningful clinical setting. 
 In response to the poor tracer characteristics of [11C]PK11195, researchers developed the 
“second generation” of TSPO antagonists:  [11C]PBR28,81 [18F]DPA-714,82-83 [18F]FEPPA,84 
[11C]DAA1106,85 [18F]PBR06,86 [18F]PBR111 (figure 1.12).87 A new second generation TSPO 
ligand [18F]GE-180, has shown greater sensitivity than [18F]PBR06 in detecting decreased 
microglial activation in a mouse model of AD.88 Despite the improved signal to noise ratio of 
these tracers, the aryloxanalide backbone caused a different mode of binding than PK11195 and 
suffered variable binding in humans.89-90 A single nucleotide polymorphism (SNP), A147T, 
severely lowers the binding affinity of these tracers to TSPO and the resultant occupancy in 
tissue.89 After an exhaustive kinetic study and genotyping “high affinity,” “mixed affinity,” and 
“low affinity” binding individuals, a compartmental model was developed for [11C]PBR28;90 
however, the clinical use of these tracers is still complicated by the lack of a reference region. 
Reference regions are defined brain structures that are void of specific binding. Having a 
reference region allows for simpler image analysis by using the ratio of a region of interest and 
the reference region, called standard uptake value ratio (SUVR).  
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Figure 1.12. TSPO PET radioligands. 
 
Cyclooxygenase (COX) 
 The enzyme cyclooxygenase (COX), also known as prostaglandin (PG) H synthase, is an 
integral membrane glycoprotein. There are two forms, encoded by distinct genes, -1 and -2, 
which preform the critical first steps in prostanoid formation.91 Prostanoids, a subclass of 
eicosanoids, consist of prostaglandins, thromboxanes, and the prostacyclins. Prostaglandins are 
mediators of inflammatory and anaphylactic reactions; prostacyclins are active in the resolution 
of inflammation. Thromboxanes are mediators of vasoconstriction.92  In the inflammatory 
response, eicosanoids are required for the initiation and resolution phases. As such, these 
molecules are critical autocrine factors to regulate vascular tone and platelet aggregation, but 
also the resolution of inflammation by lipoxins.93 COX is unique in the way it catalyzes two 
chemical reactions: first the bis-oxygenase activity catalyzing arachidonic acid to PGG2 and 
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second the peroxidase activity to reduce PGG2 to PGH2. The product, PGH2, can then be 
converted to the various prostanoids.93  
COX-1 and COX-2 are functionally identical and structurally similar, with important 
differences in the COX-2 active site and an 18 amino acid insert in the COX-2 terminus.92 COX-
1 is constitutively active and maintains basal levels of prostanoids; COX-2 is inducible under 
chronic and acute states of inflammation. This difference in expression is clearly demonstrated 
by the TATA box in the promoter of the COX-2 gene. A third form of the protein, COX-3, has 
been identified in canine and human cortex, but the functional role is largely unknown.91 In 
rodents, the COX-3 variant was determined to have no cyclooxygenase activity.93 
One of the most widely used drug classes, non-steroidal anti-inflammatories (NSAIDs) 
are the main inhibitors of COX, used for the treatment of pain and inflammation. The classical 
NSAIDs: aspirin and ibuprofen, are non-selective for the two isozymes. A dangerous side effect 
of habitual NSAID use is stomach ulcers, due to the unintended inhibition of COX-1 in the 
gastrointestinal tract.93 In response to this, medicinal chemists developed the specific COX-2 
inhibitors, Zomepirac (RS104897), RS57067,92 Celecoxib, and Rofecoxib.94 These inhibitors 
were then used as the basis for [18F]SC58125 (figure 1.13), which demonstrated COX-2 binding 
in activated macrophages; however, the tracer uptake in baboons appeared nonspecific in the 
brain.94 [11C]Celecoxib itself was developed as a PET ligand (figure 1.13).95 However, much of 
the use has been focused on evaluating “biliary excretion,” which it was found unsuitable.96 
When [11C]celecoxib and [11C]rofecoxib were evaluated in normal mice and an ischemic brain 
injury model, it was determined that they were not sensitive enough to detect COX-2 in vivo.97   
COX-1 has also been evaluated in vivo through the use of [11C]ketoprofen methyl ester 
[11C]KTP-Me.98 In a rodent model of microglial activation, this PET ligand was able to monitor 
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the time dependent activation of COX-1. However, this study is one of the only ones to 
demonstrate COX-1 as an inducible factor in inflammation. The main concern with targeting 
either COX-1 or COX-2 is the ability to see the small increase in expression, over the high basal 
level of COX-1, this has limited its use as an imaging biomarker to date. 
 
Figure 1.13. COX PET radioligands. 
 
Reactive Oxygen Species (ROS)  
 One of the most straightforward strategies for detecting neuroinflammation is to detect 
the presence of reactive oxygen species (ROS). Nitric oxide (NO) is a gaseous free radical, 
which can occur in cells from the conversion of L-arginine to L-citrulline by nitric oxide 
synthases.32 In macrophages, microglia, and astrocytes the production of NO is highly regulated 
by Ca2+/ calmodulin dependent isoforms (iNOS). This enzymatic process is highly variable in 
vitro based on different conditions of cell culture. Thus it has been challenging to elucidate this 
pathway. In human brain tissue expression of iNOS has been detected in NFT bearing neurons99 
and hippocampal sections of AD brain tissue.100 Another reactive oxygen species is superoxide, 
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the anionic form of oxygen gas. It is normally removed from cells by superoxide dismutase 
(SOD), but during high levels of NADPH oxidase activity, superoxide can react with NO to form 
peroxynitrite. Peroxynitrite is damaging to DNA and proteins within the cell; the DNA damage 
can activate necroptosis or apoptosis (figure 1.14).101  
 
Figure 1.14. ROS formation and selected damage pathway. A) Superoxide can be formed from NADPH oxidase, 
xanthine oxidase, COX, and NOS. B) Nitric oxide is a byproduct of NOS catalyzed conversion of arginine to 
citrulline. C) Superoxide is normally transformed into hydrogen peroxide by SOD. Presence of ROS in the 
cytoplasm can result in lipid peroxidation, thiol oxidation of sulfur containing amino acids and cofactors, and DNA 
damage in the nucleus.  
 
 The first chemical biology probe for observing ROS was hydromethidine, which is a 
fluorescent after oxidation. Studies with [3H]hydromethidine (HM) demonstrated blood brain 
barrier permeability as well as trapping after oxidation in vivo.102 The same group radiolabeled 
this compound with carbon-11 (figure 1.15).103 Evaluation with a lipopolysaccharide (LPS) 
induced model of neuroinflammation revealed an increase in radioligand uptake which was 
mirrored on tissue in autoradiography studies. The fluorescence based compounds require 
reaction with ROS, which in theory provides a level of sensitivity in brain areas of high 
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inflammation over others. This reaction based technique has been expanded to other molecular 
scaffolds as well. 
 The compound [11C]1-methyl-1,4-DHQ-3-carboxamide ([11C]DHQ1) relies on 
irreversible trapping after oxidation by ROS in the central nervous system (figure 1.15).104 The 
lipophilic form, structurally based on the cofactor NADH, can passively diffuse, while the 
oxidized form cannot and will be trapped; this phenomenon was demonstrated in apocynin-
treated mice. The tracer was rapidly cleared from the non-apocynin treated animals; however, the 
authors argue that one method is not sufficient to measure redox status.105 A similar effort to this 
trapping includes [18F]ROStrace, based on the dihydroethidium dye.106 The authors claim that 
one day post LPS injection, mice had increased uptake of [18F]ROStrace which correlated to 
“worse off” inflammation scores.107 [18F]FLT Boronate-caged are also designed to react with 
ROS. Fluorothymidine (FLT) mimics endogenous substrates that are transported into cells that 
are proliferating quickly by ENT1, phosphorylated by TK1, and trapped.108 The chemo-selective 
cage structure ensured transport to the correct cellular type and that the thymidine analogue 
would not be incorporated into DNA. In principle, this technique was successful but at this time 
it has not been evaluated in the CNS.  
 Finally, there has been one reaction-based effort that does not rely on trapping to occur. 
[11C]Ascorbic Acid (vitamin C) was carbon-11 labeled by our lab in collaboration with UCSF 
and Stanford, in addition to its oxidized partner, [11C]DHA. The purpose of this study was to 
evaluate the model in cancer cells; however, it is an interesting technique that could be applied to 
the CNS. Vitamin C is actively transported by sodium dependent vitamin C transporter (SVCT1-
2) which is a relatively slow process. Once oxidized by a two-electron transfer into DHA, that 
compound can be transported through the glucose transporter (GLUT) much faster. It was 
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assumed, and shown in cancer cell lines, that intracellular accumulation of [11C]VitC is an 
oxidation-dependent process, while [11C]DHA accumulation is not.109 
 
Figure 1.15. PET tracers and ligand for Reactive Oxygen Species. 
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Monoamine Oxidase (MAO) 
 Monoamine oxidases (MAOs) are flavin containing enzymes found on the outer-
mitochondrial membranes. Two isozymes, MAO-A and –B, are responsible for the oxidative 
metabolism of the monoamine neurotransmitters (dopamine, serotonin, epinephrine, 
norepinephrine, histamine, among others).110 Both isozymes are expressed in the CNS, though 
their active site structural differences influence their substrate preferences. Serotonin is the 
preferred substrate of MAO-A. As such inhibitors for MAO-A have been developed for 
treatment of major depressive disorder.111 MAO-B has been found to be expressed in 
dopaminergic neurons and in astrocytes. Through immunoreactivity studies, MAO-B has been 
found near Aβ in human brain tissue sections.112  
 Irreversible inhibitors, [11C]L-deprenyl and [11C]clorgyline, were first used for MAO-B 
and –A PET imaging, respectively, and to map the distribution of MAO in the human brain 
(figure 1.16).113 Due to high noise observed in vivo, [11C]clorgyline was replaced in use with the 
reversible ligand [11C]harmine. To improve in vivo pharmacokinetics of the MAO-B tracer, 
deuterium substitution was utilized to make [11C]deprenyl-d2 ([
11C]DED). [11C]DED imaging 
has been utilized in many human trials and demonstrated astrocyte activation in MCI and AD 
patients, supporting the hypothesis of neuroinflammation.114 
 [11C]DED is not the ideal PET ligand for MAO imaging however, because it is 
metabolized in vivo to [11C]methamphetamine.115 The presence of a brain penetrating metabolite, 
with specific binding partners different to that of the parent, complicates image analysis. A study 
with reserpine, an adrenergic blocking agent, confirmed in mice that [11C]deprenyl and the 
resultant [11C]methamphetamine metabolite binding is not specific to MAO-B. An alternative 
strategy to using this irreversible inhibitor, was to utilize [11C]1-methyl-4-phenyl-1,2,3,6-
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tetrahydropyridine ([11C]MPTP).116-117 MPTP is a selective substrate for MAO-B; however, it is 
known to cause dopaminergic cell death from its reactive metabolite MPP+ irreversibly binding 
to the electron transport chain.118-119 This toxicity prevents its use for human PET imaging. In a 
similar approach, with a nontoxic substrate, we have previously developed aryl-oxy-derivatives 
of MPTP for MAO PET imaging.120 Further development of substrates for trapped metabolite 
imaging of MAO-B will be discussed in chapter 3.  
 
Figure 1.16. PET tracers and ligands for Monoamine Oxidases. 
 
Receptor for Advanced Glycation End-products (RAGE) 
 Advanced glycation end-products (AGEs) are non-enzymatically glycated 
macromolecules that are regarded as signs of inflammation.121 These molecules are recognized 
by the receptor for advanced glycation end-products (RAGE), a pattern recognition receptor 
(PRR) of the immunoglobulin G family. RAGE signals through ligand-induced homo- or hetero-
dimerization, allowing for intracellular ligand binding. This results in pro-inflammatory 
transcription and the eventual release of soluble cytokines and chemokines.122  
 RAGE overexpression has been documented in multiple types of inflamed vascular 
tissue, including lung123 and brain.124-125 There have been few PET imaging efforts for RAGE 
because it is a relatively new biomarker and there are not many small molecule inhibitors known. 
Our efforts to develop small molecule radioligands for RAGE, and subsequent investigation into 
RAGE as a biomarker for neuroinflammation will be described in chapters 5 and 6. 
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Hypothesis, overarching dissertation goals, and chapter outline 
 As outlined previously, PET imaging of neuroinflammation is a growing field with roots 
in the classical biomarkers of peripheral inflammation (TSPO and COX). Clinical use of these 
radioligands has provided necessary insight into the physiology of neurodegeneration which 
supports the overall hypothesis. The goals of my dissertation work were broadly to develop 
novel approaches to imaging neuroinflammation. The specific aims of each chapter will be 
outlined therein; however, the work is intended to be applied to neurodegenerative disorders to 
investigate the inflammation component. The second chapter in this work explores off-target 
binding of a first generation tau tracer, [18F]flortaucipir ([18F]AV-1451; [18F]T807). This chapter 
investigates a widely used tau tracer and its relationship to monoamine oxidase- B (MAO-B). 
MAO-B in its own right plays a role in the activation of microglia (microgliosis) and is 
considered an inflammatory biomarker. Chapter 2 considers the challenges in interpreting PET 
data from a tau tracer, while unintentionally observing changes in MAO-B activity. The 
subsequent chapter 3 describes my efforts in the development of a radiotracer (substrate) for 
trapped metabolite imaging of MAO-B activity. These experiments highlight the necessity of 
understanding enzymatic mechanism as well as brain pharmacokinetics for successful tracer 
design. Chapter 4 continues in the exploration of MAO-B as a biomarker; however, it mostly 
serves as a proof-of-concept for dual PET- magnetic resonance (MR) imaging. It has been long 
thought that the need in MR for high unlabeled tracer mass would make dual modality imaging 
with the same ligand impossible. We demonstrate with substrates that do not saturate the enzyme 
that these imaging modalities can work in tandem. These chapters combined summarize my 
investigations into MAO-B and my efforts in developing a PET tracer for the enzyme. The 
remaining two chapters both focus on a far less known biomarker of inflammation, the receptor 
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for advanced glycation end-products (RAGE). Chapter 5 describes the preliminary and 
subsequent efforts to develop a small molecule ligand for RAGE, despite the receptor’s 
endogenous ligands being large peptides and other biomolecules. Chapter 6 takes a step back so 
to speak, and considers if RAGE is a biomarker for neuroinflammation at all, being that the 
majority of previous work in this field has only considered RAGE’s role in peripheral 
inflammation. The last experiment performed in this body of work was the development of the 
LPS mouse model of neuroinflammation and evaluating for RAGE. The final chapter of this 
work provides overall conclusions and recommendations for future steps for each of these 
projects. 
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CHAPTER 2 
Monoamine Oxidase B as an off-target of [18F]AV-1451 
1. Introduction 
 Control of abberant tau pathology has emerged as a leading strategy in Alzheimer’s 
Disease (AD) treatment following the late stage failure of anti-amyloid targeting therapies. 
While amyloid-beta (Aβ) plaque is found extracellularly and is one of the hallmarks of AD 
pathology, strategies to clear Aβ and prevent further aggregation have not been successful to 
ameliorate cognitive impairment in patients.1 Hyperphosphorylated tau composes the 
intracellular aggregate, neurofibrillary tangles (NFTs), and consistently correlates with cognition 
based on Braak staging.1-2 This is an important difference and improvement upon Aβ pathology 
because dementia free patients have been found to be amyloid positive based on positron 
emission tomography (PET) imaging studies.3 Amyloid targeting therapeutic strategies to date 
(outlined in chapter 1), have failed to improve cognition based outcome measures; it is the hope 
with NFT pathology having a higher correlation with cognition that targeting tau in both 
therapeutic interventions and for imaging technologies will be more successful. PET is a 
noninvasive, in vivo imaging modality that has been successfully used in multiple stages of the 
drug discovery and development process. AD research has benefited greatly from [11C]Pittsburgh 
Compound B ([11C]PiB: an Aβ selective agent) PET imaging for patient enrollment into clinical 
trials and treatment monitoring.4 As the community shifts focus toward tau pathology, selective 
tau PET agents have been developed for the same uses.5-8 
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Of the first generation tau PET agents, [18F]AV-1451 (flortaucipir, [18F]T807), has been most 
widely used in clinical studies.9-22 In AD patients, [18F]AV-1451 standard uptake value ratio 
(SUVR) was significantly higher with more advanced clinical stage (AD > mild cognitive 
impairment > older cognitively normal).19 Furthermore, when these patients were classified 
based on Aβ load (+ or -), the pattern of [18F]AV-1451 distribution in Aβ+ was similar to cross-
sectional distribution of tau reported in post-mortem pathologies.19 In addition to imaging AD 
patients, [18F]AV-1451 has been used to evaluate sporadic Creutzfield-Jakob disease (CJD). CJD 
is a rare human prion disease with rapidly progressive dementia, in which tau pathology has been 
found cerebral spinal fluid. However, in vivo [18F]AV-1451 PET imaging suggested no unique 
pattern of retention in the brain.11 In order to differentiate AD from the related dementia with 
Lewy bodies (DLB), [18F]AV-1451 has been investigated as a possible tool. Kantarci and 
coworkers found the AD dementia group had a significantly higher uptake in the medial 
temporal lobe than the DLB group.15 However, diagnosis requires a complete understanding of 
the PET ligand and its binding pattern- and there is documented non-tau, or “off-target” binding 
of [18F]AV-1451. 
 
Figure 2.1. Human [18F]AV-1451 PET Scans. A. MCI. B. Cognitive Normal. Green arrows point to the substantia 
nigra. Yellow arrows point to the choroid plexus. 
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 Through our own analysis, we have observed tracer accumulation in the substantia nigra 
and choroid plexus regions in both MCI and cognitively normal patients (figure 2.1). Time 
activity curves of these regions of interest reveal slower clearance, which might indicate specific 
binding. Independent validation efforts from several groups have confirmed localization of this 
tracer with NFTs, visualized by immunological methods, while simultaneously revealing off-
target tracer accumulation, particularly to pigmented cells of both the CNS and the periphery.10, 
16 While [18F]AV-1451 binds to these cells, it should be noted that no biochemical assays have 
been conducted to confirm off-target binding to neuromelanin itself (as opposed to a cellular 
component which may be found with melanin and in neuromelanin-containing cells). The 
choroid plexus is near the hippocampus and the concern for nonspecific binding is that this 
signal will spill over into the region of interest. A human clinical trial was performed to evaluate 
any binding differences in the choroid plexus (CP) between African American participants 
compared to white participants; the rationale being that melanin and melanocytes are higher in 
African American participants.9 Although no race differences were found, high CP signal 
affected the measurement in the hippocampus.9  
 Neuromelanin containing cells, chiefly in the substantia nigra are known to be involved 
in the dopaminergic system and to contain high amounts of monoamine oxidase (MAO).23 In 
vitro studies have revealed high-affinity interactions between [18F]AV-1451 and MAO;24-25  
however, it is not yet confirmed if these results translate to human imaging. Hansen and 
coworkers retrospectively analyzed a small cohort of patients taking MAO-B inhibitors and its 
effect on [18F]AV-1451 binding and retention.26 While their results indicate no effect on uptake, 
binding, nor retention, it is critical to note that these patients were determined to be tau negative. 
Another limitation of this study is the lack of paired block and unblocked data, as well as the 
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unknown length of time the patients had been taking MAO inhibitors. It is known from 
[11C]deprenyl-d2 ([
11C]DED: an irreversible MAO-B inhibitor) imaging that therapeutic doses 
successfully block MAO to an extreme extent and that it can take up greater than 3 weeks to 
recycle those enzymes.27 Performing this study in patients who chronically take MAO inhibitors 
would essentially ensure no effect could be observed, because the enzyme would still be 
inhibited therapeutically.  
 A different first generation tau PET ligand, [18F]THK5351 also suffers from off-target 
binding to MAO. In vivo [18F]THK5351 retention was observed in areas not associated with tau, 
and it was noted that [18F]THK5351 SUVR was significantly correlated to MAO-B level.28 In a 
prospective study, using MAO inhibitor naïve patients, Ng and coworkers demonstrated a 
significant difference in [18F]THK5351 binding and retention after pretreatment with deprenyl.29 
The confirmation of off-target binding to MAO-B in vivo has significantly limited the use of this 
radioligand. The finding from this prospective study, and the limitations of the retrospective 
[18F]AV-1451 trial,26 encouraged us to continue the investigation into [18F]AV-1451’s off-target 
binding.  
 Off-target binding of ligands used for PET imaging is problematic when distinct regions 
of brain structures need to be compared. In tau imaging, brain structures in the medial temporal 
lobe are important because tau pathology is considered to begin forming in the entorhinal 
cortex.30 The neighboring hippocampus is a region often used to determine “positivity” in tau 
PET imaging as well; it is more associated with Braak stages IV and V.2 In the case of 
[18F]AV1451, the choroid plexus (CP) and substantia nigra (SN) are very close to these 
structures and the off target binding could “spill” into these regions of interest; this would cause 
an artificial increase in the signal. Furthermore, the proposed off-target binding partner MAO-B 
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has significant expression in the reference region, the cerebellar gray cortex.31 In human PET 
imaging, the measure SUVR is often used. This is the standard uptake value ratio of the region of 
interest normalized to the reference region. Ideally, the reference region is void of specific 
binding. If [18F]AV-1451 is binding to MAO-B in vivo, it is very possible that this effect is not 
only responsible for the SN retention, but also could be affecting the SUVR measure through 
specific binding in the cerebellum. 
 Herein, we report the in vitro and in vivo evaluation of [18F]AV-1451 in respect to its 
binding to MAO. Inhibition assays with MAO-A and MAO-B confirmed that it is an inhibitor for 
both isozymes. In respect to the brain, MAO-B is more highly abundant32 and was the focus for 
studies using post-mortem human brain tissue sections. In vivo blocking studies were performed 
in healthy non-human primates to monitor the influence of reversible MAO inhibitors on 
[18F]AV-1451 binding and retention. 
2. Results 
In Vitro Binding Assessment 
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Figure 2.2. AV-1451 inhibition of MAO-A and MAO-B turnover. MAO-A: Ki = 10.48 μM, R2 = 0.8132, n = 4; 
MAO-B: Ki = 15.14 μM, R2 = 0.8285, n = 4. 
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 MAO-A and MAO-B inhibition assays revealed AV-1451 is a weak, nonselective 
inhibitor of both enzymes (figure 2.2). Activity assay used the previously described Cou 
substrate and monitored the appearance of fluorescent product.33 Substrate was used at KM for 
MAO-A and –B respectively, IC50’s and Ki’s were calculated using GraphPad Prism 7.02. 
 [18F]AV-1451 MAO-B binding was further evaluated on postmortem human brain tissue 
sections in the presence of the irreversible inhibitor deprenyl. Substantia nigra (SN) and 
cerebellum (CBL) sections were used in this study because of the nonspecific binding observed 
in the substantia nigra during human [18F]AV-1451 PET scans and the cerebellum’s use as a 
reference region. Specific binding of [18F]AV-1451 to tissue was determined from subtraction of 
the total binding signal from nonspecific binding (in excess of [19F]AV-1451). Specific binding 
was approximately 400 times higher in diseased SN sections in comparison to age matched 
control SN sections; this increase is consistent to a much lesser extent in CBL sections. Total 
binding of [18F]AV-1451 was significantly diminished in competition with deprenyl in both SN 
and CBL sections (figure 2.3). Cognitive normal tissue sections for both SN and CBL did not 
have statistically significant differences in [18F]AV-1451 total compared to nonspecific, nor the 
MAO-B inhibition challenges. 
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Figure 2.3 [18F]AV-1451 binding to human brain tissue sections. A, substantia nigra (SN), B, cerebellum (CBL). 
Binding is normalized to section area and individual experimental dose (range +/- sem, n=4). Average +/- standard 
error of the mean is shown for four diseased individuals. Specific binding was calculated as the difference of 
nonspecific binding from total. Averages are shown as percent of total binding. Low deprenyl challenge was 500 
nM, high deprenyl is excess. Significance calculated using Tukey’s multiple comparisons test.  
 
 Immunohistochemistry was performed on these postmortem tissue sections to determine 
the relationship between [18F]AV-1451 binding, MAO-B expression, and tau load. Compared to 
sections from age-matched controls, MAO-B immunoreactivity was 3-fold higher in diseased SN 
sections and 2-fold higher in diseased CBL sections (figure 2.4). In the AD and DLB conditions, 
where substantia nigra and cerebellum tissue from the same patient was available, MAO-B 
immunoreactivity was ~4 times higher in the substantia nigra compared to the cerebellum, while 
anti-tau reactivity was only found in the diseased SN sections. Pearson correlation tests were 
performed to compare MAO-B or tau immunoreactivity and the various [18F]AV-1451 binding 
conditions. The only significant correlation found was MAO-B immunoreactivity and [18F]AV-
1451 total binding in diseased SN tissue sections (figure 2.5; r= 0.9592, p= 0.0408).  
43 
 
 
Figure 2.4. Immunoreactivity on postmortem human brain tissue sections. Top: substantia nigra (SN) sections 
comparing diseased brain tissue to cognitive normal control for MAO-B immunoreactivity. Bottom: cerebellum 
(CBL) sections comparing diseased brain tissue to cognitive normal control for MAO-B immunoreactivity. 
 
Figure 2.5. Correlations between MAO-B immunoreactivity and [18F]AV-1451 binding. Pearson correlations 
calculated in GraphPad Prism 8.01, individual boxes display the calculated r and p values. * indicates significance. 
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Small Animal Blocking Studies  
 In nonhuman primate brain, blocking with the reversible MAO-A inhibitor moclobemide 
resulted in a modest increase in SUVpeak in the cerebellum and basal ganglia, while pretreatment 
with the reversible MAO-B inhibitor lazabemide produced minor increases in the SUVpeak of the 
two regions (figure 2.6). SUV values in the final four frames of imaging (approximately 55, 65, 
75, and 85 minutes post-injection) for a region of interest were averaged and divided by the 
averaged cerebellar SUV to afford SUVRs (figure 2.7). Following pretreatment with lazabemide, 
the normalized value in the basal ganglia increased slightly, while blocking with moclobemide 
decreased. 
 
Figure 2.6 [18F]AV-1451 time activity curves of nonhuman primate brain PET imaging studies. Summed frames 
presented as SUV. R_HIPP- right hippocampus, L_HIPP- left hippocampus, CBL- cerebellum, THAL- thalamus, 
BG- basal ganglia, CTX- cortex.  
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Figure 2.7. Averaged last four frames of dynamic PET scan in nonhuman primate brain. (n=2/ study) normalized to 
cerebellum. 
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3. Discussion 
 Tau PET imaging is a popular shift in neurodegenerative research from amyloid imaging, 
and however popular, it has noted limitations.7 It is widely acknowledged AV-1451 shows 
nonspecific binding in the substantia nigra region.34 Several groups have independently 
investigated this phenomenon with conflicting results regarding the cause of this off-target 
binding.35-36 While an in vitro screen reported during AV-1451’s initial development did not 
identify any binding partners that warranted a toxicity concern,37 several groups, including our 
own, have identified MAO-B as a significant off-target binding partner.38-39 
 [18F]AV-1451 shares this burden with other first generation tau tracers like 
[18F]THK5351, which also was shown to have significant binding to MAO-B, both on tissue and 
in human PET imaging studies with a MAO-B inhibitor.29, 40 Despite longstanding concerns 
regarding binding to MAO, [18F]AV-1451 has not been evaluated in a similar prospective study. 
Hansen and coworkers evaluated a retrospective cohort and determined no influence of MAO 
inhibitors on AV-1451 binding, though the scope of this study was limited.26  
 Human [18F]AV-1451 scans performed in our PET center have revealed binding in the 
substantia nigra, which appears to be specific based on a slower clearance compared to the 
reference region (figure 2.1). This finding and the aforementioned debate in the community 
about nonspecific binding led our in vitro investigation into [18F]AV-1451. In our previously 
developed activity assay, AV-1451 was determined to be a non-selective inhibitor of MAO-A 
and –B (MAO-A: Ki = 10.48 μM; MAO-B: Ki = 15.14 μM). Though not a strong inhibitor, it is 
similar to the behavior of a structurally related compound, norharmane (MAO-A: Ki = 19.63 μM; 
MAO-B: Ki = 8.52 μM). Norharmane, despite this relatively weak inhibitory constant, is a 
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classically used MAO inhibitor (figure 2.8). AV-1451 has a γ- carboline ring system, while 
norharmane has a β- carboline ring system. 
 
Figure 2.8. Structures of AV-1451 and Norharmane. 
 
 Using postmortem tissue, we challenged the binding of [18F]AV-1451 with co-incubation 
of the radioligand and the irreversible MAO-B inhibitor deprenyl (Ki= 90 nM). Deprenyl 
significantly lowered radioligand binding in both diseased and age-matched control SN and CBL 
tissue sections. The specific binding of [18F]AV-1451 is low (~50%) and deprenyl blocking 
closely mirrors the magnitude of nonspecific binding in these experiments. We believe this to be 
the first published study of competition between [18F]AV-1451 and an MAO-B inhibitor using 
autoradiographic methods on frozen brain tissue. 
 Independent autoradiography with [18F]AV-1451 has been performed by multiple groups, 
with conflicting results likely stemming from variation in methods. While the original report 
characterizing [18F]AV-1451 did not contain autoradiography studies, it described above 50% 
inhibition at the norepinephrine transporter (NET), vesicular monoamine transporter (VMAT), 
N-methyl-D-aspartate (NMDA) receptor, and mu opioid receptor at 10 µM. The authors also 
declared no inhibition of MAO-A/B at 1 µM, and thus no concern for toxicity.41 At tracer 
quantities, toxicity is almost never a concern, nonspecific binding however is often considered. 
In 2015, it was reported that the “neuromelanin containing cells” in the substantia nigra was a 
robust area of off-target binding for [18F]AV-145.34 The methods used for this tissue experiment 
were highly unorthodox however, fixing frozen sections in 100% methanol before binding with 
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the radioligand, and washing with ethanol.34 Fixing frozen tissue is almost never used in 
autoradiography because of the significant changes that occur in the membrane; to observe small 
molecule binding in a more “in vivo”-like system, hydrated frozen tissue is the standard. Fixed 
tissue is more commonly used in immunohistochemical experiments. Especially with a 
molecular target such as NFTs, with multiple possible binding sites, every aspect of the 
experimental design needs to be considered for its influence. When Pike and coworkers at the 
NIH evaluated [3H]AV-1451 and another first generation tau tracer, [3H]THK523, freeze-thaw 
and buffer effects were evaluated rigorously on the human brain homogenates.42 The authors 
found that the best conditions for reproducibility when using AD brain tissue homogenate was to 
re-homogenize the tissue after thawing, to treat the suspension to a high-power ultrasonic probe, 
and to use 0.1% Tween-20 in PBS as the assay medium. 
 Also in 2015, the other first generation tau tracers developed at Tohuku University were 
being evaluated for MAO binding.29,43 The group responded to this report with their own 
investigation and confirmed the finding of [18F]THK5351 and [18F]THK532 as MAO binding 
partners.44 Through further binding experiments, [18F]AV-1451 was found to have nanomolar 
affinity to MAO-A (Kd= 1.6 nM) and could be competed with clorgyline (irreversible MAO-A 
inhibitor).38 While Merck was developing their own tau tracer, [18F]MK-6240, MAO binding 
became a concern. Hostetler and coworkers confirmed clorglyine competition decreases [3H]AV-
1451 binding in human brain homogenates.45 Again, these studies utilized fresh frozen and 
rehydrated brain tissue, not fixed. There also could be a difference in the experimental specific 
binding when alcoholic buffers are used in the wash steps. Arstad43 and Marquie34 describe very 
low nonspecific binding in comparison to what we’ve observed experimentally, and this could be 
directly related to differences in wash steps. 
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  Immunoreactivity studies determined a significant increase in MAO-B abundance in 
diseased substantia nigra, and a significant correlation was found between total [18F]AV-1451 
binding and MAO-B immunoreactivity in this tissue. Despite the significant difference in MAO-
B immunoreactivity in the diseased CBL compared to cognitive normal, a similar correlation was 
not found with total [18F]AV-1451 total binding (figure 2.5). It is possible the trend could not be 
observed because of the high variability observed across individuals in this region and also due 
to the lack of tau in this region.46 Through our autoradiography methodology, no observable 
specific binding was found in the cerebellum (figure 2.3); however, there was a significant effect 
when challenged with deprenyl. This result in combination with the high abundance of MAO-B 
as measured in immunoreactivity, suggests the presence of binding to MAO-B in the cerebellum. 
However, binding that can be displaced by deprenyl, but not AV-1451, would not be classified as 
nonspecific. This result requires more interpretation and possible follow up studies. 
 To further investigate the role of MAO in the substantia nigra and cerebellum, [18F]AV-
1451 PET scans were done in healthy nonhuman primates. In the brain of the rhesus macaque, 
[18F]AV-1451 distributes nonspecifically (as would be expected in a non-diseased model), 
though it is interesting that SUV is highest in the cerebellum. Standardizing “equilibrium” 
[18F]AV-1451 retention to cerebellar uptake disproportionately masks the decrease in SUV 
resulting from MAOI pretreatment in the nonhuman primate brain (figure 2.7). In fact, it has 
been suggested that the clinical interpretation of [18F]AV-1451 scans should not rely on the use 
of the cerebellum as a reference region because of concerns regarding off-target binding, and our 
work supports that suggestion by the significant abundance of MAO-B and displaceability on 
tissue. While both of these preclinical models are non-diseased, these studies suggest that the in 
49 
 
vitro blocking effects of MAO inhibitors could reasonably translate to signal displacement in a 
prospective human investigation.  
 While these experiments have several limitations, we hope to encourage the tau PET 
community to continue vetting [18F]AV-1451 and other tau PET agents in human use. Enzymatic 
activity assays and tissue binding assays are limiting because they can be heavily influenced by 
experimental procedure. We aimed to provide a logical experimental design, in particular with 
our handling of post-mortem human tissue. The nonhuman primate PET scans shown do not 
include arterial input correction, and we have tried to remedy this by considering the later frames 
of the scan. Despite these limitations, our data indicate AV-1451 inhibits monoamine oxidase 
activity in vitro and binds to MAO-B on tissue sections. In vivo, MAO inhibitors change the 
uptake of AV-1451 in the cerebellum, the reference region for tau PET. 
 Furthermore, our interest in monoamine oxidase extends beyond its role as an off-target 
binding partner for this tracer. MAO-B is a marker of astrocytosis, with evidence for its co-
expression with amyloid plaques dating back to the early 1980’s.47-50 The changes of MAO-B 
activity itself has been investigated with irreversible inhibitors, reversible inhibitors, and 
substrates in PET imaging. It is quite unfortunate that not only does AV-1451 have an off-target 
binding partner, but that this binding partner also has a role in neurodegeneration. Our 
immunoreactivity studies show that MAO-B expression is increased in diseased substantia nigra 
and cerebellum sections, meaning observed changes in AV-1451 uptake in those regions may not 
be from tau deposition alone. From these in vitro and in vivo findings, we assert that a 
prospective study into the influence of MAO-B on [18F]AV-1451 PET scans is necessary. To 
truly interpret SUVR, we need to understand the binding events in the cerebellum. 
4. Methods 
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Radiochemistry 
 [18F]AV-1451 was prepared as previously described, by Dr. Andy Mossine.51 The 
synthesis of [18F]AV-1451 was fully-automated using a General Electric (GE) TRACERLab 
FXFN synthesis module. [
18F]Fluoride (~1400 mCi) was produced via the 18O(p,n)18F nuclear 
reaction with a GE PETtrace cyclotron equipped with a high-yield fluorine-18 target. 
[18F]Fluoride was delivered in a 1.5-mL bolus of [18O]H2O to the synthesis module and trapped 
on a QMA-Light sep-pak cartridge to remove [18O]H2O. [
18F]Fluoride was then eluted into the 
reaction vessel with potassium carbonate (3.5 mg in 500 μL of water). The solution of 
K2.2.2 (15 mg in 1 mL of ethanol) was added to the reaction vessel, and the [
18F]fluoride was 
azeotropically dried by heating the reaction vessel to 100 °C and drawing full vacuum for 6 min. 
After this time, the reaction vessel was subjected to both an argon stream and a simultaneous 
vacuum draw for 9 min at 100 °C. The solution of AV-1451 N-Boc nitro-precursor in DMSO 
(0.5 mg in 500 μL) was added to the dried [18F]fluoride, and was heated to 130 °C with stirring 
for 10 min. Subsequently, the reaction mixture was cooled to 50 °C, diluted with HPLC mobile 
phase (3 mL), and purified by semi-preparative HPLC (column: Phenomenex Gemini NX C18, 5 
micron, 10x250 mm; mobile phase: 40% Ethanol 10 mM Na2HPO4 pH: 9.3 ± 0.2; flow rate: 
3 mL/min; UV: 254 nm). The product peak (tR = 21–22 min) was collected into the dilution flask 
where it was concomitantly diluted with 50 mL of sterile water. The resulting solution was 
passed through an Oasis HLB cartridge, which was then washed with 10 mL of sterile water. 
[18F]AV-1451 was eluted with 0.5 mL of EtOH (USP for injection) and collected in the 
Tracerlab FXFN product vial, containing 3 mL of saline (USP). The Sep-Pak was washed with 
6.5 mL of saline to bring the final formulation volume to 10 mL. The final drug product was 
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dispensed into a septum sealed, sterile, pyrogen-free glass vial through a 0.22 μm sterile filter 
and submitted for QC testing. 
Human Brain Imaging 
 Potential research subjects were identified by the investigators from the Neurology 
Cognitive Disorders and Movement Disorders clinics (IRB study#: HUM00124161).  Eligibility 
screening involved review of existing medical records to establish diagnosis and absence of 
exclusionary criteria. Subjects were positioned on the PET scanner table, lying comfortably on 
their back.  They were asked to lie quietly, to stay awake and to keep their eyes open. A low-
dose X-ray CT scan of the head was performed for attenuation correction of emission PET 
images.  [18F]AV-1451 was injected as an IV bolus and dynamic PET imaging began 
immediately for 60 minutes: 4 x 30 sec frames; 3 x 1 min frames, 2 x 2.5 min frames; 6 x 5 min; 
2 x 10 min.  After a several minute break, additional brain images were made from 75 – 105 
minutes: 3 x 10 min. 
MAO Inhibition Assay 
 Off-target binding of [19F]AV-1451 was assessed in vitro by quantifying the inhibition of 
4-methyl-7-((1-methyl-1,2,3,6-tetrahydropyridin-4-yl)oxy)-2H-chromen-2-one (Cou) turnover 
by recombinant human MAO as previously reported.33 Briefly, inhibition was determined using 
human MAO-A and –B Supersomes (Corning Gentest) at a concentration of 80 µg/ml. Fresh 
stocks of Cou was dissolved in DMSO to give a 10 mM stock and subsequently diluted in borate 
buffer (pH 8.4) to 40 µM (MAO-A) and 1 µM (MAO-B). Fresh AV-1451 stock was dissolved in 
DMSO and further diluted for the assay range 1 to 300 µM. Reaction progress was measured by 
appearance of fluorescent product, 7-hydroxy-4-methyl-coumarin. Reactions were monitored in 
real time using a Biotek Hybrid plate reader (excitation 360nm, emission 460 nm) at 37°C; 
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reactions progressed for 60 minutes and fluorescent reads were measured every 5 minutes. The 
resultant fluorescence units were converted to concentration of product using a reference 
standard curve. Inhibition curves were plotted and parameters computed in GraphPad Prism 
(version 7.03). Assays were done in duplicate, in two independent experiments using fresh stock 
of enzyme, test compound, and reference standard. Outliers which met the Grubb’s test were 
removed. 
Human Tissue Studies. 
 Tissue Preparation.  
 Postmortem brain tissue from Alzheimer’s disease, Dementia with Lewy Bodies, and 
age-matched cognitively normal patients was obtained from the University of Michigan 
Alzheimer’s Disease Center Brain Bank. Brain sections were cut using a microtome to 20 µm 
sections and thaw-mounted onto poly-lysine coated glass slides. Slides utilized for 
immunohistochemistry were fixed in Davidson’s fixative (8.1% formaldehyde, 33.3% ethanol, 
11.1% acetic acid, Eosin Y stain) for 24 hours and then rinsed with 70% ethanol to remove 
residual formaldehyde before use. Slides utilized for autoradiography were stored at -80 °C until 
the day of experiment.  
Immunohistochemistry 
 Fixed tissue sections were incubated in PBS with 1% SDS for 5 min. Sections were then 
washed 3 x 5 min in PBS before quenching in 70% methanol with 0.3% hydrogen peroxide for 
15 min. All slides were washed 3 x 5 min in PBS-T (PBS, 0.4% Triton-X-100, pH 7.4) and 
blocked for 30 min with PBS-TBA (PBS, 0.4% Triton-X-100, 1% BSA, 0.025% sodium azide, 
pH 7.4) before incubating in a 1:200 dilution of primary antibody (anti-tau (R&D Systems, 
AF3494, 1:200) and MAO-B (Invitrogen, PIPA528338,1:200) in PBS-TBA overnight. Finally, 
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brain sections were washed 3 x 5 minutes in PBS-T to remove unbound antibody. Tissue sections 
were incubated in a 1:200 dilution of secondary antibody (anti-goat-IgG, Vector Laboratories 
BA-5000, anti-rabbit-IgG, Vector Laboratories BA-1000) in PBS-TBA for 2 hr and washed 3 x 5 
min with PBS-T. All incubations were carried out at room temperature. Slides were developed as 
instructed using the VECTASTAIN Elite ABC Kit (Standard) (Vector Laboratories PK-6100). 
Tissue sections were then washed 3 x 5 min in PBS-T before incubating for 4 min in a 0.5% w/v 
solution of diaminobenzidine in PBS-T (filtered) with 0.001% hydrogen peroxide. Giemsa 
counterstaining was utilized to visualize nucleus and cytoplasm in cells. Tissue sections were 
washed for 5 min in dH2O prior to overnight incubation in a 1:50 solution of Giemsa in dH2O. 
Slides were then rinsed for 30 sec in dH2O, 2 x 4 min in n-butanol, and 1 min in xylene. 
Permount was applied to the fixed tissue to attach coverslips to the polylysine-coated glass slides 
and allowed to set for 45 min prior to quantification. All incubations were carried out at room 
temperature. 
 Two tissue sections from each individual were used for each primary antibody and 
counted. Immunoreactivity was quantified using StereoInvestigator. A region was drawn around 
the entire tissue section and using the serial section manager, 5% of the section was counted and 
picked using a randomized rotation. Immunoreactivity is presented as cells/ µm2. Statistical 
analyses were performed in GraphPad Prism (8.01).  
Autoradiography 
 Off-target binding of [18F]AV-1451 on tissue was assessed by autoradiography in 
sections from the substantia nigra and cerebellum. Brain sections on slides were removed from -
80°C freezer and thawed at room temperature for 5 min before rehydration in phosphate buffer 
saline (PBS, pH 7.4) for another 5 min. Tissue sections were incubated with [18F]AV-1451 in the 
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presence or absence of the irreversible MAO-B inhibitor L-Deprenyl at two concentrations (500 
nM and in excess). All sections were washed 3 x 2 min with PBS at 4 °C and then rinsed in 
dH2O for 30 sec at 4 °C to remove unbound radioactivity. Finally, slides were dried under the 
continuous airflow for 30 min before exposure to a high-resolution phosphoimaging plate for 10 
minutes. The exposed plate was scanned using a GE Typhoon FLA 7000 phosphoimager. Image 
analysis was performed using ImageQuant (Molecular Dynamics) software. Regions of interest 
were drawn and converted to nmole specific molar activity. 
Primate Imaging. 
General Considerations.  
 All animal studies were performed in accordance with standards set by the University of 
Michigan Institutional Animal Care and Use Committee (IACUC). 
Primate imaging studies.  
 Imaging was done using mature female rhesus macaques (n=2, 4.673 ± 0.425 mCi, 
weight = 8.25 ± 0.15 kg). The monkey was anesthetized (isoflurane), intubated, and positioned in 
a Concorde MicroPET P4 scanner. Pharmacological intervention with the reversible inhibitors 
moclobemide (MAO-A selective, 1 mg/kg) or lazabemide (MAO-B selective, 0.5 mg/kg) was 
administered by infusion 10 minutes prior to tracer injection. Following a transmission scan, the 
animal was injected i.v with [18F]AV-1451 (4.673 ± 0.425 mCi, n=5) as a bolus over 1 min, and 
the brain imaged for 90 min (5 x 1 min frames – 2 x 2.5 min frames – 2 x 5 min frames – 7 x 10 
min frames).  
Image Analysis.  
 Emission data were corrected for attenuation and scatter, and reconstructed using the 3D 
maximum a priori method (3D MAP algorithm). Using a summed image of the entire data set, 
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3D volumes of interest (VOI) were determined by placing a seed voxel in the middle of various 
brain regions, and then using region- specific thresholds to automatically determine the extent of 
each VOI. VOIs were determine for the whole brain, striatum, thalamus, cortex, hippocampus, 
and cerebellum. Previous data sets in the same primate were used as reference determining 
specific VOIs ([11C]Flumazenil for cortex and cerebellum, [11C]DTBZ for striatum, 
[11C]Carfentenil for thalamus and hippocampus).  The VOIs were then applied to the full 
dynamic data sets to obtain the regional tissue time-radioactivity curves. Time activity curves 
were normalized between studies by the animal weight and amount of activity injected to result 
in percent injected dose per gram. 
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CHAPTER 3 
Trapped Metabolite PET Imaging of Monoamine Oxidase B 
 
 Monoamine oxidase (MAO) is a very well characterized enzyme in vitro and in vivo. We 
aimed to join the field of MAO PET imaging with a new approach, using substrates as opposed 
to using inhibitors. For much of this project, we focused on the prediction of in vivo kinetics 
based on in vitro enzyme kinetics.1  
1. Introduction 
Monoamine neurotransmitters of the classical type catecholamines (dopamine, 
epinephrine, and norepinephrine), indolamines (serotonin), and imidazoleamines (histamine), as 
well as trace amines (e.g phenethylamine and tyramine) have been a heavily studied family of 
small molecules due to their critical roles in the central nervous system (CNS). The metabolism 
of monoamines is key to their influence in various disease states. Monoamine oxidase is an 
outer-mitochondrial membrane bound, flavin-containing enzyme which oxidizes these substrates. 
There are two isozymes, A and B, which are encoded by independent genes and have structural 
differences (figure 3.1). These two enzymes have long been the target of drug development for 
an array of neurological and psychiatric diseases and disorders with numerous marketed 
compounds developed.2 This body of work has provided a varying type of starting points for the 
development of positron emission tomography (PET) imaging, ranging from irreversible and 
reversible inhibitors to substrates. Each approach has presented its own challenges and 
limitations as the radiochemistry community has endeavored to develop MAO PET imaging
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agents to better understand MAO pathophysiology to improve patient management and support 
drug development.  
 
Figure 3.1. MAO-B Structure. MAO-B acts in a homodimer, and has a short membrane-spanning domain. Structure 
shown with inhibitor deprenyl bound (yellow sticks). Reprinted with permission.3 
 
The first MAO ligands to be used as PET imaging agents in humans were 
propargylamines: [11C]clorgyline (3.1) and [11C]deprenyl (3.2), selective for MAO-A and –B 
respectively (figure 3.2). Fowler and coworkers demonstrated the rapid brain uptake in humans 
and confirmed the irreversibility by the plateau in the time activity curve (TAC).4 The 
distribution of radioactivity was highest in the corpus striatum, thalamus, and brainstem which 
paralleled respective MAO immunoreactivity on human brain tissue sections. These agents were 
confirmed as being MAO inhibitors through a blocking study with phenelzine, a non-selective 
MAO inhibitor. The analysis in human studies showed the agents were flow limited due, to a fast 
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rate of irreversible inhibition. Deuterated analogues were prepared to improve pharmacokinetic 
parameters and data analysis by slowing the rate trapping via the kinetic isotope effect (KIE). 
This approach worked well for the imaging of MAO-B by [11C]deprenyl-d2 ([
11C]DED);5 
however, [11C]clorgyline-d2 was limited by the high non-specific binding observed. Less of the 
imaging agent being trapped lead to a lower ratio in a region of interest relative to background 
non-specific binding. 
The deuterium KIE for deprenyl and deprenyl-d2 was measurable in vivo in the brain and 
peripheral organs. Fowler and coworkers illustrated this in a series of human studies involving 
smokers- because nicotine is a known MAO inhibitor, and they hypothesized that the effect of 
nicotine on the monoaminergic system could be evaluated with MAO-B PET imaging. In the 
brain, nicotine use in smokers resulted in lower overall MAO-B activity compared to a non-
smoker, yet higher activity than an individual with pharmacological intervention (figure 3.3).6 A 
similar effect was observed in the peripheral organs.7 When utilizing both [11C]deprenyl and 
[11C]DED, the deuterium kinetic isotope was able to be calculated in vivo, a confirmation to the 
assumed enzymatic mechanism. 
 
Figure 3.2. MAO Inhibitors and substrates for PET imaging. 
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Figure 3.3. [11C]Deprenyl human PET imaging comparing MAO-B activity in a non-smoker (top), smoker (middle), 
and pharmacologically blocked patient (bottom). Reprinted with permission.6 
 
 The irreversible inhibitors provided a strong foundation for PET imaging of monoamine 
oxidases with the mapping of expression and investigations into MAO-B’s role in disease. As 
previously mentioned, MAO-A imaging was not improved upon the development of 
[11C]clorgyline-d2.
8 [11C]Harmine (3.3), a reversible ligand, was utilized for further evaluation of 
MAO-A in the CNS.9-13 Although MAO-B expression is higher in the human brain, MAO-A has 
been recognized for its utility in treatment of psychiatric disorders.14 It was theorized that native 
levels of monoamine neurotransmitters were lower in subjects with major depressive disorder, 
explaining why inhibitors of monoamine transporters, receptors (SSRI’s, NSRI’s), and MAO-A 
itself (MAOI’s) are successful treatments. 
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 In 2006, a cohort of 17 subjects with depression received PET scans with [11C]harmine 
after a 5 month hiatus from treatment to eliminate possible pharmacological effects.15 The 
[11C]harmine scan included blood sampling and was fit using an unconstrained 2-compartment 
model with the goal being to determine individuals’ distribution volume  (MAO DV), or the ratio 
k3 and k4 (the radioligand transfer between free and nonspecific to the to specific binding 
compartment) normalized by flow (K1/ k2). The depressed subject cohort was compared to a 
control cohort of similar size and demographic with the overarching result being increased DV’s 
(34%) in all regions of interest examined. The most significant increase was observed in the 
prefrontal cortex, temporal cortex, posterior cingulate, and thalamus which strongly supports the 
original hypothesis of decreased monoamine neurotransmitters in depressed individuals. 
Although these results are significant, this trial is limited by distribution volume (DV) as a 
measure of MAO-A density because there is no differentiation between the free and nonspecific 
binding. The assumption, however, is that these parameters are not likely to be different between 
individuals. The ability to image psychiatric disorders and quantify physiological changes offers 
the potential to improve the understanding and treatment of the disorders, making the continued 
development and use of MAO PET imaging agent of interest. In similar study designs, 
[11C]harmine PET has been used to further investigate MAO-A’s influence on psychiatric and 
mood disorders and in the study of addiction.  
After the mapping of MAO-B in normal human brains of healthy control subjects, 
[11C]deprenyl-d2 ([
11C]DED) was used to investigate the monoaminergic system in various 
disorders, particularly neurodegeneration. It has long been recognized that monoamine oxidases 
play a role in the activation of astrocytes. In 1980, MAO-B was found to be overexpressed in 
brain sections of senile dementia patients compared to age-matched controls by 
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immunohistochemistry.16 Follow up studies determined the cells overexpressing MAO-B were 
astrocytes in only two neuronal areas: brainstem raphe and hypothalamus.17 Counterstaining with 
Congo red and Thioflavin S confirmed that these activated astrocytes were associated with senile 
plaques, later identified as amyloid plaques.18-20 Although MAO-B expression also increases in 
normal aging, it was identified as a possible marker for activated astrocytes that could be useful 
in PET imaging.  
Carter and coworkers performed a multitracer trial using [18F]fludeoxyglucose 
([18F]FDG, which images glucose metabolism), [11C]PiB, and [11C]DED PET imaging to 
investigate the differences between AD and MCI patients.21 Co-localization of MAO-B 
expressing astrocytes and amyloid plaques has been shown in human brain sections, indicating 
the possibility of MAO-B involvement in AD. Additionally, [11C]DED binding on human tissue 
was determined to be highest in the earlier Braak stages. This study design aimed to demonstrate 
that MAO-B PET imaging could be predictive of MCI before advanced AD in patients. Each 
subject, 7 AD, 8 MCI, and 14 age-matched controls, received three PET scans, without arterial 
blood sampling, using cerebellar gray as the reference region. The MCI cohort was divided into 
subgroups of [11C]PiB+ and [11C]PiB-. Increased [11C]DED binding in the frontal and parietal 
cortices were found in both PiB+ and PiB- MCI groups, as well as the AD cohort. Interestingly, 
[11C]DED binding appeared higher and widespread in the PiB+ MCI group. Despite the small 
cohort sizes, the authors argued that these results are evidence of astrocytosis in AD progression. 
Follow up studies in the same study design have been reported more recently in autosomal 
dominant AD patients from the same authors.22 
Clinical use of [11C]DED is limited because of its brain penetrant metabolite, 
[11C]methamphetamine, which can complicate analysis given its binding to alternate targets in 
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the same tissue (scheme 3.1). In general, the irreversible inhibitor approach in PET imaging has 
the major advantage in pharmacokinetic modeling over reversible ligands. Fitting to two 
compartment models is easier when the affinity of the ligand is very high, or irreversible. Having 
no washout after irreversible binding can simplify this interpretation.  However, irreversibility 
can be detrimental if one desires to perform multiple PET scans in the same individual. Fowler 
and coworkers demonstrated that it takes approximately one month in healthy individuals to turn 
over and re-express MAO-B, as visualized by [11C]DED.5 If multiple scans are necessary in the 
same individual, irreversible inhibitors may be inappropriate for a study design.  
 
Scheme 3.1. Metabolism of [11C]deprenyl into [11C]methamphetamine. 
 
 Reversible inhibitors for MAO-B PET imaging have also been developed, in an effort to 
avoid interpreting the brain penetrating metabolite of [11C]DED. [11C]SL25.1188 (3.4), a 
selective inhibitor for MAO-B was originally reported by Saba and coworkers.23 However, its 
synthesis required the use of [11C]phosgene ([11C]COCl2) which is not a radiochemical technique 
commonly available in a radiochemistry lab or desirable given the toxic properties of phosgene.  
The Vasdev laboratory in Toronto optimized this synthesis using [11C]fixation using CO2 
produced in the cyclotron target directly and further advanced this tracer for human use.24 This 
preliminary human evaluation demonstrated high maximum standard uptake value (SUVNB) and 
relatively high regional uptake values (~6) in comparison to [11C]DED, though this is likely also 
owed to the increased blood-brain barrier permeability of the radioligand.  Regional uptake 
corresponds to regional concentrations of MAO-B as measured by immunoblot as expected. 
These experiments fit well in a two compartment model and were reproducible; future studies 
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will explore different patient populations. Selectivity studies in human populations also need to 
be performed. Reversible inhibitors, such as [11C]SL25.1188 and [11C]harmine are objectively 
more challenging to clinically translate compared to irreversible inhibitors. In order to not be 
flow-limited, reversible inhibitors must have very high affinities to their target. And despite this, 
both irreversible and reversible inhibitors have a limited signal capability by having a limited 1:1 
relationship with the target enzyme. Conversely, substrates do not inhibit the enzyme and 
theoretically have an increased signal potential.  
 As an alternate to inhibition, we have investigated the use of selective MAO substrates to 
form trapped metabolites for imaging MAO enzymatic activity. Imaging of enzyme substrates is 
analogous to imaging with transporter substrates as the analysis of transporter kinetics is the 
same as utilized for enzyme turnover with the Vmax, KM, and Kcat of interest; this differs from 
radioligands where the Kd (or in the case of competitive binding KI) values are of interest. In this 
approach an MAO substrate with good brain uptake and efflux will form a product 
(radiometabolite) when it is oxidized by MAO. The development of a radiotracer substrate is an 
approach that has been used successfully and most famously in the development of 
fludeoxyglucose, which is a glucose transport substrate that is subsequently trapped in the tissue 
through phosphorylation by hexokinase. 
 The substrates for MAO were based on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP). In the 1980s, MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) was determined as 
a contaminant in the illicit synthesis of the synthetic opiate desmethylprodine (MPPP), resulting 
in symptoms of Parkinson’s disease in drug users.25-29 It was subsequently shown that MPTP is a 
substrate and inhibitor of MAO-B, producing dopaminergic cell death via the toxic metabolite 1-
methyl-4-phenylpyridinium (MPP+).30 The MAO oxidation of MPTP and other 
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tetrahydropyridines has been extensively studied, as has the mechanism of cellular toxicity of 
MPP+, and MPTP remains a valuable tool in Parkinson’s disease research.  In the 1990’s the 
Castagnoli lab developed an analogue of MPTP that contained an ether linkage between the 
tetrahydropyridine and a second arene. These substrates, instead of forming MPP+ (or a related 
toxic metabolite), are hydrolyzed to two benign metabolites. A series of these radiotracers have 
been prepared and investigated for selectivity and suitability for human translation, including 
[11C]4-methyl-7-(pyridin-4-yloxy)-2H-chromen-2-one ([11C]Cou; 3.5). 
 Although PET imaging with irreversible inhibitors of monoamine oxidases A and B has 
provided an abundance of information regarding the biology of the human brain, there remains a 
limitation. Irreversible inhibitors by nature are restricted to a 1:1 stoichiometry with their target 
enzyme. Substrates, however, do not deactivate the enzyme and potentially allow that reaction 
stoichiometry to increase. It is with this approach in mind, we have aimed to develop substrates 
for monoamine oxidases to monitor their activities in vivo. Trapped metabolite imaging has a 
long history of success in PET, particularly with FDG.  In vivo PET studies in rhesus macaque 
brain using [11C]Cou demonstrated that the metabolite formed by MAO-B oxidation and 
subsequent hydrolysis (figure 3.4A) was rapidly and efficiently trapped in the brain, which could 
be blocked by pretreatment with the reversible MAO-B inhibitor lazabemide.31   
 Although successful as an in vivo metabolic trapping substrate, the pharmacokinetics of 
[11C]Cou were suboptimal, as the rapid trapping rate made it difficult to discriminate between 
regions of high and low MAO enzymatic activity (figure 3.4B).  
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Figure 3.4 In vivo trapping of [11C]Cou. A). Cartoon model of the substrate passively diffusing across the cellular 
membrane and subsequently being oxidized by MAO. B) Time activity curve of [11C]Cou in nonhuman primate 
brain. C) Simplified kinetic model of radiotracer’s behavior in vivo. Diffusing in and out of the brain corresponds to 
k1 and k2 respectively, the ratio equal to K1. Trapping in the target cell is k3, and there should be no k4 if 100% 
trapping occurs 
 
That limitation is similar to what was observed for the irreversibly-binding MAO-B radiotracer 
[11C]deprenyl, where the in vivo pharmacokinetics were slowed and sensitivity improved using 
the kinetic isotope effect induced by deuterium atoms at the location critical for the rate-
determining oxidation step.5 As kinetic isotope effect experiments using deuterium substitutions 
on the tetrahydropyridine ring have demonstrated that the hydrogen abstraction step is also rate 
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limiting in the MAO-B mediated oxidation of MPTP,32 we have attempted to apply this concept 
to improve the in vivo pharmacokinetics of [11C]Cou (figure 3.5). In this chapter, we report here 
the synthesis of two deuterated derivatives of [11C]Cou and a comparison of their in vitro 
kinetics and in vivo brain pharmacokinetics.  
 
Figure 3.5. MAO catalyzed oxidation and subsequent hydrolysis of Cou substrate. The 4-aryloxytetrahydropyridine 
substrate [11C]Cou is oxidized by monoamine oxidase to form an iminium intermediate, which is rapidly hydrolyzed 
to yield a polar carbon-11 species and a fluorescent coumarin as metabolites. Red circle around the alpha carbon to 
the amine. 
 
2. Results 
Chemistry  
 The synthesis of Cou-d3 is shown in Scheme 3.2A: 1-Methyl-4-((4-methyl-2-oxo-2H-
chromen-7-yl)oxy)pyridin-1-ium (3.6) was prepared by reacting 4-chloro-N-methyl-pyridinium 
with 4-methylumbeliferone in a solution of sodium methoxide in DMF. Reduction of the 
pyridinium with sodium borodeuteride in deuterated methanol yielded Cou-d3 (3.7). The carbon-
11 radiolabeling was done using N-[11C]methylation of the pyridine (3.8) in ethanol-d6, followed 
by addition of sodium borodeuteride to form carbon-11 labeled product 3.7b as previously 
described (Scheme 3.2B).31  
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Scheme 3.2. Synthesis and Radiochemical synthesis of Cou-d3 and [11C]Cou-d3. All carbon-11 syntheses were 
performed with Dr. Xia Shao and Dr. Allen Brooks.  
 
 The synthesis of Cou-d7 is described in Scheme 3.3A: Iodocoumarin (3.9) was prepared 
via Pechmann condensation by treating 3-iodophenol with ethyl acetoacetate in an acidic 
solution. Reaction of 3.9 with p-toluenesulfonic acid and mCPBA in dichloromethane gave the 
iodonium salt (3.10), which was converted to the 4-methoxyphenyl substituted iodonium salt 
(3.11). A subsequent substitution reaction with 4-phenol-d5 yielded the pyridine Cou-d7 
precursor (3.12). N-Methylation and reduction of the resulting pyridinium with sodium 
borodeuteride in deuterated methanol yielded Cou-d7 (3.14).  The carbon-11 radiolabeling was 
conducted as previously described using 3.12 as a precursor (Scheme 3.3B) by alkylation with 
[11C]methyl triflate followed by addition of sodium borodeuteride to form carbon-11 labeled 
product 3.14b as previously described.31  
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Scheme 3.3. Synthesis and Radiochemical synthesis of Cou-d7 and [11C]Cou-d7. Cou-d7 standard was synthesized by 
Tony Mufarreh and Allen Brooks. All carbon-11 syntheses were performed with Dr. Xia Shao and Dr. Allen 
Brooks. 
 
Biology  
 In vitro kinetic parameters were determined by incubation of substrates (Cou, Cou-d3, 
and Cou-d7) with human MAO-B Supersomes and monitoring the appearance of the fluorescent 
coumarin product (ex: 360/ em: 460 nm) released after oxidation and hydrolysis. Supersomes 
were chosen instead of purified hMAO-B protein because of the increased activity. Supersomes 
are commercially available mitochondrial membrane preparations from insect cells 
overexpressing human MAO-B. During assay development, purified hMAO-B was used and the 
activity was very poor. Supersome assay conditions were optimized based on literature 
precedent. PBS, Tris-HCl, HEPES, and borate buffers were screened for maximal activity. 
Kynuramine, an established MAO substrate, was used for optimization. Using the Cou substrate, 
buffers were additionally screened for solubility and maximum fluorescence signal. Borate 
buffer was chosen for these properties. All three substrates displayed well-behaved Michaelis-
Menten kinetics (figure 3.6). There were no significant observed kinetic isotope effects based on 
the turnover (Vmax) or enzymatic efficiency (Vmax/KM) (Table 3.1). 
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Figure 3.6. In vitro kinetics for Cou and deuterium-substituted substrates. The velocity of fluorescent product 
appearance was plotted against concentration of substrates. Michaelis-Menten Kinetic parameters were calculated in 
GraphPad Prism (n= 6) and are displayed in table 3.1.  
 
Table 3.1. Michaelis-Menten Kinetic parameters for Cou and deuterium-substituted substrates. 
 Cou Cou-d3 Cou-d7 
KM (uM) 1.35 ± 0.12 1.55 ± 0.12 1.56 ± 0.15 
Vmax (nM/min) 21.1 ± 0.56 20.5 ± 0.48 19.9 ± 0.65 
Vmax/KM 15.63 ± 1.44 13.23 ± 1.08 12.75 ±1.51 
D(Vmax ) --- 1.03 ± 0.036 1.06 ± 0.045 
D(Vmax/KM) --- 1.18 ± 0.15 1.23 ± 0.16 
 
 The in vivo pharmacokinetics of the three MAO-B substrates were evaluated in rhesus 
monkey brain using PET imaging. The brain uptake and distribution of these MAO-B substrates 
were imaged in an adult female rhesus macaque (n=2 per substrate). Radiolabeled compounds 
were injected intravenously and the regional brain distributions of radioactivity were determined 
using dynamic microPET imaging (figure 3.7). Tissue time-radioactivity curves were generated 
for cerebellum, basal ganglia, and cortex (figure 3.8) and showed no significant changes in the 
shapes of the curves in any brain region for either of the deuterated substrates (figure 3.8)  
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Figure 3.7. PET imaging of [11C] Cou, [11C]Cou-d3, and [11C]Cou-d7 in the rhesus monkey brain.  
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Figure 3.8. Regional tissue time-radioactivity curves for PET imaging of [11C] Cou, [11C]Cou-d3, and [11C]Cou-d7 in 
the rhesus monkey brain.  
 
3. Discussion 
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 Kinetic isotope effects have been clearly demonstrated for a number of amine substrates 
of the monoamine oxidases, leading to the conclusion that the abstraction of an allylic hydrogen 
at the position alpha to the nitrogen is the rate limiting step.32-35 This has been exploited in the 
design of PET imaging agents for monoamine oxidases, where incorporation of deuterium has 
been used to slow down the rate of irreversible trapping of [11C]deprenyl, resulting in improved 
in vivo pharmacokinetics in animals and humans.5 In vitro kinetic isotope effects have also been 
demonstrated for MAO oxidation of MPTP and related analogues, 32-33 prompting our 
expectation that deuterium substitution could be employed to modify the in vivo 
pharmacokinetics of our newly developed MAO substrate, [11C]Cou. It was therefore surprising 
that our in vitro assays of MAO-B activity showed no isotope effect for deuterium substitution of 
Cou (Table 3.1); in comparison, kinetic isotope effect values for MAO oxidation of MPTP-6,6-d2 
to the corresponding 1-methyl-4-phenyl-2,3-dihydropyridinium species were 3.55 (Vmax) and 
8.01 (Vmax/ Km).
32  
 The in vivo studies in primate brain for [11C]Cou-d3 and [
11C]Cou-d7 were also consistent 
with the lack of a deuterium substitution effect because the pharmacokinetic curves for 
radiotracer trapping were similar for all three substrates, showing a rapid uptake to a plateau with 
very little washout of radioactivity, consistent with irreversible trapping. This is markedly 
different than the effect seen for [11C]deprenyl-d2, where incorporation of deuterium resulted in a 
significant egress of radioactivity after peak uptake and a lower plateau level of trapped 
radioactivity, and thus very different shapes for the brain time-radioactivity curves.5  
 Based on the mechanism of MAO-mediated oxidation of amines, and the known effect of 
deuterium substitution on MPTP oxidation kinetics, it is reasonable to assume the oxidation of 
[11C]Cou should also proceed via abstraction of the allylic C-6 proton alpha to the ring nitrogen 
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(figure 3.8). The lack of a kinetic isotope effect both in vitro and in vivo suggest that the proton 
abstraction step was not rate limiting. A possible explanation lies in the observation that our 
studies actually detect the final metabolites, the radioactive N-[11C]-methylpyridinone (in vivo 
PET) or the fluorescent coumarin (in vitro assays; figure 3.5) that form after a second step of 
hydrolysis of the intermediate 1-methyl-4-phenoxy-2,3-dihydropyridinium species (in contrast, 
the in vitro kinetic studies of deuterated MPTP measured the dihydropyridinium species). Thus, 
it is possible that the hydrolysis step was partially rate limiting and obscuring any effect from the 
deuterium substitution, an example of a masked kinetic isotope effect.34 
 The enzymatic mechanism of MAO has been investigated thoroughly; however, the mode 
of C-H bond breakage is not entirely agreed upon. The two main mechanistic theories involve 
either hydrogen abstraction or hydride transfer, which differ in their respective intermediates, but 
both claim that this step is rate limiting. Silverman and coworkers spent the better part of two 
decades gathering evidence against a possible radical mechanism and for the hydrogen 
abstraction mechanism.36-39 Investigating inhibitors of the enzyme supported the presence of a 
covalently bound intermediate to the FAD cofactor, indicating a hydrogen atom transfer. This 
mechanism was further strengthened by crystallographic evidence of the covalently bound 
inhibitor, deprenyl, in 2002.3  The Edmondson,40-41 Castagnoli,32-33, 42-45 and Heikkila27-28, 46-48 
groups also greatly contributed to the investigation into the MAO mechanism. Similar to 
Silverman’s kinetic experiments, all of these groups were able to demonstrate primary kinetic 
isotope effects upon deuterium substitution at the carbon alpha to the monoamine (figure 3.4, red 
circle). Regardless of the identity of the C-H bond breakage, hydride or hydrogen atom, there is 
evidence for this to be 1) rate limiting and 2) highly sensitive to isotopic exchange.25-26, 32, 40-41, 43 
Our results at face value would indicate that with our substrate, it is not rate limiting. However, 
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masking effects of complex enzymatic mechanisms have been observed in similar 
oxidoreductase enzymes, though not documented in MAO-B itself.34 Masking is the 
phenomenon in which non-rate limiting steps are insensitive to isotope changes. In a complex 
enzymatic mechanism such as MAO-B (figure 3.8), there are reversible steps before and after the 
rate limiting step. The first reversible step, association of the substrate to the enzyme and FAD in 
its oxidized state (k1 and k2), is isotopically insensitive. This can be assumed from the lack of 
binding isotope effect, or the change in Michaelis-Menten constant (Km; table 3.1). The rate 
limiting step (k3) is irreversible and followed by either re-oxidation of the FAD cofactor 
(irreversible, k4) or release of the imine product (reversible, k4’ and k5’) and then followed by 
hydrolysis. In both instances, it is likely that these steps are isotopically insensitive based on the 
experimentally obtained turnover rates (Vmax; table 3.1). In previously mentioned kinetic studies, 
the assays detected the immediate imine product formation, not the fully hydrolyzed final 
product. It is feasible then, that these additional steps are masking the primary kinetic isotope 
effect expected through deuterium substitution. It also possible that the oxidation step undergoes 
a different mechanism than the polar nuclear mechanism (figure 3.8). Although it is more likely 
that the deuterium kinetic isotope effect is masked in this substrate. Deprenyl, being an 
irreversibly inhibitor, does not proceed through the entire enzymatic mechanism. The deuterium 
KIE observed in deprenyl-d2 could be visible because it does not include k4, k5, and k6.  
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Figure 3.9. Proposed monoamine oxidase mechanisms.  
 
4. Conclusion  
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 The objective of this study was to utilize deuterium substitution to alter the in vivo 
pharmacokinetics of [11C]Cou, a metabolically-trapped PET imaging agent for MAO-B that 
shows rapid and essentially irreversible retention in the primate brain. From a compartmental 
modeling perspective, the goal was to reduce the rate of trapping (k3) such that a portion of the 
radiotracer taken up into the brain would flow back out (k2): this was exactly what had been 
achieved with deuteration of the irreversible radioligand [11C]deprenyl.5 Unfortunately, 
deuterium substitution of [11C]Cou failed to produce any significant change of in vitro kinetics or 
in vivo pharmacokinetics. Future efforts to improve the in vivo behavior of metabolically-trapped 
MAO substrates for PET imaging will likely require further exploration of alternative 4-aryloxy 
substituents.49  
 
5. Methods  
Biology. 
 Michaelis-Menten kinetic parameters were determined using human MAO-A and –B 
Supersomes (Corning Gentest) at a concentration of 80 µg/ml. Fresh stocks of substrate (Cou, 
Cou-d3, or Cou-d7) were dissolved in DMSO to give a 10 mM stock and subsequently diluted in 
100 mM borate buffer (pH 8.4) to various concentrations ranging from 200 µM to 1 nM. 
Reaction progress was measured by appearance of fluorescent product, 7-hydroxy-4-methyl-
coumarin. Reactions were monitored in real time using a Biotek Hybrid plate reader (excitation 
360 nm, emission 460 nm) at 37 °C; reactions progressed for 60 minutes and fluorescent reads 
were measured every 5 minutes. The resultant fluorescence units were converted to 
concentration of product using a reference standard curve. Michaelis-Menten curves were plotted 
and parameters computed in GraphPad Prism (version 7.03). Assays were done in duplicate, in 
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six independent experiments using fresh stock of enzyme, test compound, and reference 
standard. Outliers which met the Grubb’s test were removed.  
Radiochemistry. 
General Considerations 
  Reagents and solvents were commercially available and used without further 
purification, unless otherwise noted. Sodium chloride (0.9% USP) and sterile water for injection 
(USP) were purchased from Hospira; dehydrated alcohol for injection (USP) was obtained from 
Akorn Inc. Shimalite-Nickle was purchased from Shimadzu, iodine was obtained from EMD, 
phosphorous pentoxide was acquired from Fluka, molecular sieves were purchased from Alltech, 
and HPLC columns were acquired from Phenomenox. Other synthesis components were 
obtained as follows: sterile filters were purchased from Millipore, C18-light Sep-Paks and 
Porapak Q were purchased from Waters Corporation, and 10 cc sterile vials were obtained from 
HollisterStier. Sep-paks were flushed with 10 mL of ethanol followed by 10 mL of sterile water 
prior to use. 
General Procedure for Radiochemical Synthesis. 
 Production of carbon-11-labeled radiotracers was carried out using a Tracerlab FXC-Pro 
automated radiochemistry synthesis module (General Electric, GE). [11C]Carbon dioxide was 
produced using a GE PETTrace cyclotron (40 µA beam for 20 min) and converted by standard 
procedures into carbon-11-labeled methyl triflate ([11C]CH3OTf). The [
11C]CH3OTf in helium 
carrier gas was bubbled into a vial containing a solution of precursor (1 mg) dissolved in ethanol 
or ethanol-d6 (0.2 mL). At the completion of transfer of radioactivity into the reaction vial, the 
ethanol solution was then transferred to a second conical vial containing sodium borohydride or 
sodium borodeuteride (2 mg) in ethanol or ethanol-d6 (0.2 mL). The resulting mixture was stirred 
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for 5 min at room temperature, and then the reaction was quenched by addition of HPLC buffer. 
The crude product was loaded onto semipreparative HPLC loop. The product was purified by 
reverse-phase chromatography (Prodigy ODS prep, 250 x 10 mm, 10 µ, 4 mL/min, eluted with 
30% CH3CN, 70% H2O 10 mM NH4OAc) collected, diluted into H2O (40 mL), and reformulated 
using a C-18 extraction disk into a final 5 mL total volume of 10% ethanol in saline. The doses 
were assessed via standard quality control techniques and were appropriate for nonhuman 
primate studies. Overall synthesis times were 30 min from end-of-bombardment. Radiochemical 
yields were not optimized and are reported uncorrected for radioactive decay. Molar specific 
activity greater than 7000 Ci/mmol. 
Primate Imaging. 
General Considerations. 
 All animal studies were performed in accordance with standards set by the University of 
Michigan Institutional Animal Care and Use Committee (IACUC). 
Primate imaging studies. 
 Imaging was done using a mature female rhesus macaque (n=6, weight= 8 ± 1 kg) over 
36 months. The monkey was anesthetized (isoflurane), intubated, and positioned in a Concorde 
MicroPET P4 scanner. Following a transmission scan, the animal was injected i.v with 
[11C]COU (4.7 ± 0.2 mCi, n=2), [11C]COU-d3 (4.8 ±  0.4 mCi, n=2), or [
11C]Cou-d7 (0.86 ±  0.7 
mCi, n=2), as a bolus over 1 min, and the brain imaged for 90 min (5 x 1 min frames – 2 x 2.5 
min frames – 2 x 5 min frames – 7 x 10 min frames). 
Image Analysis. 
 Emission data were corrected for attenuation and scatter, and reconstructed using the 3D 
maximum a priori method (3D MAP algorithm). Using a summed image of the entire data set, 
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3D volumes of interest (VOI) were determined by placing a seed voxel in the middle of various 
brain regions, and then using region- specific thresholds to automatically determine the extent of 
each VOI. VOIs were determine for the whole brain, striatum, thalamus, cortex, hippocampus, 
and cerebellum. Previous data sets in the same primate were used as reference determining 
specific VOIs ([11C]Flumazenil for cortex and cerebellum, [11C]DTBZ for striatum, 
[11C]Carfentenil for thalamus and hippocampus).  The VOIs were then applied to the full 
dynamic data sets to obtain the regional tissue time-radioactivity curves. Time activity curves 
were normalized between studies by the animal weight and amount of activity injected to result 
in percent injected dose per gram. 
Chemistry. 
General Considerations. 
 All solvents and reagents were commercially available and used without further 
purification unless otherwise stated. 7-Methylumbeliferone was obtained from Sigma-Aldrich. 
NMR spectra were recorded with a Varian 400 MHz instrument at room temperature with 
tetramethylsilane (TMS) as an internal standard. Mass spectra were performed on a Micromass 
LCT time-of-flight mass spectrometer or an Agilent Q-TOF HPLC-MS employing the 
electrospray ioinization (ESI) method. High-performance liquid chromatography (HPLC) was 
performed using a Shimadzu LC-2010A HT system equipped with a Bioscan B-FC-1000 
radiation detector. 
4-methyl-7-((1-methyl-1,2,3,6-tetrahydropyridin-4-yl-2,3,6-d3)oxy)-2H-chromen-2-one (3.7): 4-
Methylumbeliferone (0.72 mmol) was added to sodium methoxide (0.87 mmol) dissolved in 
DMF (3 mL) and the mixture stirred for 10 min. 4-Chloro-1-methylpyridin-1-ium triflate (0.73 
mmol) was added, and the reaction was stirred for 18 h. The solvent was removed in vacuo, and 
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the resulting intermediate was suspending in methanol-d4 (3 mL). The reaction mixture was 
cooled to 0°C in a water ice bath, and sodium borodeuteride (2.9 mmol) was added slowly. After 
1 h, the solvent was removed in vacuo. Water and ethyl acetate were added to the residue, and 
the mixture was transferred to a separatory funnel. The product was extracted with ethyl acetate 
(3x), dried over sodium sulfate, filtered, and concentrated in vacuo. The product was purified by 
flash silica gel chromatography (dichloromethane, methanol gradient) and collected as a white 
solid in 36% yield. Rf: 0.34 (SiO2, 1:9 methanol: dichloromethane); 1H NMR (500 MHz; 
CD3OD3)/δ (ppm): 7.75 (1H, d, J = 10), 7.05 (1H, dd, J = 10, 5), 7.00 (1H, s), 6.22 (1H, s), 5.22 
(1H, s), 3.07 (1H, d, J=10), 2.73 (1H, d, J= 5), 2.37 (3H,s), 2.36 (3H, s), 2.30 (1H,d, J=5); . 2H 
NMR (61.402 MHz; CD3OD / δ (ppm): 3.06 (1D, s), 2.73 (1D, s), 2.36 (1D, s), 2.33 (1D, s); 
HRMS: calculated for [M]+ (M =C16H14D3NO3), 275.1470, found 275.1469. 
7-iodo-4-methyl-2H-chromen-2-one (3.9): A mixture of 3-iodophenol (4.3 g, 38.4 mmol) and 
ethyl acetoacetate (5.0 g, 38.4 mmol) were cooled to 0 °C. Sulfuric acid (12 ml, 38 mmol) was 
added dropwise, and the mixture stirred for 20 h at 40 °C. The resulting solution was slowly 
poured into a water-ice water mixture (200 ml); the resulting precipitate was collected by 
filtration, dissolved in DCM, and dried over sodium sulfate. The product was collected as a 
(green) solid in 10% yield. Rf: 0.425 (SiO2, 2:1=hexane:ethyl acetate); 
1H NMR (400 MHz; 
CDCl3)/δ (ppm): 7.75 (1H, d, J = 1.65), 7.72 (1H, dd, J = 8.33, 1.65), 7.52 (1H, d, J = 8.33), 6.36 
(1H, q, J= 1.22), 2.45 (3H, d, J = 1.22); HRMS: calculated for [M]+(M = C10H7IO2), 286.9490, 
found 286.9560.  
Hydroxy(4-methyl-2-oxo-2H-chromen-7-yl)iodonium 4-methylbenzenesulfonate (3.10): In a 
flame dried flask, a mixture of 7-iodo-4-methyl-2H-chromen-2-one [3.9] (0.2 g, 0.7 mmol), 
meta-chloroperbenzoic acid (mCPBa) (0.12 g, 0.7 mmol) and p-toluenesulfonic acid 
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monohydrate (TsOH•H2O) (0.13 g, 0.7 mmol) were dissolved in dichloromethane (2 mL) and 
stirred for 2 hours under Argon. The solution was quenched with diethyl ether (2 ml), and the 
resulting precipitate was collected by filtration and dried in vacuo. The product was collected as 
a (yellow) solid in 73% yield. 1H NMR (400 MHz; C2D6OS/ δ (ppm): 8.28 (1H, d, J = 1.69), 
8.11 (1H, dd, 8.48, 1.69), 7.95 (1H, d, J = 8.48), 7.82 (1H, d, J = 1.63), 7.71 (1H, dd, J = 8.30, 
1.63), 7.51 (1H, d, J = 8.30), 7.1 (1H, d, J = 8.48), 6.58 (1H, d, J = 1.22), 6.43 (1H, q, J = 1.20), 
2.40 (3H, d, J = 1.20), 2.45 (3H, d, J = 1.22). 
(4-methoxyphenyl)(4-methyl-2-oxo-2H-chromen-7-yl)iodonium 4-methylbenzenesulfonate (3.11): 
Hydroxy(4-methyl-2-oxo-2H-chromen-7-yl)iodoium 4-methylbenzenesulfonate [3.10] (0.26 g, 
0.86 mmol) and anisole (0.23 g, 2.15 mmol) were dissolved in chloroform (7 ml) and stirred 
overnight at room temperature (25 °C). The solvent was removed in vacuo; the resulting 
precipitate was washed with diethyl ether. The solution was dried in vacuo, and the product was 
collected as a (yellow) solid in 76% yield. 1H NMR (400 MHz; DMSO-d6/ δ (ppm): 8.33 (1H, d, 
J = 1.68), 8.19 (2H, d, J = 8.58), 8.08 (1H, dd, J = 8.19, 1.68), 7.83 (1H, d, J = 8.19), 7.43 (2H, d, 
J = 8.58), 6.51 (1H, q, J = 1.23), 3.76 (3H, s), 2.38 (3H, d, J = 1.23); HRMS: calculated for 
[M]+(M = C17H14IO3+), 392.998, found 392.9982.   
4-methyl-7-(pyridine-4-yl-d4)oxy)-2H-chromen-2-one (3.12): In a flame dried flask, a mixture of 
4-hydroxypyridine-d5 (0.054 g, 0.51 mmol) and potassium carbonate (0.14 g, 1.02 mmol) were 
dissolved in acetonitrile (3 ml) and stirred for 5 min at room temperature (25 °C). (4-
methoxyphenyl)(4-methyl-2-oxo-2H-chromen-7-yl)iodonium 4-methylbenzenesulfonate [3.11] 
(0.20 g, 0.51 mmol) was added and the mixture stirred overnight at 50 °C. The solution was 
quenched with H2O, extracted with DCM, and dried over Na2SO4. Product was purified by silica 
gel flash chromatography eluted with Hexane: Ethyl Acetate gradient mobile phase. The product 
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was collected as a (red) solid in 38% yield. Rf: 0.268 (SiO2, Ethyl Acetate); 
1H NMR (400 M 
Hz; CDCl3)/δ (ppm): 7.64 (1H, d, J = 6.19), 7.04 (1H, dd, J = 6.19, 2.28), 7.02 (1H, d, J = 2.28), 
6.27 (1H, q, J = 1.06), 2.42 (3H, d, J = 1.06); HRMS: calculated for [M]+(M = C15H7D4NO3), 
258.0990, found 258.1065.  
4-methyl-7-((1-methyl-1,2,3,6-tetrahydrophyridin-4-yl-2,2,3,3,5,6,6-d7)oxy)-2H-chromen-2one 
(3.14): In a flame dried flask, a mixture of 4-methyl-7-(pyridine-4-yl-d4)oxy)-2H-chromen-2-one 
[3.12] (0.077 g, 0.3 mmol) was dissolved in 1,2–dichloroethene (3ml). Methyl 
Trifluoromethansulfonate (2 ml) was added to reaction mixture slowly, solution stirred for 1 hour 
at 60 °C. Mixture washed with diethyl ether, precipitate (white) was collected by filtration, 
resulting in intermediate 1-methy-4-((4-methyl-2-oxo-2H-chromen-7-yl)pyridine-1-ium-2,3,5,6-
d4 [3.13]. Intermediate re-suspended in methanol-d4 (3 ml), cooled to 0
 °C, then sodium 
borodeuteride (0.031 g, 0.74 mmol) added slowly. Mixture stirred for 1 hour at room temperature 
(25 °C). Solution quenched with H2O and extracted in ethyl acetate and purified by column 
chromatography (dichloromethane: methanol mobile phase).  The product was collected as a 
(yellow) solid in 37% yield. Rf: 0.233 (SiO2, 9:1=dichloromethane: ethyl acetate); 
1H NMR (400 
MHz; CDCl3)/δ (ppm): 7.50 (1H, d, J = 8.35), 6.97 (1H, m), 6.95 (1H, d, J = 2.25), 6.16 (1H, s), 
2.39 (3H, s). 2H NMR (61.402 MHz; CHCl3/ δ (ppm): 5.20 (1D, s), 3.01 (2D, s), 2.66 (2D, s), 
2.33 (2D, s); HRMS: calculated for [M]+(M = C16H10D7NO3), 279.1721, found 279.1722. 
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CHAPTER 4 
Monoamine Oxidase: Dual PET-MR Imaging 
 
 The development of a PET/ magnetic resonance spectroscopy (MRS) hybrid imaging 
agent would allow for functional imaging by both methods with a single agent. Enzyme 
substrates that form metabolites for detection present an interesting opportunity as two unique 
metabolites can be generated, one for each modality. In addition, we hypothesize that at the 
concentrations obtained in vivo substrates should not inhibit uptake or enzymatic reaction; thus, 
they can overcome the challenge of the high concentration required for MRS while providing 
sufficient radioactivity for PET imaging at the resulting low molar activity. Here we investigate 
the possibility of imaging a MAO substrate that upon enzymatic reaction produces two 
metabolites: one for detection by PET and the other MRS.1 
1. Introduction 
 Positron emission tomography (PET) imaging is a non-invasive molecular imaging 
method that has been utilized for decades to provide functional information based on the PET 
radioisotope (β+ decay) labelled molecule used.2-3 Functional imaging is often paired with a 
form of structural imaging (computed tomography (CT), magnetic resonance (MR), etc). The 
combination of structural and functional imaging allows for an improved analysis of PET 
imaging data. Most PET scanners for clinical use include a CT scanner for this purpose. 
Recently, PET-MR scanners have been developed and allow for improved resolution over PET-
CT. 
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 MR imaging utilizes the nuclear magnetic resonance phenomenon in which nuclei in a 
strong magnetic field are perturbed by a weak oscillating magnetic field, producing an 
electromagnetic signal. Radio frequency (RF) pulses are used to excite the nuclear spin energy 
transition; the relaxation process, or returning to equilibrium after the excited state, is measured 
and offers different contrast.4 Variation in RF pulses applied and collected allows for different 
types of images. Two variables that can be altered are repetition time (TR), the amount of time 
between pulse sequences applied to the same slice, and time to echo (TE), the time between the 
RF pulse delivered and the receipt of the echo signal.4 Two common MRI sequences are T1-
weighted and T2-weighted. T1-weighted images are produced by short TE and TR times; 
conversely T2 weighted images use longer TE and TR properties.5 T1-weighted imaging can also 
be performed with the contrast agent galadinium.6  
 Typically, it is thought that high molar activity, the amount of radioactive isotope relative 
to non-radioactive isotopes defined by the amount of radioactivity for the moles of the molecule, 
is required for PET imaging (>1,000 Ci/mmol). Therefore, it is commonly thought to be 
incompatible with the higher concentrations of imaging agents required for alternate functional 
imaging methods like magnetic resonance spectroscopy (MRS).7 For imaging with ligands, 
agents that bind to a target protein such as the antagonist [11C]raclopride for the D2 dopamine 
receptor, this has been demonstrated by studies of PET imaging/autoradiography with the 
radioligand at decreasing molar activities, demonstrating loss in signal as expected from the 
Scatchard equation.8 Given the recent development of PET/MR imaging instruments it could be 
possible to not only combine the functional data from PET imaging with the 
morphological/structural data from magnetic resonance (MR) imaging but also functional MRS 
imaging data, provided a molecular imaging agent could be developed to provide PET and MRS 
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data. This would require a PET imaging agent that can provide data at the high concentration 
required for MRS imaging and the resulting low molar activity known to be problematic for 
radioligands. 
 We hypothesized that trapped metabolite imaging agents such as the monoamine oxidase 
(MAO) substrates developed by our laboratory9 can provide PET imaging data at high 
concentration/low molar activity required for MRS. Since these enzyme substrates should not 
exhibit substrate inhibition in vivo they could provide PET data at low molar activity. To provide 
more evidence for this hypothesis, we evaluated the acetylcholine esterase (AchE) substrate 1-
methylpiperidin-4-yl propionate (PMP) as well. AchE is an enzyme that catalyzes the hydrolysis 
of the neurotransmitter acetylcholine, and is thought to be one of the fastest enzymes.10 It was 
chosen to show that if the enzyme is not saturated by the necessary MR concentration, the PET 
time activity curve shape will not change.  
 
Figure 4.1 Design of PET/MR hybrid probe. Structure based on previous work developing a PET/Fluorescence 
probe and a related report on a chemical shift-switching MR probe, resulting in PET/MR probe investigated. 
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 Imaging MAO has been of active interest as it is a marker of astrogliosis in 
neurodegenerative diseases.9, 11-13 Our laboratory has explored the development of carbon-11 
radiolabelled substrates of MAO-B for use as PET imaging agents (see chapter 3).9 In our work, 
we have developed several PET imaging agents based on work from the Castagnoli lab14 and 
initial reports of a MAO-B selective fluorogenic probe.15 This led us to produce and evaluate a 
PET/fluorescence hybrid imaging agent (figure 4.1). Previously, Yamiguchi et. al. reported a 
MAO substrate MRS agent they described as a chemical shift-switching agent, as the 19F NMR 
signal of the substrate could be distinguished from that of the metabolite formed. The metabolite 
formed is a phenol just as that formed using our tetrahydropyridine pharmacophore. Therefore, 
we hypothesized that combining our previous approach for a PET imaging MAO agent with the 
phenol of interest from Yamiguchi’s work would produce a PET/MRS hybrid imaging agent that 
yielded both PET active and MRS active metabolites upon enzymatic reaction with MAO. 
 Trapped metabolite imaging agents are enzyme substrates that in their parent form can 
freely cross into cells but upon reaction form a labelled metabolite that is trapped where the 
enzymatic reaction occurred, providing a measure of enzyme present based on the extent of 
trapping in the region of interest during image pharmacokinetic analysis. We propose that 
enzymes substrates have the added benefit that they can be designed to produce multiple 
metabolites with capability of being imaged (figure 4.1). While an appropriately designed single 
trapped product would allow for PET/MRS hybrid imaging, the formation of two metabolites 
also allows for the possibility of PET/MRS hybrid bifunctional imaging. First, to test our 
hypothesis we needed to investigate a known trapped metabolite imaging agent at low and high 
molar activities to test if our hypothesis that enzyme substrates can provide PET imaging data at 
low molar activity. 
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2. Results and Discussion 
 1-[11C]Methylpiperidin-4-yl Propionate (PMP) is a substrate for acetylcholinesterase 
(AChE) used in the study of Alzheimer’s and Parkinson’s disease to measure the activity of 
AChE in cholinergic neurons.16-17 The radiotracer, an ester substrate, is hydrolyzed in vivo by 
AChE forming a hydrophilic metabolite, 1-[11C]methylpiperidin-4-ol, that is trapped in the 
compartment where the reaction occurs. PMP precursor and standard were prepared as 
previously described (scheme 4.1).18 Experiments at high and low molar activity resulted in time 
activity curves for the region of interest drawn around the brain that were nearly identical. For 
the low molar activity dose, 3 mg of the unlabelled standard was included in the dose injected 
(10 mg/mL dose, 300 µL injected, 0.52 mCi injected). This resulted in a 0.03 Ci/mmol dose 
compared to a standard dose prepared at 7,000 Ci/mmol. Time activity curve data demonstrated 
that the low molar activity dose produced usable PET data even though it was diluted 200,000 
fold (figure 4.2). In fact, the time activity curve showed higher standardized uptakes values 
(SUV) at later times. With imaging at low molar activity demonstrate with a trapped metabolite, 
we advanced next evaluated our hypothesis that a MAO substrate could produce both PET and 
MRS imaging metabolites. 
 
Scheme 4.1. Radiosynthesis of [11C]PMP. Performed as previously described.18-19 
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Figure 4.2. [11C]PMP Rodent Brain PET Imaging. Comparison of normal (7,000 Ci/mmol) vs. low (0.03 Ci/mmol) 
molar activity demonstrates quality data can be obtained at low molar activity. 
 
 
Scheme 4.2. Synthesis of AZ reference standard and precursor. A) Synthesis of reference standard (1). B. Synthesis 
of precursor for radiolabeling (2). 
 
Scheme 4.3. Radiosynthesis of [11C]AZ. Carbon-11 synthesis performed with the assistance of Dr. Xia Shao and Dr. 
Allen Brooks. 
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 We prepared the required reference standard (AZ) and precursor for radiolabelling 
consistent with procedures from our previous work (scheme 4.2). We then utilized the change in 
absorbance between the substrate, AZ, and the metabolite, 2-Fluoro-4-nitrophenol, to perform 
Michaelis-Menten kinetic analysis. The results of those experiments are presented in figure 4.3 
and show that AZ is a substrate for MAO-A and –B. The chemical shift-switching probe 
described by Yamiguichi is MAO-A selective with a KM of 37.2 µM. AZ has a lower KM for 
MAO-A at 19 µM, but even though its KM for MAO-B is higher the observed kcat is also higher, 
resulting in similar kinetic efficiency (kcat/ KM; specificity constant) for AZ with MAO-A or –B 
(table 4.1). The analysis confirmed AZ was a suitable substrate for further analysis as it had a 
lower KM than the previous shift-switching probe (37.2 µM) and natural MAO substrates 
(serotonin, 137 µM).20 19F NMR experiments of AZ and 2-fluoro-4-nitrophenol demonstrated 
that AZ could be utilized as a MRS (chemical shift-switching) agent. To confirm this in our 
experimental conditions, enzymatic reactions with MAO-A and AZ were run to 2 time points (15 
and 90 min) and quenched by addition of excess clorgyline (10 µM). In figure 4.4 the signal for 
the substrate at -130.9 ppm is replaced by signal for phenol metabolite at -136.4 ppm over time. 
With AZ confirmed in vitro as a MAO chemical shift-switching agent, carbon-11 labelling was 
undertaken to observe if [11C]AZ could be utilized as a PET imaging agent at low molar activity. 
 The procedure to radiolabel [11C]AZ was similar to the method previously described in 
our work (scheme 4.3).9 Briefly, [11C]carbon dioxide was converted by standard procedure into 
[11C]CH3OTf and sparged thru a solution of the pyridine precursor in ethanol (1 mg, 0.2 mL). 
The [11C]methyl pyridinium intermediate was transferred to a conical vial containing NaBH4 in 
ethanol (2 mg, 0.3 mL) and stirred for 5 min. [11C]AZ was then purified by HPLC and 
reformulated into a 10% ethanol in saline dose (10.6 ± 5.6 mCi; non-decay corrected 1.2% 
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radiochemical yield based on 900 mCi of starting [11C]CH3OTf; 30 min from end of 
bombardment) for use in animal imaging studies. For doses of low molar activity [11C]AZ, 
reference standard was added to the saline used for reformulation and in both cases molar 
activity was calculated by standard curve analysis using HPLC (UV-254 nm) of the dose 
solution. 
 
 
Figure. 4.3 Michaelis-Menten kinetic analysis data for MAO-A and –B by absorbance assay. 
 
Table 4.1. Michaelis-Menten kinetic parameters for AZ in MAO-A and MAO-B.  
 kcat (min-1) KM (µM) kcat/KM (min-1µM-1) 
MAO-A 0.0416 ± 0.0016 19 ± 2.3 0.0022 
MAO-B 0.24 ± 0.048 67 ± 4.5 0.0036 
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Figure 4.4. 19F NMR experiments (376 MHz). Time-dependent formation of 2-fluoro-4-nitrophenol metabolite (-136 
ppm) and secondary metabolite (-129 ppm) via oxidation of substrate AZ (-130 ppm) by MAO-A.  
 
 Imaging in Sprague Dawley rats was carried out with [11C]AZ at high (normal molar 
activity for clinical use of PET radiotracers) and low molar activity. Experiments conducted at 
high (7,000 Ci/mmol) and low (0.68 Ci/mmol) molar activity [11C]AZ gave the same time 
activity curve shape, and again higher SUV in the later frames was observed with the lower 
molar activity [11C]AZ doses, as seen in figure 4.5. In addition, the reconstructed Sprague 
Dawley images with all frames summed demonstrate the greater uptake of low molar activity 
[11C]AZ as more activity is observable in the PET images (higher nCi/cc signal; high molar 
activity 0.44 mCi, low molar activity 0.47 mCi injected).  
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Figure 4.5 Summed frame images of [11C]AZ. A) sagittal plane from low molar activity experiment vs. B) from high 
(normal) molar activity. Time activity comparison corrected to SUV (n=2) for each experiment. 
 
3. Conclusion 
 PET imaging of trapped metabolites formed from enzyme substrates can be achieved at 
high concentration and resulting low molar activity, which is required for any potential hybrid 
PET/MRS imaging agent. In fact, lower molar activity resulted in a higher SUV late, which 
improves detection of enzymatic activity. Enzymatic substrates that form trapped metabolites are 
a promising way forward to design PET/MRS hybrid imaging agents. The ability to form two 
metabolites where one is PET active and the other MRS active also raises the possibility of 
designing bifunctional PET/MRS hybrid imaging agents in addition to using the approach to 
design a probe that measure the same data by both PET and MRS. The development of 
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PET/MRS imaging agents will allow for collecting functional data from both PET and MR 
instruments, taking advantage of the development of PET/MR systems. Substrate imaging as 
evidence by such radiotracers as [11C]PMP and others demonstrates the utility of substrate based 
imaging in the study pathology, staging of disease and monitoring treatment. With the concept 
validated, work is currently underway investigating the design of PET/MRS probes that are more 
sensitive to facilitate use in animal studies. 
4. Methods 
Chemistry 
General Considerations.  
 All solvents and reagents were commercially available and used without further 
purification unless otherwise stated. 2-Fluoro-4-nitrophenol, 4-hydroxypyridine, and 4-
chloropyridine hydrochloride were obtained from Sigma-Aldrich. NMR spectra were recorded 
with a Varian 400 MHz instrument at room temperature with tetramethylsilane (TMS) as an 
internal standard. Mass spectra were performed on a Micromass LCT time-of-flight mass 
spectrometer or an Agilent Q-TOF HPLC-MS employing the electrospray ionization (ESI) 
method. High-performance liquid chromatography (HPLC) was performed using a Shimadzu 
LC-2010A HT system equipped with a Bioscan B-FC-1000 radiation detector.  
Preparation of 4-(2-fluoro-4-nitrophenoxy)-1-methyl-1,2,3,6-tetrahydropyridine (1): 2-Fluoro-4-
nitrophenol (0.11 g; 0.72 mmol) was added to sodium methoxide (0.047 g; 0.87 mmol) dissolved 
in DMF (3 mL), and the mixture was stirred for 10 min. 4-Chloro-1-methylpyridin-1-ium triflate 
(0.20 g; 0.72 mmol) was added, and the reaction was stirred for 18 h. The solvent was removed 
in vacuo, and the resulting intermediate was suspended in methanol (3 mL). The reaction mixture 
was cooled to 0 °C in a water ice bath, and NaBH4 (0.069 g; 1.81 mmol) was added slowly. 
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After 1 h, the solvent was removed in vacuo. Water and ethyl acetate were added to the residue, 
and the mixture was transfer to a separatory funnel. The product was extracted with ethyl acetate 
(3×), dried over sodium sulfate, filtered, and concentrated in vacuo. The product was purified by 
flash silica gel chromatography (dichloromethane, methanol gradient; 0%MeOH/100% DCM  
10%MeOH/90%DCM). The product was collected as a yellow semi-solid in 45% yield (0.082 
g). 1H NMR (400 MHz; MeOH-d4)/δ (ppm): 7.99-7.95 (2H, m), 7.26 (1H, t, J = 8.7), 5.03 (1H, 
br), 2.96 (2H, dd, J = 6.0, 2.6), 2.66 (2H, t, J = 6.0), 2.33-2.31 (5H, m); 19F NMR (376 MHz; 
MeOH-d4)/δ (ppm): -130.0; HRMS calcd for [M + H]+ (M = C12H13FN2O3), 253.0983; found, 
253.0983. 
Preparation of 4-(2-fluoro-4-nitrophenoxy)pyridine (2): Phenol starting material (0.25 g; 1.6 
mmol) was added to potassium tert-butoxide (0.33 g; 2.9 mmol) dissolved in DMF (7 mL). The 
reaction mixture was heated at 140 °C, 4-chloropyridine hydrochloride (0.20 g; 1.33 mmol) was 
added, and the reaction was stirred for 18 h. The reaction was cooled to room temperature and 
quenched with aqueous saturated sodium bicarbonate. The product was extracted with ethyl 
acetate (3×), dried over sodium sulfate, filtered, and concentrated in vacuo. The product was 
purified by flash silica gel chromatography (hexanes, ethyl acetate gradient; 0%EtOAc/100% 
hexanes 50% EtOAc/50% hexanes). The product was collected as a red solid in 10% yield (0.031 
g). 1H NMR (400 MHz; MeOH-d4)/δ (ppm): 8.41 (2H, d, J = 6.0), 8.17 (1H, dd, J = 10.3, 2.5), 
8.10 (1H, d, J = 9.0), 7.43 (1H, t, J = 8.5), 7.0 (2H, d, J = 6.0); 19F NMR (376 MHz; MeOH-d4)/δ 
(ppm): -126.9; HRMS calcd for [M + H]+ (M = C11H7FN2O3), 235.0513; found, 235.0514. 
Biology 
Absorbance Assay  
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 Experimental Michaelis-Menten kinetic parameters were calculated for the compounds 
using hMAO-A and –B Supersome (Creative Biomart). In brief, assays were performed using 
Supersomes (mitochondrial membrane preps of insect cells overexpressing human MAO-A or –
B) at a concentration of 80 ug/ml. Fresh stocks of substrate were dissolved in DMSO and diluted 
to various concentrations ranging from 200 uM to 1 nM. Reaction progress was measured by 
appearance of absorbant product, 2-fluoro-4- nitrophenol. Reactions were monitored in real time 
using a Biotek Hybrid plate reader (absorbance 410 nm) at 37 °C for 60 min. The resultant 
absorbance units were converted to concentration of product using a reference standard curve. 
Michaelis-Menten curves were plotted and parameters computed in GraphPad Prism. Assays 
were done in duplicate, in three independent experiments using fresh stock of enzyme, test 
compound, and reference standard. 
19F NMR Assay  
 Turnover was observed for compounds using MAO-A Supersome (Creative Biomart). In 
brief, assays were performed using Supersomes (mitochondrial membrane preps of insect cells 
overexpressing human MAO-A) at a concentration of 12 unit/ml (unit of activity defined by 
manufacturer and varied stock to stock). Fresh stocks of substrate were dissolved in DMSO and 
diluted to 100 uM in HEPES (100mM, pH 7.4). Reaction progressed in glass vials at 37 °C until 
desired stop time. Reaction was stopped at 0, 15, and 90 minutes by addition of clorgyline in 
excess (1.6 mM). Entire reaction solutions were transferred to a 5 mm NMR tube for 19F-NMR 
spectroscopy. NMR spec details: 19F NMR experiments were performed on a Varian 400 MHz 
instrument (376 MHz for 19F-NMR) at room temperature, 4096 scans were performed for each 
sample with a 1 second relaxation delay between scans, and data was analyzed with Mnova 
software from Mestrelab Research. 
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Radiochemistry 
General Considerations 
 Reagents and solvents were commercially available and used without further purification, 
unless otherwise noted. Sodium chloride (0.9% USP) and sterile water for injection (USP) were 
purchased from Hospira; dehydrated alcohol for injection (USP) was obtained from Akorn Inc. 
Shimalite-Nickle was purchased from Shimadzu, iodine was obtained from EMD, phosphorus 
pentoxide was acquired from Fluka, molecular sieves were purchased from Alltech, and HPLC 
columns were acquired from Phenomenex. Other synthesis components were obtained as 
follows: sterile filters were acquired from Millipore, C18-light Sep-Paks and Porapak Q were 
purchased from Waters Corporation, and 10 cc sterile vials were obtained from HollisterStier. 
Sep-Paks were flushed with 10 mL of ethanol followed by 10 mL of sterile water prior to use.  
Radiochemical Synthesis of 4-(2-fluoro-4-nitrophenoxy)-1-[11C]methyl-1,2,3,6-
tetrahydropyridine ([11C]AZ): Production was carried out as previously described using a 
TracerLab FXC-Pro automated radiochemistry synthesis module (General Electric, GE).9 
[11C]Carbon dioxide was produced using a GE PETTrace cyclotron (40 μA beam for 30 min) and 
converted by standard procedures into carbon-11- labeled methyl triflate ([11C]CH3OTf). The 
[11C]CH3OTf in helium carrier gas was bubbled into a vial containing a solution of 4-(2-fluoro-4-
nitrophenoxy)pyridine (1 mg) dissolved in ethanol (0.2 mL). At the completion of transfer of 
radioactivity into the reaction vial, the ethanol solution was then transferred to a second conical 
vial containing sodium borohydride (2 mg) in ethanol (0.3 mL). The resulting mixture was 
stirred for 5 min at room temperature, and then the reaction was quenched by addition of HPLC 
buffer (30% MeCN, 10 mM NH4OAc, pH 4.5). The crude product was loaded onto a semi-
preparative HPLC loop. The product was purified by reverse-phase chromatography (Prodigy 
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ODS prep, 250 × 10 mm, 10 μ, 4 mL/min), collected (retention time of 5.7 min), diluted into 
dilution flask containing H2O (40 S10 mL) and 1% NH4OH (2 mL), and reformulated using a C-
18 extraction disk into a final 5 mL total volume of 10% ethanol in saline. The doses produced 
(10.6 ± 5.6 mCi; non-decay corrected Radiochemical Yield = 1.2% based on 900 mCi of starting 
[11C]CH3OTf; Radiochemical Purity greater than 99%) were assessed via standard quality 
control techniques and were appropriate for rodent and nonhuman primate studies. Overall 
synthesis times were 30 min from end-of-bombardment. 
Radiochemical Synthesis of [11C]Methylpiperidin-4-yl proprionate ([11C]PMP): Production was 
carried out as previously described using a TracerLab FXC-Pro automated radiochemistry 
synthesis module (General Electric, GE).19 [11C]Carbon dioxide was produced using a GE 
PETTrace cyclotron (40 μA beam for 30 min) and converted by standard procedures into carbon-
11- labeled methyl triflate ([11C]CH3OTf). The [
11C]CH3OTf in helium carrier gas was bubbled 
into a vial containing a solution of precursor (0.5 mg) dissolved in DMF (0.1 mL). 4‐piperidinyl 
propionate hydrochloride (0.5 ± 0.1 mg) was dissolved in aqueous saturated sodium bicarbonate 
(~20 μL) and ethyl ether (2 mL) was added, and the solution was mixed vigorously on a vortex 
mixture for 1 min. Anhydrous sodium sulfate (0.5 g) was then added to absorb the water, and the 
dried ether was filtered into DMF (100 μL). The ether was evaporated under nitrogen, leaving 
the precursor in DMF as freebase.  [11C]methyl triflate was bubbled through the precursor 
solution at 15 mL/min for 3 min. The reaction mixture was then diluted with 1 mL of HPLC 
mobile phase and purified using semipreparative HPLC (column: Phenomonex Luna C18, 
250 × 10 mm, mobile phase: 20 mm NH4OAc in 5% EtOH, flow rate: 4 mL/min). The product 
peak was collected (RT ~12–14 min) for 2 min (8 mL), diluted with USP saline (2 mL) to 
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provide a final ethanol concentration <5%, and passed through a 0.22 µm sterilizing filter into a 
sterile dose vial. 
Rodent PET Imaging 
General Considerations 
 All animal studies were performed in accordance with the standards set by the University 
Committee on Use and Care of Animals (IACUC) at the University of Michigan. Rodent 
imaging studies were done with female Sprague Dawley rats. The animals were anesthetized 
(isoflurane), intubated, and positioned in a Concorde MicroPET R4 scanner. 
 Normal molar activity [11C]PMP Scan (animal weight = 264 g):  Following a transmission scan, 
the animal was injected i.v. (via tail vein catheter as a bolus over 1 min) with [11C]PMP (0.33 
mCi; 7,000 Ci/mmol) and the head imaged for 60 min (5 x 1 min frames – 2 x 2.5 min frames – 2 
x 5 min frames – 4 x 10 min frames). Low molar activity [11C]PMP Scan (animal weight = 299 
g):  Following a transmission scan, the animal was injected i.v. (via tail vein catheter as a bolus 
over 1 min) with [11C]PMP (0.52 mCi; 0.03 Ci/mmol) and the head imaged for 60 min (5 x 1 
min frames – 2 x 2.5 min frames – 2 x 5 min frames – 4 x 10 min frames). Normal molar activity 
[11C]AZ Scan (n = 2, animal weight = 182, 358 g):  Following a transmission scan, the animal 
was injected i.v. (via tail vein catheter as a bolus over 1 min) with [11C]AZ (0.45, 0.44 mCi; 
3000, 7000 Ci/mmol) and the head imaged for 60 min (5 x 1 min frames – 2 x 2.5 min frames – 2 
x 5 min frames – 4 x 10 min frames). Low molar activity [11C]AZ Scan (n = 2, animal weight = 
324, 270 g):  Following a transmission scan, the animal was injected i.v. (via tail vein catheter as 
a bolus over 1 min) with [11C]AZ (0.47, 0.56 mCi; 0.68, 0.30 Ci/mmol) and the head imaged for 
60 min (5 x 1 min frames – 2 x 2.5 min frames – 2 x 5 min frames – 4 x 10 min frames). In each 
case, emission data were corrected for attenuation and scatter, and reconstructed using the 3D 
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maximum a priori (3D MAP) method. By using a summed image, regions of interest (ROI) were 
drawn over the whole brain on multiple planes, and the volumetric ROIs were then applied to the 
full dynamic data set to generate time-radioactivity curves. 
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CHAPTER 5 
Imaging the Receptor for Advanced Glycation End-products 
 
 As an alternative to monoamine oxidase (MAO), the novel biomarker the receptor for 
advanced glycation end products (RAGE) was evaluated for its utility in neuroinflammation. The 
literature surrounding this receptor was incredibly light in comparison to MAO- and we were 
excited to explore this new biology in two approaches. The preliminary extracellular approach 
has been published,1 and we hope to submit the second manuscript soon.  
1. Introduction 
Chronic inflammation of the central nervous system (CNS) features a series of concerted 
actions to identify a harmful agent, limit its impact, and repair any damage.2 The 
neuroinflammatory state can be described pathophysiologically by the presence of cytokines and 
chemokines in the cerebral spinal fluid (CSF) and interstitial spaces, blood-brain barrier (BBB) 
dysfunction, activated microglia, and infiltration of peripheral immune cells within the CNS.2 In 
a neuroinflammatory state, overactivated microglia cause aberrant damage because of a self-
propagating destructive cycle in which activated microglia secrete proinflammatory signals and 
in turn activate neighboring microglia and astrocytes.3  
Advanced glycation end products (AGEs) are a common biomarker of inflammation in 
vitro and are the result of non-enzymatic and nonspecific glycation of macromolecules in an 
oxidative environment.4 In addition to inactivating enzymes, glycation can cause aggregation and 
protein cross-linking.4 AGEs cause an inflammation cascade by signaling through the Receptor 
for Advanced Glycation End products (RAGE), an integral membrane receptor in the 
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immunoglobulin-G family.5-7 RAGE is a pattern recognition receptor and recognizes a variety of 
ligands: the non-enzymatically glycated amino acid residue carboxymethyllysine (CML), insulin, 
HMGB1, S100B, Aβ peptide, and others.5 Ligand binding to RAGE homodimers or RAGE-Toll-
like receptor heterodimers results in activation of a variety of downstream signaling pathways, 
though one of the only known intracellular RAGE ligand is diaphanous 1 (Dia-1).8-9 Through 
this intracellular signaling, NF-κB is activated which initiates transcription of cytokines and 
other proinflammatory mediators and a positive feedback loop in which RAGE expression is 
increased.6 Microglia have been documented overexpressing RAGE in hippocampal neurons, an 
area of the brain strongly associated with neurodegeneration.10-12 There are multiple splice-
isoforms of RAGE which have been speculated to act differently than the full length, membrane 
bound form of RAGE (figure 5.1). The soluble esRAGE (formed from alternative mRNA 
splicing) circulates and possibly acts as a scavenger receptor, sequestering ligands from the full 
length receptor.13 The full length receptor is upregulated in the presence of its ligands, but little is 
understood about ectodomain shedding and the relationship with esRAGE in this state.  
 
Figure 5.1 RAGE domains and common isoforms. The active form of the receptor contains all three extracellular 
domains, a transmembrane region, and a short, disordered intracellular domain. The intracellular domain is required 
for signaling. An inactive form of this receptor contains all of the extracellular domains; however, the cytosolic 
domain has been cleaved. Ligand binding to this form does not result in intracellular signaling. The soluble form of 
RAGE lacks the transmembrane and cytosolic domains. It considered to be a “decoy” or scavenger receptor. 
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 A recombinant form of the soluble RAGE (sRAGE) was engineered to be used as a 
RAGE inhibitor.14 Inhibition of RAGE through this method was shown to block the development 
and progression of many pathological states in animal models: cardiovascular disease,15 
diabetes,14 and cancer.16 Therapeutic efforts to inhibit RAGE have had limited success to date. 
The small molecule inhibitor of the extracellular domain, azeliragon (TTP-488), failed efficacy 
in phase II and phase III clinical trials in mild-cognitive impaired Alzheimer’s disease (AD) 
patients.17 Antibody, peptide, and DNA aptamer-based inhibitors have shown preclinical success, 
none have been translated clinically yet.  
 Imaging the receptor for advanced glycation end-products would provide the necessary 
visualization of the receptor’s involvement in disease. Previous imaging efforts include 99mTc-
labeled anti-RAGE antibodies for SPECT imaging, which showed promise in the mouse model 
of hind limb ischemia.18 However, major limitations of antibody imaging agents are the long 
biological half-life and high background signal. Another biologic approach was [18F]S100A4, a 
small protein ligand for RAGE. Although it was never used after this preliminary synthesis 
because the labeled product was unstable and only had micromolar affinity for RAGE.19 
Recently, Konopka et al., reported a RAGE-targeted nanoparticle approach for imaging using the 
fourth generation PAMAM dendrimer and a NOTA chelator for rhodamine (fluorescence) or 
copper-64 (PET imaging).20 The authors developed a multimodal nanoparticle to target RAGE 
with the attached ligand, CML modified human serum albumin. The nanoparticle was evaluated 
in a mouse model of peripheral arterial damage (PAD): hind limb ischemia in non-diabetic mice. 
In the model, PET imaging showed 3.4x higher uptake in hind limbs of the ischemic mice 
compared to normal mice at one week, which is supported by previous immunohistochemistry 
analysis of this model.18 A limitation of this study is non-specific binding. An investigation into 
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other binding partners is surely required; in the HUVEC binding experiment the anti-RAGE 
competition only blocked 80% of nanoparticle binding. Despite the success of these efforts, each 
of them are macromolecules and would have limited use in the CNS. Our approach for CNS PET 
imaging of RAGE requires small molecule ligands and we have explored radioligands for the 
extracellular and intracellular domains. 
2. Extracellular Approach 
 A number of small-molecule mediators of RAGE interactions have been reported.21-22 N-
Benzyl-4-chloro-N-cyclohexylbenzamide (FPS-ZM1, figure 5.2) is a multimodal RAGE-specific 
inhibitor that reduced amyloid-β (Aβ) mediated brain dysfunction in a mouse model of AD. 
Despite having high lipophilicity (CLogP = 5.25; ChemBioDraw), FPS-ZM1 appeared to be a 
promising scaffold around which to develop a PET radiotracer because of its high affinity (25 
nM Ki against RAGE−Aβ1−40), BBB permeability,21 lack of toxicity in mice or cells, and 
amenability to nucleophilic aromatic radiofluorination. Moreover, in a mouse model of AD with 
confirmed Aβ pathology (aged APPsw/0 mice overexpressing human Aβ), FPS-ZM1 was found to 
inhibit RAGE-mediated influx of circulating Aβ into the CNS and reduce microglia activation.21 
The failed therapeutic agent azeliragon (TTP-488) was briefly considered for PET imaging; 
however, due its large size and lipophilicity it was not chosen for development. In this work, we 
report the synthesis and preliminary preclinical evaluation of [18F]RAGER (figure 5.2). 
 
Figure 5.2. Small molecule inhibitors and PET radioligands for RAGE.  
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2.1 Chemistry  
 
Scheme 5.1. A. Synthesis of RAGER HPLC reference standard (2). B. Synthesis of precursor radiosynthesis (3) and 
radioligand ([18F]2). 
 
 The first step when developing novel PET radiotracers is to synthesize both the precursor 
to be radiolabeled and the corresponding unlabeled reference standard to confirm identity of the 
radiolabeled product by HPLC. Unlabeled reference standard 2 was produced in good yield (80% 
over two steps) via a reductive amination of benzaldehyde and cyclohexylamine to give 1, 
followed by acylation with 4-fluorobenzoyl chloride (Scheme 5.1). Trimethylammonium 
precursor 3 was prepared for radiolabeling as the charged precursor and uncharged product were 
expected to have markedly different retention times by reverse-phase HPLC. Precursor 3 was 
synthesized in the same manner as the reference standard, by acylation of intermediate 1 with p- 
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(N, N dimethylamino)benzoyl chloride; subsequent alkylation with methyl iodide provided 3 in 
10% yield (over three steps).  
 Radiosynthesis of [18F]RAGER was automated using a commercial synthesis module 
(General Electric Tracerlab FXFN) by reacting trimethylammonium precursor 3 with [
18F]fluoride 
in the presence of Kryptofix-2.2.2 (K2.2.2) in DMF at 130 °C for 30 min. Subsequent purification 
by semipreparative HPLC and reformulation yielded [18F]RAGER (4) in satisfactory 
radiochemical yield (44 ± 10 mCi; 2.9% nondecay corrected based upon 1.5 Ci of [18F]fluoride), 
excellent radiochemical purity (RCP) (>99%), and high specific activity (3740 ± 495 Ci/mmol); 
n = 6. Formulated [18F]RAGER was stable for at least 60 min after the end of synthesis. 
2.2 Tissue Studies  
 Tissue samples from an Alzheimer’s patient were obtained, along with samples from a 
healthy control, to evaluate [18F]RAGER. RAGE expression is known to be significantly 
elevated in the cortex.23-24  In AD cortex sections, a 2.9-fold increase in RAGE expression was 
observed compared with normal control tissue. This is consistent with the known increased 
expression of RAGE in AD from the literature.24 Adjacent sections were then incubated with 
[18F]RAGER, 4 (figure 5.3). The images confirm colocalization of [18F]RAGER in gray matter 
areas with known RAGE expression, previously identified by immunohistochemistry. There was 
higher uptake in the AD samples than the normal control samples. Nonspecific binding was 
investigated by repeating incubations in the presence of 1000-fold excess of unlabeled RAGER, 
which confirmed that binding in the gray matter regions was displaceable to background levels. 
However, despite the reported specificity of the parent compound,21 we did observe significant 
nonspecific binding in the white matter (the white matter signal in the nonspecific binding 
experiments shown in figure 5.4 actually appears higher than that for the total binding 
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experiments. The cause of this is unclear, but it is possible that all of the displaced radiotracer in 
the nonspecific samples gets retained in the white matter leading to the higher signal. 
 
Figure 5.3. In vitro binding of [18F]RAGER to human brain tissue sections. Both AD and normal cognitive control 
tissues are from frontal cortex. 
 
 Although RAGER has lower lipophilicity (experimental log P = 3.5; CLogP = 4.85, 
ChemBioDraw) than FPS-ZM1 (CLogP = 5.25, ChemBioDraw), it is still lipophilic, and we 
believe this is the origin of the high white matter binding. Correcting for nonspecific binding 
allowed estimation of Kd and Bmax in both the AD tissue and normal control tissue (Table 5.1). 
Using both AD and control tissue samples, the Kd was found to be approximately 15 nM, similar 
to the reported Ki of 25 nM for FPS-ZM1. The Bmax in AD tissue was found to be 2.8-fold higher 
than the Bmax in normal control tissue, which is also consistent with the 2.9-fold increase in 
RAGE expression confirmed by immunohistochemistry (vide supra). The binding potential (BP), 
estimated by the Bmax/Kd value, is useful forpredicting the suitability of a radiotracer for imaging 
a target binding site in human subjects. [18F]RAGER has a BP of 1.86 in AD tissue, suggesting 
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potential suitability of this scaffold for future applications in clinical PET imaging and the 
feasibility of imaging RAGE with PET. 
Table 5.1. In Vitro Binding assessment of [18F]RAGER using human cortical brain sections. 
 Kd (nM) Bmax (nM) BP (Bmax/  Kd) 
AD  15.5 28 1.86 
Cognitive Normal 15.5 10 0.65 
 
 
2.3. Preclinical Imaging 
 In vivo behavior of the radiotracers was investigated initially in rodents (n = 3). PET 
scans were conducted in Sprague−Dawley rats, and imaging was conducted for 90 min 
postinjection of the radiotracer. Following the scan, images were summed (figure 5.4A) and a 
region-of-interest (ROI) was drawn over the whole brain on multiple planes. The volumetric 
ROIs were then applied to the full dynamic data set to generate a time−radioactivity curve 
(figure 5.4B). The curve showed rapid uptake of [18F]RAGER (peak SUV ≈ 2.5). Peak uptake 
occurred within 3 min post injection and was followed by virtually complete washout over the 
duration of the PET scan.  
 Encouraged by these results, we also evaluated the imaging properties of [18F]RAGER in 
non-human primates. Similar imaging results were obtained in rhesus macaque (Figure 5.4C). A 
ROI was drawn initially for the whole brain and used to generate a time−radioactivity curve 
(Figure 5.4D), which revealed rapid uptake of [18F]RAGER in the primate brain (peak SUV ≈ 
2.3). Peak uptake again occurred within 3 min postinjection, and was followed by washout over 
the duration of the PET scan. Washout was faster in rodents than primates, and we attribute this 
to increased tissue volumes and lower blood flow in the primates.  
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Figure 5.4. Representative microPET imaging data for rodent and nonhuman primate. A, summed images 0−90 min 
post-iv-injection of the radiotracer (dotted oval = brain); B, rodent whole brain time−radioactivity curves) and non-
human primate C, summed images 0−90 min post-iv injection of the radiotracer; D, nonhuman primate whole brain 
time−radioactivity curves) imaged with [18F]RAGER. 
 
The radiotracer provided reasonable levels of uptake in all gray matter regions (peak SUVs range 
from 2−4; see Figure 5.5 for regional time− radioactivity curves of [18F]RAGER in non-human 
primate brain). For example, there was high uptake apparent in the cortex and cerebellum, which 
agrees with the reported distribution of RAGE.24 Notably, there was also extensive bilateral 
uptake and markedly slower washout associated with the hippocampal regions, which suggests 
specific binding. This is also consistent with the known expression of RAGE, where it has been 
shown that some RAGE expression is normal in the healthy hippocampus but that elevated levels 
are present in the hippocampus of the Alzheimer’s disease brain.24 
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Figure 5.5 [18F]RAGER regional time−radioactivity curves in the non-human primate brain. Presented as 
standardized uptake value (SUV). 
 
 Very little white matter binding was apparent, in contrast to the high degrees of 
nonspecific binding that complicated the in vitro studies described above, although there was 
extensive uptake in the brain stem and an unknown region outside of the brain (possibly tissue 
associated with the nasal cavity). The cause of differing nonspecific binding between the in vitro 
and in vivo studies could simply be that there is less [18F]RAGER available to bind in the brain 
during the in vivo studies because of uptake in the periphery (there is high RAGE expression in 
the lung25), binding to circulating soluble RAGE or could be due to metabolism effects. To 
investigate the latter possibility, we next investigated metabolism of RAGER.  
2.4. Metabolism and Biodistribution  
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Figure 5.6 RAGER metabolism, plasma protein binding, and biodistribution. A) Metabolism in rat liver microsomes 
(verapamil shown as assay control). B) Plasma protein binding (verapamil shown as assay control). C) 
Biodistribution in normal Sprague dawley rat. 
 
 Metabolism of RAGER was examined by incubation with rat liver microsomes (figure 
5.6A). The LC-MS/MS data analysis indicates extremely fast metabolism of the radiotracer, with 
a half-life of 0.66 min and only ∼0.5% of authentic RAGER remaining at 5 min. Although we 
have not confirmed this metabolism profile in vivo, the rodent time−radioactivity curves are 
consistent with rapid metabolism and do not suggest that any labeled metabolites enter the brain. 
Rapid metabolism would explain the difference between the high nonspecific binding observed 
in vitro and the low levels apparent in the PET images. We have also not examined metabolism 
in primates but would expect it to be slower than that in rats. This could lead to higher 
nonspecific binding in primates, which would be consistent with the slower washout apparent in 
the primate time−radioactivity curves (figure 5.4). The rapid metabolism also suggests that brain 
uptake in known areas of RAGE expression is likely occurring before first pass metabolism, 
which is again consistent with the rapid peak uptake of the radiotracer in both rats and primates. 
 Plasma protein binding analysis revealed 96% of the small molecule radioligand is 
plasma protein bound, indicating a very low free fraction available to pass through the BBB and 
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engage in specific binding to RAGE (figure 5.6B). Plasma protein binding is not often a primary 
concern in radioligand development. In multiple parameter operator prediction tools, it is ranked 
after lipophilicity, hydrogen bond donors and acceptors, and apparent permeability.26 There is 
not a consensus on what qualifies as an acceptable free fraction in plasma for a radioligand, 
considering that [11C]flumazenil has 40%  and [11C]raclopride has 98% plasma protein 
binding.27-28 It is also unclear whether plasma protein binding is a direct predictor of nonspecific 
binding once the radioligand has entered the CNS, though plasma protein binding and 
nonspecific binding both correlate with lipophilicity.   
 To further evaluate this radioligand, biodistribution studies were performed in normal 
Sprague Dawley rats (n=4/ sex/ time point) at four different time points (5, 30, 60 and 120 
minutes post radioligand injection (figure 5.6C). As expected from the rodent PET imaging, the 
radioligand was completely washed out of the brain after 30 minutes. There is no bone uptake, 
indicating there is not radiolysis or metabolic defluorination. Independently, Kong et al.29 and 
Bongarzone et al.30 have also investigated [18F]fluoro-FPS-ZM1 and [11C]FPS-ZM1 as a 
radioligand for RAGE. Results across the three groups have been similar: blood-brain barrier 
permeability was confirmed in rodent and biodistribution trends were similar to those determined 
in mice. Interestingly, although RAGE is documented to be highly expressed in the lungs, there 
is no observable accumulation of [18F]RAGER in this organ. This lack of lung uptake was also 
observed in the biodistribution of the RAGE targeting nanoparticle and further investigation is 
required.20 
2.5. Off-Target Binding 
To evaluate any potential off-target binding partners, the LeadProfile Screen was 
performed (Cerep Panlabs). At a concentration of 10 µM, the extracellular ligand RAGER only 
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achieved >50% inhibition in 4 assays: androgen receptor, GABAA receptor, dopamine 
transporter, and melatonin MT1 receptor (table 5.2). A dose response curve was generated for 
these four targets and the IC50’s and Ki’s were determined. [19F]RAGER exhibited a Ki of 93 nM 
for MT1; the other three off-targets all showed Ki’s of greater than 1 µM. At radioligand 
concentrations, only MT1 was considered a possible off-target binding partner warranting further 
experiments. Compared to the 15 nM KD for [
18F]RAGER in tissue, the radiotracer exhibited a 6 
fold higher affinity for RAGE compared to MT1. [
3H]Melatonin was utilized as the competitive 
ligand for binding in the assay and it is assumed that [18F]RAGER binds in the same site.  
Table 5.2. Off-target binding of RAGER. All assays were performed at 10 µM [19F]RAGER to determine the 
percent inhibition; secondary dose response IC50’s and Ki’s are reported. Full table available in Appendix A. 
Assay Name Species % Inhibition IC50 (µM) Ki (µM) 
Androgen  Human 59 4.37 2.57 
GABAA  Rat 55 10.4 8.46 
Dopamine Transporter Human 52 8.61 6.84 
Melatonin MT1 Human 96 0.18 0.093 
 
 MT1 is a G-coupled transmembrane receptor expressed only in the CNS.
31 Its endogenous 
ligand, melatonin, is well known for its role in circadian rhythm control. Melatonin has not 
displayed any documented affinity for RAGE and has high affinity (< 1 nM) to melatonin 
receptors (MT1 and MT2).
31 MT1 is mostly expressed in the hypothalamus, though it is also 
expressed at lower levels in the hippocampus and other areas of the human brain.31 Unlike MT1, 
RAGE expression is inducible by the level of inflammation in the microenvironment; in the 
presence of cytokines and other proinflammatory mediators, its ligands, RAGE activity and 
expression increases.7 RAGE is expressed ubiquitously at low levels in the CNS and is 
documented to be overexpressed in hippocampal neurons in AD.12 Studies with [18F]RAGER 
show the highest uptake in the thalamus and basal ganglia in a healthy nonhuman primate, which 
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may overlap with the areas of MT1 expression.
1 However, there is limited information available 
regarding the expression levels of RAGE in healthy control tissue. 
 To identify any areas of MT1 expression and determine if those areas overlapped with 
[18F]RAGER binding, immunohistochemistry was performed on fixed human brain tissue 
sections using mouse anti-human MT1 antibody.  To serve as the neuroinflammatory brain 
sections, frontal cortex tissue sections were harvested from AD and DLB patient samples. A 
region and age matched healthy control was used for comparison. Increased MT1 
immunoreactivity was observed in AD and DLB/AD tissue sections (figure 5.7). This 
phenomenon is previously documented.32 Anti-RAGE antibodies also display increased 
immunoreactivity in AD and DLB tissue sections. Although the increased binding trend in 
disease tissue is shared by MT1 and RAGE, there is a large difference in abundance. In diseased 
tissues, MT1 is more abundant than RAGE, which indicates a real possibility for off-target 
binding. To validate the specific binding, [18F]RAGER autoradiography on human brain sections 
was performed and the native MT1 ligand, melatonin, was used as the nonspecific blocking 
agent. 
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Figure 5.7. Postmortem human tissue immunoreactivity and [18F]RAGER autoradiography.  
 
Competitive binding experiments were performed with 10 µM melatonin and 
[18F]RAGER in human brain tissue sections. Region and age matched healthy control tissue was 
compared with AD and DLB brain sections. Melatonin (10 µM) was not able to displace 
[18F]RAGER in any section of human brain tissue in both control and disease brain tissue 
sections (figure 5.7). This indicated strongly that nonspecific binding of [18F]RAGER is not due 
to off-target binding to MT1.  
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This competitive binding experiment indicates that specific binding on tissue is not to the 
MT1 receptor. This result seems to conflict with the in vitro assay, which used [
3H]melatonin for 
Ki determination. If RAGER has demonstrable affinity for the MT1 receptor in the Ki assay, it is 
expected that at least a portion of [18F]RAGER binding would be displaced by excess melatonin 
in both white and grey matter. As we observed, the nonspecific binding of this radioligand is 
high in the white matter. Additionally, based on the low MT1 immunoreactivity of the human 
brain tissue in this region, it is not unreasonable that the specific binding was not affected by 
melatonin blocking.  
Data from in vitro binding experiments is often difficult to correlate to in vivo binding 
behavior, so additional competitive binding studies were performed in healthy animals. Small 
animal PET imaging studies were first performed in healthy rodents with a non-therapeutic dose 
of melatonin. Melatonin is well known to cross the blood-brain barrier passively.33 An adult 
Sprague Dawley rat was administered intravenously 5 µg/kg melatonin in saline 10 minutes prior 
to [18F]RAGER bolus injection and imaging for 90 minutes. The time activity curve (TAC) was 
corrected for animal weights and injected dose to display the curve as standard uptake value 
(SUV) versus time. Melatonin blocking had no effect on [18F]RAGER uptake compared to 
baseline (figure 5.8 A, B). Consistent with the preliminary study, washout of the radioligand 
occurs very quickly in the rodent brain.1 Biodistribution studies in rodent confirm a complete 
washout of [18F]RAGER after 60 minutes. The melatonin blocking did not change the shape of 
the time activity curve (figure 5.8C).  
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Figure 5.8. [18F]RAGER rat brain imaging with melatonin blocking. A. [18F]RAGER uptake in rodent whole brain 
(white circle). B. Melatonin Blocking of [18F]RAGER in rodent brain. C. Time activity curve presented as SUV. 
Sagittal summed (0-90 min) PET image of rodent administered with 310 +/- 50 µCi of [18F]RAGER. 
 
Due to the quick washout of [18F]RAGER in rodent brain, we did not expect to see a 
large decrease in specific binding. A small decrease is observed, but this could be due to the 
blocking agent influencing the input function (figure 5.8). The rat brain has an increased number 
of metabolizing enzymes in the CNS in addition to very active xenobiotic export transporters 
which could be responsible for the observed fast washout.  In the nonhuman primate studies, 
washout of [18F]RAGER is slower and lead us to expect that melatonin blocking might be more 
evident than in rodent. Specific binding was assessed with both blocking and displacement 
studies. We chose these two study designs to prove that if pre-administration altered the uptake 
that it would be due to competitive binding and not affecting an input function. Because these 
imaging studies are performed without arterial blood sampling, we cannot correct for input 
function. An infusion of blocking agent prior to the radioligand infusion could alter the input 
function. In the displacement study, the radioligand is infused first- and the competitor ligand is 
not given until 40 minutes into the scan. This design allows the competitive ligand, melatonin, to 
displace any specifically bound radioligand.  
In the blocking study, 5 µg/kg melatonin in saline was dosed intravenously 10 minutes 
prior to [18F]RAGER dosing and imaging for 90 minutes (figure 5.9). This PET scan with 
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melatonin pre-administration did not reveal any decrease in radioligand uptake, maximal SUV, 
or significant change in the shape of the time activity curve compared to baseline (figure 5.10).  
 
Figure 5.9. [18F]RAGER monkey brain PET imaging with melatonin competition. Coronal and transverse summed 
(0-90 min) PET images of nonhuman primate administered with 3.6 +/- 0.7 mCi (n=4). A [18F]RAGER baseline. B 
[18F]RAGER pre-blocking 5ug/kg melatonin, C [18F]RAGER displacement study with 10 µg/kg melatonin.  
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Figure 5.10. Time activity curves of nonhuman primate PET imaging studies. Presented as SUV. A. [18F]RAGER 
baseline scans (n=2). B. [18F]RAGER 5 ug/kg melatonin blocking study. C. [18F]RAGER 10 ug/kg melatonin 
displacement study. Regions of interest displayed: R_HIPP (Right hippocampus) L_HIPP (Left hippocampus) CBL 
(cerebellum) THAL (thalamus) BG (basal ganglia) CTX (cortex). 
 
A displacement study was also performed with melatonin. In this experiment, 10 µg/kg 
melatonin in saline was dosed 40 minutes into the 90 minute scan of [18F]RAGER (figure 5.9). A 
higher dose of melatonin was chosen for this experiment to increase the likelihood of observing 
displacement. Time activity curves for baseline, blocking, and displacing studies are presented as 
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SUV (Figure 5.10). Similarly, this scan did not differ significantly in maximal SUV or shape 
from the baseline PET scan. This strongly indicates that [18F]RAGER binding in the nonhuman 
primate is specific to RAGE and there is no specific binding to MT1. 
2.6. [18F]RAGER Summary 
 In summary, we have demonstrated the synthesis and preliminary preclinical evaluation 
of [18F]RAGER: the first small molecule BBB-permeable PET radioligand for the RAGE. We 
have confirmed upregulation of RAGE in AD post-mortem cortical tissue with 
immunohistochemistry and demonstrated that [18F]RAGER co-localizes with areas of RAGE 
distribution. MicroPET imaging in rodent and non-human primate confirmed brain uptake and 
extensive washout, and the latter indicated that the radiotracer accumulates in areas of known 
RAGE expression. [18F]RAGER has a BP of 1.86 in AD tissue, suggesting potential suitability of 
this scaffold for future applications in clinical PET imaging of RAGE, but leaving scope for 
improvement. Independently, Zong et al. developed [18F]fluoro-FPS-ZM1, the same compound 
as [18F]RAGER, and reported similar blood-brain barrier permeability in mice.29 Bongarzone et 
al. have developed [11C]FPS-ZM1 that demonstrated similar in vivo tissue binding characteristics 
to [18F]RAGER.4  
 The in vitro screening for alternative binding partners (surprisingly) indicated that 
RAGER is not very promiscuous, with some interactions with DAT, Androgen, GABAA, and 
MT1 receptor (table 5.2). MT1 is known to be overexpressed in AD patient brains,
32 and this was 
confirmed in our own immunohistochemistry analysis of AD and DLB-AD brain tissue (figure 
5.7). However, competitive binding studies with melatonin on brain tissue sections did not affect 
[18F]RAGER binding (figure 5.7). This disconnect from the in vitro screening to in vitro tissue 
binding was a concern. The brain sections used were determined to be high in MT1 abundance 
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and at 10 µM of melatonin (excess) a decrease in binding was expected if [18F]RAGER bound to 
MT1. We chose to move into small animal imaging, acknowledging the in vitro complications of 
working with [18F]RAGER.  
 The solubility of RAGER is very poor. Anecdotally, we’ve heard from the group at 
King’s College working with [11C]FPS-ZM1 that they’ve also observed increased total binding 
in the presence of unlabeled compound (our experimental measure of “nonspecific binding”). 
This results in a calculated negative specific binding measurement. Together we posit the excess 
unlabeled compound is crashing out of solution on the tissue, and prevents the labeled [18F]/[11C] 
compound from being washed off the tissue section. Early on in this project, we attempted 
autoradiography with [18F]RAGER and had used plastic chambers (our usual preference in order 
to keep the assay volume low) and we measured no activity on the tissue sections. Confused, we 
counted the assay buffer and the plastic chambers themselves, and found most of the activity was 
in the plastic! In the optimization process, we had screened different buffer additives like bovine 
serum albumin (BSA), Triton-X (a detergent), and Tween-20 (a detergent). In the presence of 
BSA, there was also no activity on the tissue- which gave us an indication about plasma protein 
binding, which was later confirmed (figure 5.6B). Another assay attempt we had dissolved the 
cold compound in methanol- when 100 µL was added to a glass chamber containing 200 mL of 
assay buffer, the unlabeled compound crashed out of solution and white solids could be seen at 
the bottom of the chamber. DMSO had to be used instead, and this was a limitation on 
concentrations because we prefer to keep DMSO 1% v/v or less.  
 Solubility issues followed us into the in vivo experiments as well. Not shown, we 
attempted a rodent blocking study with unlabeled RAGER. Although we had performed no 
toxicity studies in house, the original report of FPS-ZM1 had claimed tolerability up to 100 
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mg/kg in mouse.21 We had chosen 1 mg/kg for a blocking study- and formulation was a problem. 
We contacted the first and corresponding authors of this original report to inquire of their dose 
formulation and received no reply. Attempts to make the salt form of RAGER were 
unsuccessful, though the salt form would have been easier to formulate. 10% ethanol, 5% 
methanol, and 1% DMSO (v/v) in water, saline, and PBS combinations were all attempted with 
no avail. We explored less conventional formulations and found PEG was suitable to keep 
RAGER in solution. The first rodent blocking study with this formulation was successful- it 
showed increased total uptake. Since RAGER has high plasma protein binding, and likely 
specific binding in the periphery, a blocking study was likely to result in an initial increase. The 
second rodent blocking study (of the same design) resulted in the death of the rodent during the 
scan. The scan was halted when blood was observed in the urine; the animal was removed from 
the anesthesia chamber, but unfortunately did not recover from anesthesia. This event was 
reported and observed as random: the first rodent had survived the scan, and the formulated 
blocking dose had been made fresh that morning and had passed quality control (QC) inspection. 
Similarly, the radioligand dose had passed QC inspection. A third blocking scan was attempted- 
and the rodent died during the scan with the same unexplained bleeding. We hypothesized that 
the unlabeled compound could be falling out of solution in the blood stream and causing damage 
in the liver (probably the source of bleeding). Obviously, this was a turning point in the project 
because we had concerns about the toxicity and safety of the compound. For the safety of our 
animals, we decided to no longer perform blocking studies with this compound. For the monkey 
blocking studies, melatonin (a well characterized and safe compound) was used, and no “self” 
blocking was completed. 
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 The melatonin blocking and displacement studies indicated no in vivo binding of 
[18F]RAGER to MT1 (figure 5.10). This result combined with the in vitro tissue studies would 
indicate that MT1 is not a binding partner and may be a complete disconnect from the Cerep 
panel results. We rationalize this disconnect by acknowledging that there will always be a 
difference between cell-based, tissue, and in vivo behavior of compounds based on those 
environments. RAGER binding is heavily influenced by the assay environment, as described 
through our autoradiography method development. The Cerep panel methods were out of our 
control in a way, so it is difficult to speculate if the specific instruments or items used in the 
assays (like plastic) could have influenced these results. The overall conclusion might be that 
RAGER has very high nonspecific binding, but this isn’t observed in PET imaging.  
3. Intracellular Ligand Approach 
[18F]RAGER was designed to inhibit ligand binding in the extracellular domains. This 
approach does not offer selectivity over the other isoforms of RAGE (figure 5.1). An additional 
concern with targeting the extracellular domain is that it is highly homologous throughout the 
isoforms of RAGE. There are 22 identified human isoforms of RAGE, some are active and still 
membrane bound, and some are soluble and free floating in the blood and CSF.34 The most 
predominant isoform is sRAGE, which lacks the intracellular C-tail domain.7 The relationship 
between the membrane-bound and soluble isoforms are not well understood. It could increase the 
noise and/or nonspecific binding in vivo if the radioligand had affinity to all of the isoforms of 
RAGE. A more appropriate domain to target with a small molecule radioligand is the 
intracellular C-terminus, for which there were recently identified small molecule inhibitors.35 
The intracellular C-tail is only found in active, full length RAGE which is an important 
distinction in the inflammation pathway.35 With the goal of selectivity for the full length, 
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membrane bound isoforms of RAGE, we developed [18F]InRAGER ([18F]4) and 
[11C]InRAGER2 ([11C]6) and herein report the preliminary syntheses and off-target screening. 
3.2 Synthesis of Reference Standards 
 
Scheme 5.2. Synthesis of InRAGER. 
 Synthesis of the InRAGER standard was accomplished in a one-step microwave assisted 
reaction. 2-bromo-2’,4’-difluoro-acetophenone was added to N-(3-hydroxyphenyl)thiourea 
dissolved in ethanol, reaction progressed at 50 °C, 100 W, for 5 minutes stirring, procedure 
adapted from Kabalka and Mereddy (scheme 5.2).36 Water was added to the reaction vessel and 
the resultant precipitate was collected, purification was not required.  
 
Scheme 5.3. Synthesis of [11C]InRAGER2 reference standard. 
 Synthesis of the InRAGER2 standard was accomplished over three steps in 8% overall 
yield (scheme 5.3). 4-amino-5-chloro-2-methoxybenzoic acid was acetylated and then converted 
to 4-amino-5-chloro-2-methoxybenzoyl chloride (5) in neat thionyl chloride. Intermediate (5) 
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was suspended in DCM at 0 °C and TEA was added; thiazol-2-amine was added and solution 
progressed overnight at room temperature.  
3.3 Preclinical Evaluation 
 InRAGER and InRAGER2 were discovered through high throughput screening, and little 
is known from the literature about their activities. We submitted these compounds for a 
biological screening assay at 10 µM (Cerep Panel). The results indicated some promiscuity of 
InRAGER (table 5.3). Of the 68 assays performed, InRAGER inhibited 13 of them at 60% or 
greater. The list contains receptors and transporters that are widely expressed throughout the 
CNS and would challenge the interpretation of binding in vitro and in vivo of this compound.   
Table 5.3 Off-target binding of InRAGER. Full table available in Appendix A. 
Assay Name Species % Inhibition 
Adenosine A2A Human 75.7 
Adenosine A3 Human 98.8 
BZD (peripheral) Rat 63.2 
CCK1 (CCKA) Human 76.4 
κ (KOP) Human 83.1 
EP2 Human 73.6 
5-HT2A Human 67.3 
5-HT2B Human 97.1 
UT Human 77.7 
norepinephrine transporter Human 94.6 
COX-1 Human 100.7% 
COX-2 Human 100% 
MAO-B Human 72.7% 
 
 InRAGER2 appears to be less promiscuous than InRAGER (table 5.4). The results 
obtained from the off-target screening indicated the 5-HT2B, adenosine A3, benzodiazepine, and 
UT receptors and COX-1 enzyme are shared off-targets of both InRAGER and InRAGER2 
(tables 5.3 and 5.4). Additionally, InRAGER2 has a modest IC50 for the constitutively expressed 
COX-1 enzyme. These CNS off-targets will be considered during translation to imaging. 
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Table 5.4 Off-target binding of InRAGER2. Full table available in Appendix A. 
Assay Name Species % Inhibition IC50 (µM) Ki (µM) 
5-HT2B Human 95.1 0.26 0.13 
Adenosine A3 Human 74.6 1.4 0.83 
BZD (peripheral) Rat 84.9 0.48 0.44 
COX-1 Human 71.8 12 NA 
UT Human 81.2 1.4 1 
 
3.4 Radiochemistry 
 
Scheme 5.4. Synthesis of precursors and radiochemical synthesis of [18F]InRAGER ([18F]6). 
 
 Strategies to radiolabel InRAGER involved our previously developed copper catalyzed 
fluorination methods using boronic acid37 and arylstannane precursors.38 Synthesis of stannane 
(8) and boronic acid (9) InRAGER precursors are shown in scheme 5.4A. Intermediate 3-((4-(4-
bromo-2-fluorophenyl)thiazol-2-yl)amino)phenol (7) was synthesized by the same microwave 
reaction detailed in scheme 5.2. The arylbromine of 7 was formed into the Grignard and then 
reacted with trimethyltin chloride to form the arylstannane precursor 8 in 42% yield total. The 
boronic acid precursor 9 was synthesized from the same microwave reaction detailed in scheme 
5.2, in 45% yield with column purification required (scheme 5.4B). 
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 Proposed radiofluorination for both precursors 8 and 9 is shown in scheme 5.4C. First, 
the radiofluorination was attempted manually and followed the described optimum conditions.37-
38 No reaction was observed in the case of either precursor, despite changes in pyridine and 
catalyst concentration. We suspected copper binding to the thiourea moiety. In the interest of 
time, radiosynthesis for preliminary evaluation of [18F]InRAGER in rodent was performed by 
radioisotopic exchange. The reference standard 4 was reacted with [18F]KF in DMF at 130 °C for 
30 minutes and purification on a Gemini C18 250 mm x 10 mm prep column (55% 10 mM 
NH4CO3: 45% MeCN, pH 7.4).  
3.5 [18F] InRAGER Imaging 
 PET imaging in healthy Sprague Dawley rat revealed blood-brain barrier permeability of 
[18F]InRAGER (figure 5.11). The maximum SUV was less than the observed for [18F]RAGER; 
however, the washout phase appears to be slower (figure 5.4B). This could signify more specific 
binding in vivo than [18F]RAGER. However, when the other binding partners of [18F]InRAGER 
are considered (table 5.3), the source of this specific binding cannot assumed to be RAGE. 
 
Figure 5.11. [18F]InRAGER PET imaging in rodent. 0.142 mCi injected, 305 g rodent. Whole brain region is shown 
in the time activity curve, presented as SUV. 
 
3.6 InRAGER Summary 
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 The ability to decipher full-length active RAGE abundance independent from the soluble 
and inactive isoforms would be an exciting tool for investigating RAGE biology. Toward that 
end, we initiated the development of radioligands specific for the intracellular binding site of 
RAGE’s C-terminus for Dia1, InRAGER (4) and InRAGER2 (6). Preliminary evaluation of 
[18F]InRAGER showed good brain uptake (figure 5.11), but identified possible promiscuity in 
the CNS (table 5.3). Binding to multiple, highly abundant proteins in the neurovascular unit is a 
significant hurdle to overcome in radioligand development. In particular, the possible binding of 
InRAGER to adenosine and serotonin receptors, and norepinephrine transporter (NET) are 
concerning. The involvement of neurotransmitter systems in neurodegenerative disorders is 
studied in its own right (like monoamine oxidase, detailed in chapters 3 and 4), and these 
proteins could have their own effects in disease.  
 Another challenge in this radioligand strategy was the radiolabeling step itself. For a 
preliminary rodent imaging study, isotope exchange was utilized. In development, multiple 
strategies were attempted to utilize contemporary radiochemistry methods like boronic ester37 
and trimethyltin precursors.38 In tandem with the radiochemistry optimization, the off-target 
binding results were obtained and the decision was made to halt this effort. We began to develop 
InRAGER2 as a possible carbon-11 radioligand. 
 The reference standard for InRAGER2 was synthesized (scheme 5.3) and fewer off-target 
effects were predicted from the Cerep panel (table 5.4). It is more probable that InRAGER2 
could serve as a selective RAGE ligand, and this compound will be further developed. The in 
vitro characterization for RAGE is still lacking; the compound was found to inhibit the 
intracellular RAGE domain’s binding to Dia1.35 To our knowledge, this compound has not been 
evaluated for binding on tissue. Autoradiography is recommended for future evaluation of this 
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compound, dependent upon carbon-11 labeling is successful. Future work for this project is 
further detailed in chapter 7.  
4. Methods 
Chemistry 
General Considerations 
 All the chemicals employed in the syntheses were sourced commercially and used 
without further purification. 1H NMR spectra were obtained at 400 MHz on Varian NMR 
spectrometer in CD3OD or d6-DMSO solutions at room temperature with tetramethylsilane 
(TMS, δ = 0) as an internal standard. 13C NMR spectra were obtained at 100 MHz, and 19F-NMR 
spectra were obtained at 376 MHz. Chemical shifts (δ) are reported in ppm, and coupling 
constants are reported in hertz. Multiplicity is defined by s (singlet), d (doublet), t (triplet), q 
(quartet), and m (multiplet). High performance liquid chromatography (HPLC) was performed 
using a Shimadzu LC-2010A HT system equipped with a Bioscan B-FC-1000 radiation detector. 
Mass spectra were performed on a Micromass VG 70-250-S magnetic sector mass spectrometer, 
Micromass AutoSpec Ultima magnetic sector mass spectrometer, or Agilent Q-TOF HPLC-MS 
using the electrospray ionization (ESI) method or electron ionization (EI) method. 
Preparation of N-Benzyl-N-cyclohexyl-4-fluorobenzamide (2: RAGER). Cyclohexylamine (250 
mg, 2.52 mmol) and benzaldehyde (267 mg, 2.52 mmol) were dissolved in methanol (5 mL). 
Sodium sulfate was added, and the mixture was stirred for 18 h at 50 °C. The mixture was 
filtered, and the filtrate was concentrated in vacuo. The white semisolid was redissolved in 
methanol and cooled to 0 °C. Sodium borohydride (133 mg, 3.53 mmol) was slowly added, and 
the reaction was stirred at rt for 4 h. The reaction was quenched with saturated ammonium 
chloride solution. The intermediate product was extracted with dichloromethane (3×) and dried 
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over sodium sulfate, and solvent was removed in vacuo. The intermediate product was dissolved 
in dichloromethane (6 mL), and the solution was cooled to 0 °C. Triethylamine (306 mg, 3.02 
mmol) and 4-fluorobenzoyl chloride (439 mg, 2.77 mmol) were added, and the solution was 
stirred for 18 h under argon. The reaction was quenched with H2O, and the product was extracted 
with dichloromethane (3×) and purified by flash chromatography (SiO2, 3:1 = hexanes/ethyl 
acetate). This process yielded the product as white, crystalline solid (628 mg, 80%); Rf = 0.52 
(SiO2, 3:1 = hexanes/ethyl acetate); 
1H NMR (400 MHz; DMSO-d6)/ δ (ppm) 0.97−1.63 (10H, 
m), 3.48 (1H, br), 4.63 (2H, s), 7.21− 7.51 (9H, m); 13C NMR (100 MHz; DMSO-d6)/δ (ppm) 
25.03, 25.80, 31.45, 51.17, 59.20, 115.98, 126.85, 127.08, 128.76, 129.06, 134.14, 139.96, 
163.84, 170.61; 19F NMR (376.3 MHz, DMSO-d6)/δ (ppm) −111.71(1F, s); HPLC: 98%, 
retention time =22 min, column Phenomenex Gemini C18, 250 mm × 4.6 mm, mobile phase 10 
mM NH4HCO3 in 58% MeCN, plus 2 mL/L sat. NH4OH solution, flow rate = 1.0 mL/min, 
wavelength = 254 nm; HRMS calculated for [M + H]+ (M = C20H22FNO) 312.1758, found 
312.1756. 
Preparation of 4-(Benzyl(cyclohexyl)carbamoyl)-N,N,N-trimethylbenzenaminium Iodide (3). To 
a vial was added N-benzyl-Ncyclohexyl- 4-(dimethylamino)benzamide (35.0 mg, 0.104 mmol) 
and methyl iodide (60.7 mg, 0.428 mmol). The vial was sealed, heated to 45 °C, and stirred. 
Additional methyl iodide (60.7 mg, 0.428 mmol, 20 times) was added over a few hours. After 5 
h, an off-white, insoluble semisolid was observed. After 12 h, the solvent was evaporated under 
vacuum. The solid residue was washed with hexanes (3 × 2 mL) and diethyl ether (1 × 2 mL) 
and dried under vacuum to yield the product as an off white solid (35.6 mg, 0.0744 mmol, 72%); 
Rf = 0.53 (SiO2, 3:1 = dichloromethane/methanol); 1H NMR (400 MHz; CD3OD, 55 °C)/δ 
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(ppm) 1.09(3H, m), 1.59−1.73(7H, m), 3.70 (9H, s), 4.67(2H, s), 7.22−7.30(5, m), 7.66(2H, s), 
7.98(2H, s); HRMS calculated for [M+H]+ (M = C23H31N2O) 351.2431, found 351.2429. 
Preparation of 3-((4-(2,4-difluorophenyl)thiazol-2-yl)amino)phenol) (4: InRAGER). 2-bromo-
2’,4’-difluoro-acetophenone (235 mg, 1 mmol) was added to N-(3-hydroxyphenyl)thiourea (168 
mg, 1 mmol) dissolved in ethanol (10 mL), reaction progressed at 50 °C, 100 W, for 5 minutes 
stirring.36 Water (5 mL) was added to the reaction vessel and the resultant precipitate was 
collected, purification was not required. 1H NMR (400 MHz; MeOD/ δ (ppm) 8.11 (1H, dd), 
7.22 (1H, m) 7.08 (2H,m), 6.92 (1H, m), 6.89 (1H, m), 6.55 (2H, dd). 19F NMR (347 MHz; 
MeOD/δ (ppm) -111 (1F,s), -109 (1F, s). HPLC: 98%, retention time= 38 min, column: 
Phenonomenex Gemini C18, 250 mm x 4.6 mm, mobile phase 10 mM NH4HCO3 in 45% MeCN 
at pH 7.4, flow rate= 2.0 mL/min, wavelength= 254 nm; HRMS calculated for [M+H]+ (M= 
C15H10F2N2OS) 305.0555, found 305.0563. 
Preparation of 4-amino-5-chloro-2-methoxybenzoyl chloride (5). Acetic anhydride (6.033 mmol, 
0.57 ml) was added to 4-amino-5-chloro-2-methoxybenzoic acid (5.0 mmol, 1.008 g) dissolved 
in pyridine (2.5 ml). The reaction stirred at room temperature for 5 hours and then the solvent 
was removed by rotary evaporation. Water was added (10 ml) to the solution and acidified to pH 
2 with concentrated HCl. The precipitate was further washed with water, dried, and used without 
purification in the subsequent step. Thionyl chloride (10 mmol, 10 ml) was added to the dried 
intermediate and the reaction proceeded at reflux for 3 hours. Reaction was neutralized by 
additional of cold methanol. 1H NMR (400 MHz; MeOD/ δ (ppm) 7.26 (m, 2H), 5.30 (m, 3H) 
1.25 (m, 3H). 
Preparation of 4-acetamido-5-chloro-2-methoxy-N-(thiazol-2-yl)benzamide (6: InRAGER2). 
Triethylamine (1.48 mmol, 205 uL) was added to intermediate 5 (0.496 mmol, 130 mg) 
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dissolved in DCM at 0 °C. To this stirring solution, thiazole-2-amine (0.595 mmol, 60 mg) was 
added. The solution stirred overnight and was warmed to room temperature. The reaction 
mixture was washed with water and brine, then purified (2%-10% MeOH/DCM gradient; 10g 
SiO2). 
1H NMR (400 MHz; CD3OD/ δ (ppm) 8.568 (m, 1H), 7.985 (m, 1H), 7.70 (m, 1H) 6.935 
(m, 1H), 4.060 (s, 3H) 1.25 (s, 3H). HRMS calculated for [M+H]+ (M= C13H12ClN3O3S) 
326.0361, found 326.0360. 
Preparation of 3-((4-(4-bromo-2-fluorophenyl)thiazol-2-yl)amino)phenol (7) 2-bromo-2’-fluoro-
acetophenone (295 mg, 1 mmol) was added to N-(3-hydroxyphenyl)thiourea (168 mg, 1 mmol) 
dissolved in ethanol (5 mL), reaction progressed at 50 °C, 100 W, for 5 minutes stirring. Water 
(5 mL) was added to the reaction vessel and the resultant precipitate was collected and washed 
through a frit with DCM. HRMS calculated for [M+H]+ (M= C15H10BrFN2OS) 364.9754, found 
364.9755. 
Preparation of 3-((4-(2-fluoro-4-(trimethylstannyl)phenyl)thiazol-2-yl)amino)phenol (8) 
Magnesium turnings in THF were activated with heat (30 °C); at reflux, a solution of 
intermediate 7 in THF (1M) was added dropwise over 25 minutes. Reaction progressed at reflux 
overnight. The reaction mixture was cooled to room temperature and a solution of 
trimethyltinchloride in THF (3.4 mmol, 677 mg) was added. The reaction progressed at room 
temperature for three hours. To quench the reaction, it was poured into an equal volume of cold 
saturated NH4Cl solution. Product was extracted with 2 x 10 mL volumes of ether, washed with 
water, and the solvent removed by rotary evaporation. Product was purified by column 
chromatography (20% EA/Hex gradient). 1H NMR (400 MHz; CD3OD/ δ (ppm) 8.067 (m, 1H), 
7.41 (m, 1H), 7.23 (m, 2H), 7.14 (m, 2H) 6.56 (m, 2H), 0.67 (s, 9H). 
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Preparation of (3-fluoro-4-(2-((3-hydroxyphenyl)amino)thiazol-4-yl)phenyl)boronic acid (9) 4-
bromoacetyl-3-fluorophenylboronic aicd (261 mg, 1 mmol) was added to N-(3-
hydroxyphenyl)thiourea (168 mg, 1 mmol) dissolved in ethanol (5 mL), reaction progressed at 
50 °C, 100 W, for 5 minutes stirring. Water (5 mL) was added to the reaction vessel and the 
resultant precipitate was collected, purification was not required. 1H NMR (400 MHz; MeOD/ δ 
(ppm) 8.09 (1H, dd), 7.91 (1H, m) 7.47 (2H,m), 7.03 (1H, m), 6.89 (1H, m), 6.55 (2H, dd)). 19F 
NMR (347 MHz; MeOD/δ (ppm) -111 (1F,s), -109 (1F, s); HRMS calculated for [M+H]+ (M= 
C15H10BF2N2O3S) 331.0718, found 331.0728. 
Radiochemistry 
General Considerations 
 Unless otherwise stated, reagents and solvents were commercially available and used 
without further purification: sodium chloride, 0.9% USP, and sterile water for injection, USP, 
were purchased from Hospira; ethanol was purchased from American Regent; HPLC grade 
acetonitrile was purchased from Fisher Scientific. Other synthesis components were obtained as 
follows: sterile filters were obtained from Millipore; sterile product vials were purchased from 
Hollister-Stier; QMA-light and C18-light Sep-Paks were purchased from Waters Corporation. 
Sep- Paks were flushed with 10 mL of ethanol followed by 10 mL of sterile water prior to use.  
[18F]RAGER (4). [18F]KF was prepared using a TRACERLab FXFN automated radiochemistry 
synthesis module (General Electric, GE). [18F]Fluoride was produced via the 18O(p,n)18F nuclear 
reaction using a 16 MeV GE PETTrace cyclotron (40 μA beam for 30 min generated 1500 mCi 
of [18F]fluoride). The [18F]fluoride was delivered to the synthesis module (in a 1.5 mL bolus of 
[18O]water) and trapped on a QMA-light Sep-Pak to remove [18O]water. [18F]Fluoride was eluted 
into the reaction vessel using K2CO3 (3.5 mg in 0.5 mL of water). A solution of K2.2.2 (15 mg in 1 
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mL of acetonitrile) was added to the reaction vessel, and the resulting solution was 
azeotropically dried by heating the reaction vessel to 100 °C and drawing vacuum for 4 min. 
After this time, the reaction vessel was subjected to an argon stream and simultaneous vacuum 
draw for an additional 4 min. RAGER precursor 3 (1.5 mg dissolved in 0.5 mL of DMF) was 
delivered to the reaction vessel, and the reaction was heated to 130 °C and stirred for 30 min. 
After this time, the reactor was cooled to 55 °C and 2 mL of semipreparative HPLC solvent was 
added to the crude reaction mixture. This mixture was injected onto a semipreparative HPLC 
column (column Phenomenex Gemini C18, 250 mm × 10 mm; mobile phase 10 mM NH4HCO3 
in 58% MeCN, pH 9.0 adjusted with 2 mL/L sat. NH4OH, flow rate = 2.5 mL/min. The product 
peak (∼36−37 min retention time) was collected and diluted into a round-bottom flask 
containing 50 mL of water. The solution was then passed through a C-18 extraction disk to 
remove organic solvent. The disk was washed with 5 mL of sterile water. The product was eluted 
with 0.5 mL of ethanol followed by 4.5 mL of normal saline. The final formulation was passed 
through a 0.2 μM needle filter into a sterile dose vial. We obtained 44.6 ± 10 mCi (1650 ± 385 
MBq), 3.0% uncorrected yield, > 99% RCP, 3740 ± 495 Ci/mmol (138 ± 18 GBq/mmol), pH = 
5.5, n = 6. Quality Control. Quality control of radiopharmaceutical doses was conducted using 
the following tests. Visual Inspection. Doses were examined visually to confirm that they were 
clear, colorless, and free of particulate matter. Dose pH. The pH of the doses was analyzed by 
applying a small amount of the dose to pH-indicator strips and determined by visual comparison 
with the provided scale. HPLC Analysis. Radiochemical purity of [18F]RAGER was assessed 
using Shimadzu LC-2010A HT system equipped with the UV and Rad detectors (column 
Phenomenex Gemini C18, 250 mm × 4.6 mm; mobile phase 10 mM NH4HCO3 in 58% MeCN, 
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pH 9 adjusted with 2 mL/L sat. NH4OH solution; flow rate = 1.0 mL/min; wavelength = 254 nm; 
room temperature; product peak ≈ 22.5 min. 
[18F]InRAGER (6). [18F]KF was prepared using a TRACERLab FXFN automated 
radiochemistry synthesis module (General Electric, GE). [18F]Fluoride was produced via the 
18O(p,n)18F nuclear reaction using a 16 MeV GE PETTrace cyclotron (40 μA beam for 30 min 
generated 1500 mCi of [18F]fluoride). The [18F]fluoride was delivered to the synthesis module (in 
a 1.5 mL bolus of [18O]water) and trapped on a QMA-light Sep-Pak to remove [18O]water. 
[18F]Fluoride was eluted into the reaction vessel using K2CO3 (3.5 mg in 0.5 mL of water). A 
solution of K2.2.2 (15 mg in 1 mL of acetonitrile) was added to the reaction vessel, and the 
resulting solution was azeotropically dried by heating the reaction vessel to 100 °C and drawing 
vacuum for 4 min. After this time, the reaction vessel was subjected to an argon stream and 
simultaneous vacuum draw for an additional 4 min. InRAGER (4) (3 mg dissolved in 0.5 mL of 
DMF) was delivered to the reaction vessel, and the reaction was heated to 130 °C and stirred for 
30 min. After this time, the reactor was cooled to 55 °C and 2 mL of semipreparative HPLC 
solvent was added to the crude reaction mixture. This mixture was injected onto a 
semipreparative HPLC column (column Phenomenex Gemini C18, 250 mm × 10 mm; mobile 
phase 10 mM NH4HCO3 in 55% MeCN, pH 7.5, flow rate = 4 mL/min. The product peak (∼35 
min retention time) was collected and diluted into a round-bottom flask containing 50 mL of 
water. The solution was then passed through a C-18 extraction disk to remove organic solvent. 
The disk was washed with 5 mL of sterile water. The product was eluted with 0.5 mL of ethanol 
followed by 4.5 mL of normal saline. The final formulation was passed through a 0.2 μM needle 
filter into a sterile dose vial. We obtained 0.500 mCi in 99% RCP, pH = 5.5, n = 1. Quality 
Control. Quality control of radiopharmaceutical doses was conducted using the following tests. 
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Visual Inspection. Doses were examined visually to confirm that they were clear, colorless, and 
free of particulate matter. Dose pH. The pH of the doses was analyzed by applying a small 
amount of the dose to pH-indicator strips and determined by visual comparison with the provided 
scale. HPLC Analysis. Radiochemical purity of [18F]InRAGER was assessed using Shimadzu 
LC-2010A HT system equipped with the UV and Rad detectors (column Phenomenex Gemini 
C18, 250 mm × 4.6 mm; mobile phase 10 mM NH4HCO3 in 55% MeCN, pH 7.5; flow rate = 2.0 
mL/min; wavelength = 254 nm; room temperature; product peak ≈ 13 min. 
Preclinical Evaluation 
Immunohistochemistry 
 Fixed tissue sections were incubated in PBS with 1% SDS for 5 min. Sections were then 
washed 3 x 5 min in PBS before quenching in 70% methanol with 0.3% hydrogen peroxide for 
15 min. All slides were washed 3 x 5 min in PBS-T (PBS, 0.4% Triton-X-100, pH 7.4) and 
blocked for 30 min with PBS-TBA (PBS, 0.4% Triton-X-100, 1% BSA, 0.025% sodium azide, 
pH 7.4) before incubating in a 1:200 dilution of primary antibody (anti-RAGE, Novus Biologics 
(NBP242913) or anti-MTNR1A, Life Technologies Inc (PA519109)) in PBS-TBA overnight. 
Finally, brain sections were washed 3 x 5 minutes in PBS-T to remove unbound antibody. Tissue 
sections were incubated in a 1:200 dilution of secondary antibody, anti-rabbit-IgG, Vector 
Laboratories BA-1000) in PBS-TBA for 2 hr and washed 3 x 5 min with PBS-T. All incubations 
were carried out at room temperature. Slides were developed as instructed using the 
VECTASTAIN Elite ABC Kit (Standard) (Vector Laboratories PK-6100). Tissue sections were 
then washed 3 x 5 min in PBS-T before incubating for 4 min in a 0.5% w/v solution of 
diaminobenzidine in PBS-T (filtered) with 0.001% hydrogen peroxide. Giemsa counterstaining 
was utilized to visualize nucleus and cytoplasm in cells. Tissue sections were washed for 5 min 
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in dH2O prior to overnight incubation in a 1:50 solution of Giemsa in dH2O. Slides were then 
rinsed for 30 sec in dH2O, 2 x 4 min in n-butanol, and 1 min in xylene. Permount was applied to 
the fixed tissue to attach coverslips to the polylysine-coated glass slides and allowed to set for 45 
min prior to quantification. All incubations were carried out at room temperature. 
Immunoreactivity was quantified using ImageQuant. A region was drawn around the entire 
tissue section and using the serial section manager, 5% of the section was counted and picked 
using a randomized rotation. Immunoreactivity is presented as cells/ µm2. Statistical analyses 
were performed in GraphPad Prism (8.01). 
Autoradiography 
 Brain sections on slides were removed from -80°C freezer and thawed at room 
temperature for 5 min before rehydration in phosphate buffer saline (PBS, pH 7.4) for another 5 
min. Then, brain sections were incubated with a range of concentrations of [18F]RAGER for Kd 
and Bmax determination. Incubation times were determined by equilibrium experiments; 30 
minute incubations were used for [18F]RAGER. Assay buffer included 0.5% Tween-20, and all 
incubations were performed in glass beakers. All sections were washed 3 x 2 min with PBS at 4 
°C and then rinsed in dH2O for 30 sec at 4 °C to remove unbound radioactivity. Finally, slides 
were dried under the continuous airflow for 30 min before exposure to a high-resolution 
phosphoimaging plate for 10 minutes. The exposed plate was scanned using a GE Typhoon FLA 
7000 phosphoimager. Image analysis was performed using ImageQuant (Molecular Dynamics) 
software.  
Plasma Protein Binding and Metabolism 
 The University of Michigan Pharmacokinetics (PK) Core determined plasma protein 
binding affinities to RAGER. Three doses of RAGER were prepared in DMSO (1 mM, 100 µM, 
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and 10 µM) and verapamil in DMSO (100 µM) was used as a positive control. RAGER was added 
to mouse plasma (final RAGER concentrations of 10 µM, 1 µM, and 0.1 µM) in duplicate. 200 µL 
of sample was added into the sample chamber, and 350 µL of PBS buffer was added to the 
neighboring buffer chamber. Solutions were incubated at 37 °C for 5 hours in the sample chamber 
(Thermo Singlue-use RED plate). Post incubation, corresponding plasma and buffer samples were 
mixed in equal volume and the internal standard was added in cold acetonitrile to precipitate 
proteins. The solution was vortexed and incubated on ice for 30 minutes. The entire solution was 
centrifuged for 10 minutes at 3500 rpm; the supernatant was analyzed by LC/MS/MS (Column: 
Waters XBridge C18). Metabolism performed as previously described.1 
Biodistribution in Sprague Dawley Rat 
 Two males (weight: 260 +/- 30 g) and two females (weight: 200 +/- 15 g) were utilized per 
time point were intravenously injected with [18F]RAGER (n= 16, 80 +/- 40 uCi) via tail-vein at 5, 
30, 60, and 120 minutes.  Post-administration animals were euthanized, dissected, and then each 
tissue was weighed and analyzed for radioactivity using PerkinElmer 2480 automatic gamma 
counter. Biodistribution studies confirmed brain permeability and quick washout, with radioligand 
absent from brain at the 60 and 120 minute time points. Limited exposure was observed in other 
organs, and some accumulation was observed in the later time points in the small intestine. No 
bone uptake was observed indicating that there was no radiolytic defluorination of [18F]RAGER. 
Off-target Screening 
  RAGER, InRAGER, and InRAGER2 reference standards were evaluated in the 
LeadProfile Screen (Cerep Panlabs) set of assays. Test concentration was 10 µM. Follow up Ki 
and IC50 measurements were performed on RAGER and InRAGER2 for assays that reported >50% 
inhibition in the preliminary screen. Full tables of results are listed in Appendix A. 
147 
 
Imaging 
General Considerations 
 All animal studies were performed in accordance with standards set by the University 
Committee on Use and Care of Animals (UCUCA) at the University of Michigan. 
Rodent Imaging Studies 
 Studies were done using male Sprague Dawley rats (n=3, weights= 330 +/- 40g). The 
animals were anesthetized (isoflurane), intubated, and positioned in a Concorde MicroPET P4 
scanner. Following a transmission scan, the animals were inject i.v (via tail vein) with 
[18F]RAGER (310 +/- 50 uCi) as a bolus over 1 min, and the brain imaged for 90 min (5 x 1 min 
frames – 2 x 2.5 min frames – 2 x5 min frames – 7 x 10 min frames). For the melatonin blocking 
study, melatonin was injected 10 min prior to imaging (5 ug/kg iv). [18F]InRAGER rodent imaging 
study was performed in the same manner. 
Primate imaging studies 
 Imaging was done using a mature female rhesus macaque (n=4, weight= 7.2 +/- 0.3 kg). 
The monkey was anesthetized (isoflurane), intubated, and positioned in a Concorde MicroPET P4 
scanner. Following a transmission scan, the animal was injected i.v with [18F]RAGER (3.6 +/- 0.7 
mCi) as a bolus over 1 min, and the brain imaged for 90 min(5 x 1 min frames – 2 x 2.5 min frames 
– 2 x5 min frames – 7 x 10 min frames). For the first melatonin blocking study, 10 minutes prior 
to [18F]RAGER injection, the animal was given a bolus injection i.v of melatonin (5 ug/kg). For 
the second melatonin blocking study, the animal was given a bolus injection i.v of melatonin (10 
ug/kg) 40 minutes into the [18F]RAGER scan. 
Image Analysis 
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 Emission data were corrected for attenuation and scatter, and reconstructed using the 3D 
maximum a priori method (3D MAP algorithm). Using a summed image of the entire data set, 3D 
volumes of interest (VOI) were determined by placing a seed voxel in the middle of various brain 
regions, and then using region- specific thresholds to automatically determine the extent of each 
VOI. VOIs were determine for the whole brain (rodent) or whole brain, striatum, thalamus, cortex, 
hippocampus, and cerebellum (primate). Previous data sets in the same primate were used as 
reference determining specific VOIs ([11C]flumazenil for cortex and cerebellum, [11C]DTBZ for 
striatum, [11C]carfentenil for thalamus and hippocampus).  The VOIs were then applied to the full 
dynamic data sets to obtain the regional tissue time-radioactivity curves. Time activity curves were 
normalized between studies by the animal weight and amount of activity injected to result in 
standardized uptake value (SUV) curves. 
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CHAPTER 6 
Investigation into RAGE as a Neuroinflammatory Biomarker 
 
 After our efforts to develop small molecule radioligands to use as molecular probes in the 
study of RAGE biology, we decided to focus on more biological techniques because the small 
molecule’s behavior in vivo was not selective enough. In order to optimize these RAGE ligands, 
we needed to understand how RAGE is involved in neuroinflammation. We decided to evaluate 
RAGE in the widely used animal model of lipopolysaccharide (LPS) induced inflammation. If 
this model shows increased RAGE activity, it could be further used for ligand optimization. 
1. Introduction  
 The receptor for advanced glycation end-products (RAGE) was isolated and 
characterized in the early 1990’s by researchers focused on vascular dysfunction. Schmidt and 
coworkers described the receptor based on its first recognized ligands, advanced glycation end-
products (AGEs).1 AGEs are non-enzymatically glycated macromolecules such as proteins, 
peptides, DNA, lipids, and etc. These modifications occur in oxidative environments in the 
presence of glucose, which provides a logical explanation for this receptor’s involvement in 
diabetes and related neuropathy.2 The isolated gene contained three putative binding sites for 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a transcription factor 
well known for its pro-inflammatory nature. After cellular experiments using both endothelial 
and smooth muscle cells with lipopolysaccharide (LPS) stimulation, NF-κB binding sites were 
confirmed and it was also discovered that the RAGE gene itself is regulated by NF-κB.3 Ligand 
binding and transcriptional activation increases the expression of RAGE, and thus the cell’s 
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sensitivity to other ligands in the extracellular environment. This positive feedback loop has been 
confirmed in other studies along with a variety of other ligands including amyloid-beta (Aβ) 
peptide.3 
 The involvement of RAGE in Alzheimer’s disease (AD) has been attributed to the fact 
Aβ is a ligand for RAGE signaling.4-5 It was claimed that RAGE mediates the interaction 
between Aβ and neuronal cells, resulting in oxidative stress.4 Experimentally, 125I-labelled Aβ 
peptide was shown to generate thiobarbituric acid reactive substances (TBARS), and this effect 
was not dependent on apolipoproteins; ApoE is known to bind Aβ peptide and was expected to 
have an effect on the binding to endothelial cells. Aβ binding proteins were identified from a pull 
down assay;4 however, this assay was performed in bovine lung. The authors claimed to use this 
tissue because it is an endothelial-cell rich, and plentiful in comparison to human brain tissue. 
The protein found from this experiment was bovine RAGE; the experiment was repeated in 
human brain homogenates and confirmed RAGE as a significant binding partner.4 In 1996, this 
was an exciting discovery in regards to the possible mechanism of action of Aβ peptide’s 
neurotoxicity and gave support to the budding neuroinflammatory hypothesis. Soon after, it was 
found that RAGE bound and internalized 125I-labelled Aβ peptide in a time and temperature 
dependent manner, partially sensitive to anti-RAGE blockade.5 Combined, this body of work 
indicated a role for RAGE in neuroinflammation as two-fold: 1) Aβ peptide ligand binding 
promotes NF-κB transcription and proinflammatory signals and 2) RAGE can internalize Aβ 
peptide and thus prevent clearing it from the CNS. 
 These claims were supported by thoughtful experiments; however, the claims rely 
entirely on the experimental choice to use bovine lung tissue in the preliminary Aβ peptide pull-
down assay.4 Although the reasoning was explained to be entirely rooted in the availability of the 
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tissue type and because it is easier work with (lipids in brain tissue were challenging to work 
around), the choice could possibly have influenced the results. The same group isolated and 
characterized RAGE in bovine lung tissue in 1992 based on identifying proteins that bind 
advanced glycation end-products.6-7 Transcytosis of Aβ peptide being time and temperature 
dependent are classic signs of a transporter-like process; however, blocking the RAGE binding 
site with excess antibody only prevented 36% of internalization.5 Internalization of Aβ requires 
RAGE expression on the apical side of the blood-brain barrier endothelial cells; however, RAGE 
expression has been evaluated in astrocytes, microglia, and neurons as well.8 The real interest 
with RAGE as a neuroinflammatory biomarker relies on its presence in the hippocampus- an area 
identified by amyloid PET scanning to be involved with the earlier deposition of Aβ plaques.9 
The earliest sites of brain atrophy are the medial temporal lobe, this study suggested that atrophy 
in the hippocampus occurs preferentially with Aβ plaque accumulation.9 Increased 
immunoreactivity in hippocampal neurons of AD brains sections have supported the theory of 
RAGE’s involvement in Aβ accumulation.8, 10 
 In the classic LPS model of neuroinflammation, RAGE has been shown to be increased 
modestly in male mice and rats. LPS has long been used to induce peripheral inflammation, it is 
a known toll-like receptor 4 (TLR4) ligand. It has been previously demonstrated that relatively 
low doses, 5 mg/kg, given i.p can cause chronic neuroinflammation up to 10 months post 
induction; this experiment in particular followed TNFα, MCP-1, IL-1β, and NF-κB p65 
expression in wild-type mice.11  Male C57BL/6 J mice, which received 0.3 mg/kg doses of LPS 
by i.p injections, demonstrated a ~2 fold increase in normalized RAGE abundance after 1 day.12 
A study using Wistar rats (5 mg/kg LPS, i.p) also found increases in RAGE levels in the 
prefrontal cortex (~3 fold), cerebellum (~2 fold), and substantia nigra (SN: ~1.5 fold) compared 
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to vehicle control.13 The highest region of expression was the SN, and RAGE was found to be 
co-localized with tyrosine hydroxylase (a marker of dopaminergic neurons). Interestingly, no 
difference was found in the hippocampus- the region suggested by human 
immunohistochemistry (IHC) to be a region of high RAGE expression. Furthermore, the IHC 
analysis showed that in all brain structures, the cell site of RAGE expression had changed from 
endothelial-like structures to neuronal cells.13  
 The goal of this chapter, and to close the RAGE project, was to confirm if RAGE is a 
neuroinflammation biomarker by utilizing LPS induction in mice. We have chosen to follow this 
experimental model11 using the same wild type strain of mice and LPS dose; however, our time 
points are only 1 day and 14 days. Another important difference in our study compared to the 
literature is that we use of both male and female mice. Despite the literature precedent for only 
using male mice, there is no documented explanation for this choice. Our hypothesis consisted of 
the simple principle, if RAGE is a sensitive biomarker, then abundance changes will be evident 
at 1 day and increase 14 days in both sexes, in a similar manner to the other NF-κB transcribed 
genes: IL-1β and TNFα. Furthermore, we aimed to evaluate the selectivity of small molecule 
radioligands by performing autoradiography in this mouse brain tissue. The tissue binding 
studies should correspond to the immunoreactivity observed, assuming the small molecule 
ligands are selective and specific for RAGE. 
2. Results 
Establishing the Model  
 The mortality rate for this study was 0%; every individual survived the duration of the 
study. There was no significant change in weight/ alertness score during the 14 day LPS 
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induction (figure 6.1). Based on the dosage used, 5 mg/kg, and utilizing intraperitoneal injection, 
mortality was not considered a high risk. 
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Figure 6.1 Body weight changes over time in 14 day cohorts. Not shown: body score description did not change over 
the course of the experiment. The mean body weight of males did not statistically differ. There is a significant 
difference between mean body weight in females, due to one individual mouse beginning at 14g. At the day of 
sacrifice, there was no significant difference in body weight between the female LPS and female vehicle groups. 
 
Immunohistochemistry of the known biomarkers confirmed the induction of neuroinflammation 
in all of the experimental cohorts (figure 6.2). Males exhibited significantly higher levels of IL-
1β (1.5-10 fold) and TNFα (10-20 fold) in both the experimental cohorts. Although lower in 
abundance, the female cohorts also demonstrated a significant increase in both known 
biomarkers at 24 hour and 14 days compared to vehicle control.  
RAGE immunoreactivity 
 RAGE abundance increased in the male experimental cohorts only, not in the female 
cohorts. The increase, approximately 2.5 fold, was statistically significant (figure 6.2). The 
magnitude of change in RAGE abundance does not change between 1 day and 14 days, unlike 
the known biomarkers of this model TNFα and IL-1β.  
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Figure 6.2. Immunoreactivity of Inflammatory Biomarkers. TNFα and IL-1β immunoreactivity were compared for 
both sexes at 1 day and 14 day post LPS induction. Tukey’s multiple comparison test was used to evaluate the mean 
values. Bars show mean ± standard error of the mean; * p< 0.05, ** p< 0.01, *** p< 0.001.  
 
Autoradiography with [3H]RAGE ligands 
 Binding studies were performed on frozen tissue with three ligands for the extracellular 
domain of RAGE (figure 6.3). [3H]RAGER, based on [3H]FPS-ZM1, are both previously 
characterized for their binding to RAGE, with [3H]RAGER experimentally calculated Kd= 15 
nM. [3H]azeliragon (TTP-488) is not well documented for its binding properties and thus, we 
attempted to determine the Kd and Bmax on rat brain tissue before using the experimental LPS 
mouse tissue. Unfortunately on rat brain tissue, the exact Kd and Bmax could not be determined 
based on concentration range limitations. It was assumed the Kd for [
3H]azeliragon on tissue was 
greater than 150 nM. Binding assays were performed at 1 nM of [3H]ligand, below Kd for each 
ligand. Total binding and nonspecific binding were determined experimentally and specific 
binding was calculated as the difference (figure 6.4). 
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Figure 6.3.RAGE Ligands. Radioligands provided by Marc Skadden at Abbvie.  
 
Figure 6.4. Autoradiography Summary. In vitro binding studies (4 tissue sections/ animal) were performed to 
evaluate A) total binding, B) nonspecific binding, and to determine C) specific binding of three RAGE ligands. 
Tukey’s multiple comparison test was used to evaluate the mean values. Bars show mean ± standard error of the 
mean; * p< 0.05, ** p< 0.01, *** p< 0.001. 
 
 RAGE immunoreactivity of the mouse brain tissue suggested there should only be an 
observable change in RAGE binding in the male cohorts. Total binding (figure 6.4A) of the 
[3H]RAGE ligands did not differ significantly in the male and female cohorts in either time point 
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versus vehicle control. However, there was an increase in nonspecific binding (figure 6.4B) in 
the 1 day female cohort and 14 day male cohort (p= 0.0015, p= 0.0058).  Nonspecific binding 
refers to the so called off-target, or nondisplaceable binding of this radioligand. It could be 
relating to a difference in white matter, or unidentified off-target binding partner in the tissue. 
Calculating the specific binding from subtracting nonspecific from total (figure 6.4C) for 
[3H]RAGER reveals no significant differences across the groups. 
 The structurally related compound [3H]FPS-ZM1 also didn’t contain differences in total 
binding the male cohorts. Though, there was a significant increase in [3H]FPS-ZM1 total binding 
in the female 1 day cohort over vehicle control (p=  0.0126). [3H]FPS-ZM1 nonspecific binding 
was increased in the 1 day and 14 day male cohorts (p= 0.0026, p= 0.035); however, it was 
decreased in the 1 day female cohort (p< 0.0001).  It is very interesting to observe a decrease in 
NSB in this female cohort, while in the [3H]FPS-ZM1 total binding of the same cohort there was 
an increase. Calculating the specific binding from subtracting nonspecific from total (figure 
6.4C) still reveals a significant increase in the 1 day female cohort [3H]FPS-ZM1 binding over 
control (p= 0.0253). The [3H]FPS-ZM1 specific binding in the 1 day male group was determined 
to be negative; a phenomenon which highlights an impracticality of this measurement. The 
nonspecific binding being increased, and  higher than total binding, results in the perceived 
“negative” specific binding being significantly lower than vehicle control (p=0.0260). 
 [3H]Azeliragon total binding was also increased in the female 1 day cohort (p= 0.0003). 
However, the large variation in nonspecific binding did not show significance against the vehicle 
control in females. The 1 day male cohort had a small increase in nonspecific binding (p= 
0.0337); however, there was no detected difference in specific binding in the male groups. The 
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[3H]azeliragon specific binding in females was determined to be significantly lower in the 14 day 
cohort to control (p= 0.0083).  
3. Discussion 
 RAGE immunoreactivity of the mouse brain sections indicate that RAGE is not a 
sensitive biomarker of neuroinflammation in the murine LPS model. Unlike the known 
biomarkers IL-1β and TNFα, the change in RAGE expression did not continue to increase over 
time (figure 6.2). The documented effects of the LPS model indicate measurable changes in 
inflammatory biomarkers up to ten months after induction, with continuous increase in certain 
biomarkers.11 An increase was only measurable in the male cohorts; there are no previously 
identified sex differences in RAGE brain expression. Male mice are almost exclusively used for 
the LPS induced neuroinflammation because of the proposed protective effects of estrogen. A 
compelling investigation into these differences in the inhaled LPS model of the lung-bone 
inflammatory responsive confirmed these differences.14 LPS exposure in male mice, and 
ovarectomized female mice, lead to bone quality deterioration on the measures of bone mineral 
density and ratio of bone volume/ tissue volume. Control female mice did not have bone 
deterioration. Furthermore, estradiol supplementation of ovarectomized female mice and males 
protected against bone deterioration. There has not been a similar study involving the protective 
effect of estradiol against neuroinflammation, to my knowledge. 
 The hypothesis for this work stated that RAGE should be increased in both sexes; as the 
overall goal of the project is to develop a radioligand for PET imaging neuroinflammation in AD 
patients- and two-thirds of AD patients are female.15 While the work surrounding estradiol and 
estrogen as having protective effects is compelling, we don’t believe this translates to human 
disease in the case of neuroinflammation. If the majority of patients are female, it is appropriate 
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to utilize female animals in models of disease precisely because of the sex differences. 
Developing a radioligand for RAGE based on the LPS model would not be apt based on these 
findings because RAGE levels are not increased in female mouse brain. 
 The secondary evaluation of RAGE ligands for their selectivity and specificity in this 
tissue must be evaluated in the light that the female brain tissue has no change in RAGE 
abundance, and the male cohorts’ change is small. The observed changes in the female cohorts’ 
total, nonspecific, and specific binding strongly indicates the lack of specificity amongst these 
radioligands (figure 6.4). 
 However, there are significant differences between fixed and frozen tissue, used for 
immunohistochemistry and autoradiography respectively. Fixed tissue has been washed 
repeatedly and many soluble factors native to live tissue have been removed. Being that RAGE 
has a significant soluble splice-isoform, it is possible that the fixed tissue used for 
immunohistochemistry does not include count of this soluble factor. Fresh frozen tissue, 
however, could still contain this isoform as it has been treated with fewer and less harsh 
conditions. This could show a difference between ligand binding and immunoreactivity. Though, 
one would expect this phenomenon to be observed in both the male and female brain sections. 
 Another curiosity concerning this data set is the differing magnitudes of binding of the 
ligands. [3H]RAGER and [3H]azeliragon seem to be binding to the same degree in both male and 
female cohorts (figure 6.4A), despite the lower Kd of [
3H]RAGER. [3H]FPS-ZM1, however, very 
structurally similar to [3H]RAGER, is nearly 4 fold higher in total binding. In nonspecific 
binding, this trend is only true for the male cohorts while unexpectedly [3H]azeliragon increases 
greatly.  
162 
 
 The differences in nonspecific binding, in particular the increases over total binding, were 
expected with [3H]RAGER based on previous experience with [18F]RAGER.16 On human tissue, 
we observed higher nonspecific binding than total binding on white matter. The cause of 
nonspecific binding was never identified (see chapter 5), and it was also suspected to be a 
physiochemical effect associated with logP. Excess cold mass falling out of solution, with the 
radioligand, and not being removed through washes of the tissue. These effects could be at play 
with these [3H]RAGE ligands; however, like the previous discussion about sRAGE, it would be 
expected that this phenomenon would affect all groups equally.  
4. Conclusion  
 Overall this work argues that while small increases in RAGE were observed in males, it 
is not a sensitive or appropriate biomarker of neuroinflammation in the LPS murine model. 
Future evaluation of RAGE and its role in neuroinflammation should be performed in alternative 
animal models or strictly using human tissue. The RAGE ligands: FPS-ZM1, RAGER, and 
azeliragon, do not show appear to show specificity or selectivity to RAGE as measured by 
autoradiography on mouse tissue but any small change in RAGE expression could be masked by 
very high nonspecific binding. Further optimization of RAGE ligands is recommended before 
clinical translation, particularly to ensure specific adequate binding.   
5. Methods 
LPS Model 
Normal black mice (C57Bl/6J) were divided into experimental and vehicle control cohorts. 
Experimental cohorts were divided by sex (n=8/ each) into time groups (n=4/ each) for either 24 
hour or 14 day induction. Vehicle control cohorts were divided by gender (n=4/ each) and time 
(n=2/ each) for the same time points. Experimental cohorts received 5 mg/kg LPS (from 
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Escherichia coli O111:B4) in saline intraperitoneally. Weight and body score description was 
monitored in the 14 day cohort approximately every 3 days. Sacrifice was performed by cervical 
ligation and brain removal; brains were immediately sectioned on the sagittal plane and flash 
frozen in dry ice. Sections were stored at -80 °C until further use.  
Tissue Preparation 
 Half of the brain sections were cut using a microtome to 20 µm sections and thaw-
mounted onto poly-lysine coated glass slides. Slides utilized for immunohistochemistry were 
fixed in Davidson’s fixative (8.1% formaldehyde, 33.3% ethanol, 11.1% acetic acid, Eosin Y 
stain) for 24 hours and then rinsed with 70% ethanol to remove residual formaldehyde before 
use. Slides utilized for autoradiography were stored at -80 °C until the day of experiment. The 
corresponding halves of brain sections were grouped by cohort and homogenized together in 1X 
PBS (7.4). Homogenized solutions were utilized for scintillation proximity assay experiments on 
the same day as homogenization in order to limit the influence of freeze/ thaw cycles. 
Immunohistochemistry 
 Fixed tissue sections were incubated in phosphate buffer saline (PBS) with 1% SDS for 5 
min. Sections were then washed 3 x 5 min in PBS before quenching in 70% methanol with 0.3% 
hydrogen peroxide for 15 min. All slides were washed 3 x 5 min in PBS-T (PBS, 0.4% Triton-X-
100, pH 7.4) and blocked for 30 min with PBS-TBA (PBS, 0.4% Triton-X-100, 1% BSA, 
0.025% sodium azide, pH 7.4) before incubating in a 1:200 dilution of primary antibody (anti-
IL-1β, Fisher (AF401NA), anti-TNFα, Fisher (PIPA546945), or anti-RAGE, Fisher, 
(NBP242913)) in PBS-TBA overnight. Finally, brain sections were washed 3 x 5 minutes in 
PBS-T to remove unbound antibody. Tissue sections were incubated in a 1:200 dilution of 
secondary antibody (anti-goat-IgG, Vector Laboratories BA-5000, anti-rabbit-IgG, Vector 
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Laboratories BA-1000) in PBS-TBA for 2 hr and washed 3 x 5 min with PBS-T. All incubations 
were carried out at room temperature. Slides were developed as instructed using the 
VECTASTAIN Elite ABC Kit (Standard) (Vector Laboratories PK-6100). Tissue sections were 
then washed 3 x 5 min in PBS-T before incubating for 4 min in a 0.5% w/v solution of 
diaminobenzidine in PBS-T (filtered) with 0.001% hydrogen peroxide. Giemsa counterstaining 
was utilized to visualize nucleus and cytoplasm in cells. Tissue sections were washed for 5 min 
in dH2O prior to overnight incubation in a 1:50 solution of Giemsa in dH2O. Slides were then 
rinsed for 30 sec in dH2O, 2 x 4 min in n-butanol, and 1 min in xylene. Permount was applied to 
the fixed tissue to attach coverslips to the polylysine-coated glass slides and allowed to set for 45 
min prior to quantification. All incubations were carried out at room temperature. 
 Four tissue sections from each animal (2 sections/ slide) were used for each primary 
antibody and counted. Immunoreactivity was quantified using StereoInvestigator. A region was 
drawn around the entire tissue section and using the serial section manager, 5% of the section 
was counted and picked using a randomized rotation. Immunoreactivity is presented as cells/ 
µm2. Statistical analyses were performed in GraphPad Prism (8.01).  
Autoradiography 
 Brain sections on slides were removed from -80°C freezer and thawed at room 
temperature for 5 min before rehydration in PBS ( pH 7.4) for another 5 min. Then, brain 
sections were incubated with a range of concentrations of tritiated ligands and unlabeled ligands 
([3H]RAGER, [3H]FPS-ZM1, or [3H]azeliragon). Incubation times were determined by 
equilibrium experiments; 30 minute incubations were used for [3H]RAGER and [3H]FPS-ZM1, 
60 minutes for [3H]azeliragon at room temperature. All sections were washed 3 x 2 min with 
PBS at 4 °C and then rinsed in dH2O for 30 sec at 4 °C to remove unbound radioactivity. Finally, 
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slides were dried under the continuous airflow for 30 min before exposure to a high-resolution 
phosphoimaging plate for 2 weeks. The exposed plate was scanned using a GE Typhoon FLA 
7000 phosphoimager. Image analysis was performed using ImageQuant (Molecular Dynamics) 
software. Regions of interest were drawn and converted to DPM/ µg protein using the Amersham 
standards, and then using the individual ligand’s specific molar activity converted to nmole/ µg 
protein. 
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CHAPTER 7 
 Conclusions & Future Directions 
“I never look back, darling! It distracts from the now.” – Edna Mode, The Incredibles 
1. Overall Conclusions 
 The number of individuals with neurodegenerative disorders, particularly Alzheimer’s 
disease (AD), is growing and is projected to continue increasing.1 Despite this reality, there are 
no available treatments for AD.2 Positron emission tomography (PET) imaging has been a 
valuable tool in this drug discovery and development process, and has been used to advance 
pathological research of AD. PET imaging strategies in AD have followed the biomarkers used 
in the drug discovery pipeline, with an early focus on amyloid-β (Aβ)3 and tau neurofibrillary 
tangles (NFTs), neurotransmitter systems, and neuroinflammation.4 The focus of this thesis has 
been on using PET imaging to investigate AD pathology, and research projects have bridged 
bench to bedside. Firstly, the tau ligand [18F]AV-1451, that is routinely employed for clinical tau 
PET scans in our PET center, was investigated for its off-target binding effects to monoamine 
oxidase (MAO). Secondly, MAO is a marker of microgliosis, the activation of microglia, and we 
considered to use it as a biomarker for PET imaging neuroinflammation. We developed 
substrates for imaging MAO-B activity, using a trapped metabolite approach.5 Inspired by this 
principle, we used an MAO substrate, [11C]AZ to demonstrate that it would be possible to use an 
enzyme substrate for dual PET-magnetic resonance (MR) imaging. PET-MR with a single agent 
was typically considered impossible because PET imaging would not work at the high mass (low 
specific activity) generally required for PET imaging. We demonstrated that MAO was not 
saturable in vivo at the necessary MR concentration, and that PET scans could be acquired with 
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no detriment to signal quantification.6 Lastly, we evaluated ligands for a new biomarker of 
neuroinflammation, the receptor for advanced glycation end-products (RAGE), using an 
extracellular7 and intracellular approach. We evaluated RAGE as a biomarker using the standard 
lipopolysaccharide (LPS) murine model of neuroinflammation. We found 2 fold increases in 
male mouse brain, consistent with literature;8 however, no significant change in female mouse 
brain. Given the small changes in RAGE expression and the pronounced sex difference in rodent, 
we recommend that this model not be used in the future to evaluate or optimize new RAGE 
ligands. 
 This body of work has made progress in the field of AD research, with particular focus 
toward investigating MAO and RAGE as suitable neuroinflammatory biomarkers. Despite this 
progress, many questions remain. In the subsequent sections, ideas for future steps are outlined 
for each chapter. 
2. Monoamine Oxidase as an Off-Target of [18F]AV-1451 
 In summary, we confirmed that AV-1451 is an inhibitor of monoamine oxidase (MAO) 
activity through the in vitro assay we had previously developed.5 We demonstrated that [18F]AV-
1451 binding on tissue can be displaced with MAO inhibitors, and that total [18F]AV-1451 
binding correlates positively to MAO-B immunoreactivity in human, diseased substantia nigra 
tissue. Using mature, female rhesus macaques, we showed that pretreatment with an MAO 
inhibitor changed the equilibrium binding in various brain regions, including in the cerebellum 
(the reference region). The combined results suggest that MAO is playing a role in human 
[18F]AV-1451 PET imaging and that a prospective clinical trial investigating this issue in human 
tau PET is worth performing. 
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 The eventual goal of this work was to demonstrate preclinical proof of concept to justify 
a clinical trial. This trial would recruit MAO inhibitor (MAO-I) naïve patients and have them 
undergo a baseline [18F]AV-1451 PET scan and a second scan following pretreatment with a low 
dose of deprenyl 1 hour before. Standard uptake value ratio (SUVR) is a measure can often 
underestimate the effect of off-target binding, and as such it would be ideal to do dynamic 
scanning in these patients. Though this is not always appropriate in patient populations because 
dynamic scans require the individual to stay in the PET scanner for nearly two hours, it is still 
possible. It would also, ideally, include arterial blood sampling- a process that is uncomfortable 
and invasive to the patient, but which is essential for understanding subtle changes that might 
stem from MAO inhibition. 
 It is worth considering, before undertaking such a clinical trial, what the impact might be 
on the field. Off-target binding to MAO has been known (but not necessarily accepted) by the 
community since 2012; however, this has not really affected the use of [18F]AV-1451. With the 
development of [18F]MK-6240, which in some accounts appears to be a better tracer due to its 
higher overall signal. We would predict that [18F]AV-1415 scans will become less widely used in 
the next five years. Realistically speaking, after 6 months to a year (the time required to conduct 
such a clinical trial), this information might not be able to impact how tau PET is conducted. 
3. Trapped Metabolite PET Imaging of MAO-B 
 MAO-B is an incredibly well characterized enzyme, and yet there is still debate over how 
substrates are oxidized. In a small way, this work contributed to the discussion over this in vivo 
enzymatic mechanism. We developed an assay using human MAO supersomes and a fluorogenic 
substrate to evaluate the kinetic isotope effect (KIE) from deuterium substitution. The in vitro 
assay predicted no observable change in turnover; which was confirmed in vivo using PET 
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imaging. The basis for the expected KIE was rooted in the hydrogen abstraction (HAT) 
mechanism and oxidation being the rate limiting step in the mechanism. Our results indicate that 
for this substrate, either HAT is not the mechanism experienced or other steps are partially rate 
limiting and mask the expected KIE.5 The next step for the [11C]Cou project would be clinical 
translation. Arterial blood sampling during the PET scan would allow for kinetic modeling. It is 
possible that with input function correction, this radiotracer is better behaved than assumed in 
nonhuman primate brain with no input function. 
4. Monoamine Oxidase: Dual PET-MR Imaging 
 This study served as a proof of concept for using one agent for both detection by PET and 
MRS. The feasibility was proven in our rodent studies showing no change in the time activity 
curves of [11C]PMP and [11C]AZ at high and low specific activity.6 The obvious next step for 
this project would be to acquire an MR scan using our AZ substrate; however, our lab does not 
have a small animal MR and so we are setting up a collaboration with Joan Greve’s MR 
laboratory in Biomedical Engineering to conduct this work. Furthermore, before using AZ as a 
PET-MR agent in the clinic, a toxicity study would need to be performed. In order to use the 
high mass of compound necessary for MR, a toxicity study is necessary. This project is a proof 
of concept and is not intended to sell [11C]AZ as a good MAO dual PET-MR tracer for clinical 
imaging, but instead serve as an example for future dual imaging strategies. 
5. Imaging the receptor for advanced glycation end-products 
5.1 Intracellular 
 Small molecule inhibitors of RAGE were not discovered until high throughput screening, 
also performed by the Schmidt group, discovered FPS-ZM1.9 This hit compound was validated 
as a RAGE-Aβ peptide inhibitor in vitro, and showed decreased Aβ fibril accumulation in an AD 
172 
 
mouse model. Independently, FPS-ZM1 has been used as an inhibitor and shown to reduce AGE-
induced oxidative stress in primary microglia.10 Despite this hit compound never being 
optimized after a structure-activity relationship study revealed flat SAR,11 this compound is cited 
in six separate patents for various use in chronic obstructive pulmonary disease (COPD),12 
cachexia,13-14 AD,15-16 and renal failure.17 
 In chapter 5, the RAGE project focused on the development of radioligands for the 
extracellular and (to a lesser extent) intracellular domains of RAGE. The original proposal for 
this project, as outlined in my candidacy document, was to synthesize a small library of RAGER 
analogues with the goal of improving specific binding (retention of radioligand) in vivo. FPS-
ZM1 was always a hit compound, not a lead, and we aimed to do some hit optimization for the 
purpose of radioligand development. However, as the evaluation of [18F]RAGER progressed, and 
nonspecific binding became an inescapable issue, the analogue side of this project was put on 
hold in order to better understand the basic biology of RAGE as an imaging biomarker. The 
details of the proposed experiments, as well as the progress made, will be described in the 
following sections. 
 A direct binding assay using surface plasmon resonance (SPR) was proposed to evaluate 
the RAGER analogue library. Assay development required the overexpression and purification 
of RAGE-VC1 domains, condition optimization, and positive controls (known RAGE-VC1 
ligand S100A had been selected for this). The RAGE-VC1 with 6xHis tag was gifted to me by 
Dr Laure Yatime; the crystallographer responsible for proposing a dimer structure for these 
domains (figure 7.1).18-19 A small library of 13 RAGER analogues were synthesized (figure 7.2). 
5.2 RAGE-VC1 protein purification 
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Transformation. 2uL of pETM11-RAGEVC1 to Shuffle T7 E.coli cells. Incubate on ice for 30 
min. Cells were heat shocked at 42 °C for 30 s before 625 µL of fresh 2XYT media was added. 
Cells were allowed to shake at 37 °C for 1 h, then a 50 µL sample was spread onto a warm 
kanamycin-agar plate. The plate was incubated overnight at 37 °C. 
Culture + Overexpression. A single, isolated colony was picked from the plate with a sterile 
toothpick. The toothpick was dropped into a plastic tube containing fresh 2XYT media (10 mL) 
and kanamycin. The culture was incubated overnight at 37 °C. Next, the starter culture was 
diluted into 1 L of 2XYT media with kanamycin. A 1 mL sample was removed to serve as a 
“blank” to read OD600. The culture was incubated at 37 °C until OD600 = 0.7 (about 3 hours). 
Overexpression was induced with 1 mM IPTG. The culture was incubated and shaken overnight 
at 18 °C. 
Purification. Cells were harvested by centrifugation (9000 g for 20 min at 4 °C). Cell pellet was 
resuspended in 25 mL of buffer A (50 mM HEPES, 300 mM NaCl, 30 mM imidazole, 1 mM 
PMSF, pH 7.4). Cells were sonicated (required multiple rounds). Solution was clarified by 
centrifugation (31,000 g for 20 min at 4 °C) and the supernatant was filtered. Supernatant was 
applied to 5 mL Ni-column (HisTrap FF column) and begin program “Histrap FF RAGE”, 4% B 
and then 40%B). Fractions were collected and concentrated before dilution with 50mM HEPES 
(pH 7.5) to reach a final salt concentration of 250 mM. These were then applied to 9-mL Source 
15S cation exchange. Elution performed with a 100-ml linear gradient from 250-650 mM NaCl 
for VC1, elute as single peak around 440 mM NaCl. Fractions were collected and analyzed by 
SDSPAGE (figure 7.2). 
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Figure 7.1. SDS-PAGE analysis of RAGE-VC1 purification. Lane 1. Crude, post-sonification. 2. Cell pellet. 3. 
Lysate. 4. HisTrap FF column flow through. 5. CIEX flow through. 6. Fractions (4-6). 7. Fractions (8-9). 8. Ladder. 
His Trap elutate (not shown) was used immediately into the CIEX column. 
 
5.3 Synthesis of RAGE Analogue reference standards 
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Figure 7.2. RAGER Analogues 
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Scheme 7.1. Generic Synthesis for RAGER analogues. 
 
Preparation of N-benzyl-N-cyclopropyl-4-fluorobenzamide (3-RAGER). Cyclopropylamine 
(2.52 mmol, 143 mg) and benzaldehyde (2.52 mmol, 267 mg) were dissolved in methanol (5ml). 
Sodium sulfate was added and the mixture stirred at 50 °C overnight. After filtration, the filtrate 
was concentrated in vacuo to remove unreacted benzaldehyde. The resultant semisolid was 
redissolved in methanol (5ml), cooled to 0°C; sodium borohydride was slowly added. The 
reaction stirred for 4 hours and then was quenched with saturated ammonium chloride solution. 
The intermediate was extracted in dichloromethane and did not require purification. 
Triethylamine (3.02 mmol, 306 mg) was added to the intermediate dissolved in dichloromethane, 
mixture was cooled to 0°C and 4-fluorobenzoyl chloride (2.772 mmol, 439.5 mg) was added. 
The solution was stirred overnight under argon. The reaction was quenched with H2O and the 
product extracted in dichloromethane. Product was purified by flash chromatography. 1H NMR 
(400 MHz; CDCl3/ δ (ppm) 7.52 (d, 2H), 7.34 (m, 3H), 7.09 (m, 2H), 4.74 (s, 2H), 2.59 (m, 1H), 
0.58 (s, 2H), 0.48 (s, 2H)). 19F NMR (347 MHz; CDCl3/δ (ppm) -110.53 (s, 1F). HRMS 
calculated for [M+H]+ (M= C17H16FNO) 270.1289, found 270.1282.  
Preparation of N-benzyl-N-cyclopentyl-4-fluorobenzamide (5-RAGER) Cyclopentylamine (2.52 
mmol, 214.6 mg) and benzaldehyde (2.52 mmol, 267 mg) were dissolved in methanol (5ml). 
Sodium sulfate was added and the mixture stirred at 50 °C overnight. After filtration, the filtrate 
was concentrated in vacuo to remove unreacted benzaldehyde. The resultant semisolid was 
redissolved in methanol (5 ml), cooled to 0 °C; sodium borohydride was slowly added. The 
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reaction stirred for 4 hours and then was quenched with saturated ammonium chloride solution. 
The intermediate was extracted in dichloromethane and did not require purification. 
Triethylamine (3.02 mmol, 306 mg) was added to the intermediate dissolved in dichloromethane, 
mixture was cooled to 0°C and 4-fluorobenzoyl chloride (2.772 mmol, 439.5 mg) was added. 
The solution was stirred overnight under argon. The reaction was quenched with H2O and the 
product extracted in dichloromethane. Product was purified by flash chromatography. 1H NMR 
(400 MHz; MeOD/ δ (ppm) 7.429 (s, 1H), 7.324 (m, 2H), 7.238 (m, 2H), 7.066 (m, 2H), 4.612 
(s, 2H), 1.642 (m, 5H). 19F NMR (347 MHz; MeOD/δ (ppm) -111.060 (s, 1F); HRMS calculated 
for [M+H]+ (M= C19H20FNO) 298.1602, found 298.1611.  
Preparation of N-cyclopently-4-fluoro-N-(pyridine-4-ylmethyl)benzamide (5P-RAGER) 
Cylcopentlyamine (2.52 mmol, 214.6 mg) and isonicotinaldehyde (2.52 mmol, 270 mg) were 
dissolved in methanol (5ml). Sodium sulfate was added and the mixture stirred at 50 °C 
overnight. After filtration, the filtrate was concentrated in vacuo to remove unreacted 
isonicotinaldehyde. The resultant semisolid was redissolved in methanol (5ml), cooled to 0°C; 
sodium borohydride was slowly added. The reaction stirred for 4 hours and then was quenched 
with saturated ammonium chloride solution. The intermediate was extracted in dichloromethane 
and was purified by flash chromatography (gradient, DCM to 10% MeOH: Rf= 0.4). 
1H NMR 
(400 MHz; CDCl3/ δ (ppm) 8.54 (d; 2H), 7.30 (d; 2H), 3.81 (s; 2H), 3.11 (s; 1H), 1.85 (m; 1H), 
1.71 (m; 2H), 1.54 (m; 2H), 1.53 (m; 2H), 1.41 (m; 2H). HRMS calculated for [M+H]+ (M= 
C11H16N2) 176.13, found 177.1386. Triethylamine (3.02 mmol, 306 mg) was added to the 
intermediate dissolved in dichloromethane, mixture was cooled to 0°C and 4-fluorobenzoyl 
chloride (2.772 mmol, 439.5 mg) was added. The solution was stirred overnight under argon. 
The reaction was quenched with H2O and the product extracted in dichloromethane. Product was 
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purified by flash chromatography. 1H NMR (400 MHz; MeOD/ δ (ppm) 8.711 (s, 2H), 8.139 (m, 
2H), 7.421 (m, 2H), 7.257 (m, 2H), 5.402 (s, 2H), 1.23 (m, 5H). 19F NMR (347 MHz; MeOD/δ 
(ppm)-104.54 (s, 1F); HRMS calculated for [M+H]+ (M= C18H19FN2O) 299.1554, found 
299.1565.  
Preparation of N-cyclohexyl-N-((1-methyl-1H-imidazol-5-yl)methyl)-4-fluorobenzamide. (C-IZ 
RAGER) Cyclohexylamine (2.52 mmol, 250 mg) and 1-methyl-1H-imidazole-5-carbaldehyde 
(2.52 mmol, 277 mg) were dissolved in methanol (5ml). Sodium sulfate was added and the 
mixture stirred at 50 °C overnight. After filtration, the filtrate was concentrated in vacuo to 
remove unreacted 1-methyl-1H-imidazole-5-carbaldehyde. The resultant semisolid was 
redissolved in methanol (5ml), cooled to 0°C; sodium borohydride was slowly added. The 
reaction stirred for 4 hours and then was quenched with saturated ammonium chloride solution. 
The intermediate was extracted in dichloromethane and did not require purification. 
Triethylamine (3.02 mmol, 306 mg) was added to the intermediate dissolved in dichloromethane, 
mixture was cooled to 0°C and 4-fluorobenzoyl chloride (2.772 mmol, 439.5 mg) was added. 
The solution was stirred overnight under argon. The reaction was quenched with H2O and the 
product extracted in dichloromethane. Product was purified by flash chromatography. 1H NMR 
(400 MHz; MeOD/ δ (ppm) 7.55 (s, 1H), 7.44 (d, 2H), 7.20 (m, 2H), 6.90 (d, 1H), 5.49 (s, 1H), 
4.64 (s, 1H), 3.71 (s, 3H), 1.77 (s, 3H), 1.58 (m, 3H), 1.09 (s, 2H)). 19F NMR (347 MHz; 
MeOD/δ (ppm) -112.52 (s, 1F). HRMS calculated for [M+H]+ (M= C18H22FN3O) 315.1747, 
found 316.1827.  
Preparation of N-cyclohexyl-4-fluoro-N-(furan-2-ylmethyl)benzamide. (F-RAGER) 
Cyclohexylamine (2.52 mmol, 250mg) and furfural (2.52 mmol, 242 mg) were dissolved in 
methanol (5ml). Sodium sulfate was added and the mixture stirred at 50 °C overnight. After 
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filtration, the filtrate was concentrated in vacuo to remove unreacted furfural. The resultant 
semisolid was redissolved in methanol (5 ml), cooled to 0°C; sodium borohydride was slowly 
added. The reaction stirred for 4 hours and then was quenched with saturated ammonium 
chloride solution. The intermediate was extracted in dichloromethane and did not require 
purification. Triethylamine (3.02 mmol, 306 mg) was added to the intermediate dissolved in 
dichloromethane, mixture was cooled to 0 °C and 4-fluorobenzoyl chloride (2.772 mmol, 439.5 
mg) was added. The solution was stirred overnight under argon. The reaction was quenched with 
H2O and the product extracted in dichloromethane. Product was purified by flash 
chromatography. 1H NMR (400 MHz; MeOD/ δ (ppm) 7.77 (m 4H), 7.10 (m, 3H), 5.87 (s, 2H), 
2.05- 1.74 (m, 11H). HRMS calculated for [M+H]+ (M= C18H20FNO2) 302.1551, found 
302.1558.  
Preparation of N-cyclohexyl-4-fluoro-N-(isoxazol-5-ylmethyl)benzamide (IX-RAGER). 
Cyclohexylamine (2.52 mmol, 250mg) and isoxazole-5-carbaldehyde (2.52 mmol, 244 mg) were 
dissolved in methanol (5ml). Sodium sulfate was added and the mixture stirred at 50 °C 
overnight. After filtration, the filtrate was concentrated in vacuo to remove unreacted isoxazole-
5-carbaldehyde. The resultant semisolid was redissolved in methanol (5 ml), cooled to 0 °C; 
sodium borohydride was slowly added. The reaction stirred for 4 hours and then was quenched 
with saturated ammonium chloride solution. The intermediate was extracted in dichloromethane 
and did not require purification. Triethylamine (3.02 mmol, 306 mg) was added to the 
intermediate dissolved in dichloromethane, mixture was cooled to 0°C and 4-fluorobenzoyl 
chloride (2.772 mmol, 439.5 mg) was added. The solution was stirred overnight under argon. 
The reaction was quenched with H2O and the product extracted in dichloromethane. Product was 
purified by flash chromatography (10g SiO2, 2% MeOH/ DCM – 10% MeOH/DCM). 1H NMR 
180 
 
(400 MHz; MeOD/ δ (ppm) 8.189 (m, 2H), 8.123 (m, 2H), 7.38 (m, 1H), 7.19 (m, 1H), 4.78 (s, 
2H), 1.88-1.25 (m, 11H). 19F NMR (347 MHz; MeOD/δ (ppm)-104.23 (s, 1F); HRMS calculated 
for [M+H]+ (M= C17H19FN2O2) 303.1503, found 303.1508.  
Preparation of N-cyclohexyl-4-fluoro-N-(oxazol-5-ylmethyl)benzamide (OX-RAGER). 
Cyclohexylamine (2.52 mmol, 250mg) and oxazole-5-carbaldehyde (2.52 mmol, 244 mg) were 
dissolved in methanol (5ml). Sodium sulfate was added and the mixture stirred at 50 °C 
overnight. After filtration, the filtrate was concentrated in vacuo to remove unreacted oxazole-5-
carbaldehyde. The resultant semisolid was redissolved in methanol (5 ml), cooled to 0 °C; 
sodium borohydride was slowly added. The reaction stirred for 4 hours and then was quenched 
with saturated ammonium chloride solution. The intermediate was extracted in dichloromethane 
and did not require purification. Triethylamine (3.02 mmol, 306 mg) was added to the 
intermediate dissolved in dichloromethane, mixture was cooled to 0°C and 4-fluorobenzoyl 
chloride (2.772 mmol, 439.5 mg) was added. The solution was stirred overnight under argon. 
The reaction was quenched with H2O and the product extracted in dichloromethane. Product was 
purified by flash chromatography. 1H NMR (400 MHz; MeOD/ δ (ppm)8.14 (s, 1H), 7.43 (d, 
2H), 7.20 (d, 2H), 7.10 (s, 1H), 4.71 (s, 2H), 3.57 (s, 1H), 3.30 (solvent), 1.77 (m, 4H), 1.64 (m, 
3H), 1.12 (m, 3H)). 19F NMR (347 MHz; MeOD/δ (ppm) -112.50 (s, 1F)); HRMS calculated for 
[M+H]+ (M= C17H19FN2O2) 302.1431, found 303.1510.  
Preparation of N-benzyl-4-fluoro-N-(piperidin-4-yl)benzamide.(PIP-RAGER) 4-
aminopiperidine (3 mmol, 300.5mg) and benzaldehyde (3mmol, 321.3mg) were dissolved in 
methanol (5ml). Sodium sulfate was added and the mixture stirred at 50 °C overnight. After 
filtration, the filtrate was concentrated in vacuo to remove unreacted benzaldehyde. The resultant 
semisolid was redissolved in methanol (5 ml), cooled to 0 °C; sodium borohydride was slowly 
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added. The reaction stirred for 4 hours and then was quenched with saturated ammonium 
chloride solution. The intermediate was extracted in dichloromethane and did not require 
purification. Triethylamine (3.02 mmol, 306 mg) was added to the intermediate dissolved in 
dichloromethane, mixture was cooled to 0°C and 4-fluorobenzoyl chloride (2.772 mmol, 439.5 
mg) was added. The solution was stirred overnight under argon. The reaction was quenched with 
H2O and the product extracted in dichloromethane. Product was purified by flash 
chromatography. 1H NMR (400 MHz; MeOD/ δ (ppm) 7.74 (m, 2H), 7.32 (m, 4H), 7.11 (m, 
3H), 5.88 (s, 2H), 2.04-1.25 (m, 9H). 19F NMR (347 MHz; MeOD/δ (ppm) -108.08 (s, 1F); 
HRMS calculated for [M+H]+ (M= C19H21FN2O) 313.1711, found 313.1716.  
Preparation of N-benzyl-4-fluoro-N-(pyrimidin-4-yl)benzamide. (PM-RAGER) 4-
aminopyrimidine (3 mmol, 285.3mg) and benzaldehyde (3mmol, 321.3mg) were dissolved in 
methanol (5ml). Sodium sulfate was added and the mixture stirred at 50 °C overnight. After 
filtration, the filtrate was concentrated in vacuo to remove unreacted benzaldehyde. The resultant 
semisolid was redissolved in methanol (5 ml), cooled to 0 °C; sodium borohydride was slowly 
added. The reaction stirred for 4 hours and then was quenched with saturated ammonium 
chloride solution. The intermediate was extracted in dichloromethane and was purified by 
column chromatography (gradient, DCM to 10% MeOH, Rf= 0.3125).
 Triethylamine (3.02 
mmol, 306 mg) was added to the intermediate dissolved in dichloromethane, mixture was cooled 
to 0°C and 4-fluorobenzoyl chloride (2.772 mmol, 439.5 mg) was added. The solution was 
stirred overnight under argon. The reaction was quenched with H2O and the product extracted in 
dichloromethane. Product was purified by flash chromatography. 1H NMR (400 MHz; MeOD/ δ 
(ppm) 8.19 (m, 4H), 8.116 (m, 2H), 7.434 (m, 2H), 7.12 (m, 4H), 5.34 (s, 2H)). 19F NMR (347 
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MHz; MeOD/δ (ppm) -104.5 (s, 1F); HRMS calculated for [M+H]+ (M= C18H14FN3O) 
313.1711, found 313.1711.  
Preparation of N-cyclohexyl-4-fluoro-N-(pyridine-4-ylmethyl)benzamide (P-RAGER). 
Cyclohexylamine (2.52 mmol, 250mg) and isonicotinaldehyde (2.52 mmol, 270 mg) were 
dissolved in methanol (5ml). Sodium sulfate was added and the mixture stirred at 50 °C 
overnight. After filtration, the filtrate was concentrated in vacuo to remove unreacted 
isonicotinaldehyde. The resultant semisolid was redissolved in methanol (5 ml), cooled to 0 °C; 
sodium borohydride was slowly added. The reaction stirred for 4 hours and then was quenched 
with saturated ammonium chloride solution. The intermediate was extracted in dichloromethane 
and purified by flash chromatography (gradient, DCM to 10% MeOH, Rf= 0.3125). 
1H NMR 
(400 MHz; CDCl3/ δ (ppm) 8.54 (d; 2H), 7.29 (d; 2H), 3.84 (s, 2H), 2.47 (s, 1H), 1.90 (m, 1H), 
1.82 (m, 3H), 1.72 (m, 1H), 1.20 (m, 5H). HRMS calculated for [M+H]+ (M= C12H18N2) 190.15, 
found 191.1543. Triethylamine (3.02 mmol, 306 mg) was added to the intermediate dissolved in 
dichloromethane, mixture was cooled to 0°C and 4-fluorobenzoyl chloride (2.772 mmol, 439.5 
mg) was added. The solution was stirred overnight under argon. The reaction was quenched with 
H2O and the product extracted in dichloromethane. Product was purified by flash 
chromatography. 1H NMR (400 MHz; MeOD/ δ (ppm) 8.537 (m, 4H), 7.287 (m, 4H), 3.84 (s, 
2H), 2.47-1.199 (m, 11H)).HRMS calculated for [M+H]+ (M= C19H21FN2O) 312.16, found 
313.1722.  
Preparation of N-benzyl-4-fluoro-N-(tetrahydro-2H-pyran-4-yl)benzamide. (p-THP-RAGER) 
Tetrahydro-2H-pyran-amine (2.52 mmol, 255 mg) and benzaldehyde (2.52 mmol, 267 mg) were 
dissolved in methanol (5ml). Sodium sulfate was added and the mixture stirred at 50 °C 
overnight. After filtration, the filtrate was concentrated in vacuo to remove unreacted 
183 
 
benzaldehyde. The resultant semisolid was redissolved in methanol (5 ml), cooled to 0 °C; 
sodium borohydride was slowly added. The reaction stirred for 4 hours and then was quenched 
with saturated ammonium chloride solution. The intermediate was extracted in dichloromethane 
and did not require purification. Triethylamine (3.02 mmol, 306 mg) was added to the 
intermediate dissolved in dichloromethane, mixture was cooled to 0 °C and 4-fluorobenzoyl 
chloride (2.772 mmol, 439.5 mg) was added. The solution was stirred overnight under argon. 
The reaction was quenched with H2O and the product extracted in dichloromethane. Product was 
purified by flash chromatography. 1H NMR (400 MHz; MeOD/ δ (ppm) 7.87 (m, 1H), 7.49 (s, 
2H), 7.32 (m, 2H), 7.23 (m, 1H), 7.16 (d, 2H), 3.89 (s, 2H), 3.51 (m, 2H), 1.87 (m, 4H), 1.62 (m, 
4H)). 19F NMR (347 MHz; MeOD/δ (ppm) -110.85 (d, 2F), -112.64 (s, 1F); HRMS calculated 
for [M+H]+ (M= C19H20FNO2) 313.1478, found 314.1561. 
Preparation of N-cyclohexyl-4-fluoro-N-(thiophen-2-ylmethyl)benzamide.(TF-RAGER) 
Cyclohexylamine (2.52 mmol, 250mg) and thiophene-3-carbaldehyde (2.52 mmol, 282 mg) were 
dissolved in methanol (5ml). Sodium sulfate was added and the mixture stirred at 50 °C 
overnight. After filtration, the filtrate was concentrated in vacuo to remove unreacted thiophene-
3-carbaldehyde. The resultant semisolid was redissolved in methanol (5 ml), cooled to 0 °C; 
sodium borohydride was slowly added. The reaction stirred for 4 hours and then was quenched 
with saturated ammonium chloride solution. The intermediate was extracted in dichloromethane 
and did not require purification. Triethylamine (3.02 mmol, 306 mg) was added to the 
intermediate dissolved in dichloromethane, mixture was cooled to 0 °C and 4-fluorobenzoyl 
chloride (2.772 mmol, 439.5 mg) was added. The solution was stirred overnight under argon. 
The reaction was quenched with H2O and the product extracted in dichloromethane. Product was 
purified by flash chromatography. 1H NMR (400 MHz; MeOD/ δ (ppm) 8.07 (m, 3H), 7.85 (d,1 
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H), 7.15 (m, 3H), 4.88 (s, 2H), 3.84 (m, 1H), 1.96 (m, 2H), 1.79 (m, 2H), 1.36 (m, 2H), 1.33 (d, 
2H), 1.23 (d, 2H)). 19F NMR (347 MHz; MeOD/δ (ppm) -108.68 (s, 1F), -111.18 (s, 1F); HRMS 
calculated for [M+H]+ (M= C18H20FNOS) 318.1322, found 318.1311.  
Preparation of N-cyclohexyl-4-fluoro-N-(thiazol-5-ylmethyl)benzamide (TZ-RAGER). 
Cyclohexylamine (3 mmol, 297.5mg) and 5-thiazolecarboxaldehyde (3 mmol, 339.4 mg) were 
dissolved in methanol (5ml). Sodium sulfate was added and the mixture stirred at 50 °C 
overnight. After filtration, the filtrate was concentrated in vacuo to remove unreacted 5-
thaizaolecarboxaldehyde. The resultant semisolid was redissolved in methanol (5 ml), cooled to 
0 °C; sodium borohydride was slowly added. The reaction stirred for 4 hours and then was 
quenched with saturated ammonium chloride solution. The intermediate was extracted in 
dichloromethane and did not require purification. Triethylamine (3.02 mmol, 306 mg) was added 
to the intermediate dissolved in dichloromethane, mixture was cooled to 0 °C and 4-
fluorobenzoyl chloride (2.772 mmol, 439.5 mg) was added. The solution was stirred overnight 
under argon. The reaction was quenched with H2O and the product extracted in dichloromethane. 
Product was purified by flash chromatography. 1H NMR (400 MHz; MeOD/ δ (ppm) 8.90 (s, 
1H), 8.00 (m, 1H), 7.42 (m, 2H), 7.42 (m, 2H), 7.22 (m, 2H), 3.55 (s, 2H), 3.48 (m, 1H), 1.56 
(m, 6H), 1.14 (m,1H), 1.11 (m, 4H)). 19F NMR (347 MHz; MeOD/δ (ppm) -109.05 (s, 1F), -
112.42 (s, 1F); HRMS calculated for [M+H]+ (M= C17H19FN2OS) 319.1275, found 319.1283.  
5.4 [11C]InRAGER2 
 From chapter 5, InRAGER2 appeared to be less promiscuous than InRAGER based on 
the receptor screening results. The precursor was never made due to time constraints but below is 
a proposed route (scheme 7.2). The starting material is a chlorinated derivative of salicylic acid, 
so it is very cheap. The next steps for this project are relatively straight forward: 1) synthesize 
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the precursor, 2) optimize the radiosynthesis, 3) evaluate ligand binding on tissue and 4) in 
healthy animal.  
 
Scheme 7.2. Proposed synthesis of InRAGER2 precursor and proposed radiosynthesis. 
6. Investigation into RAGE as an inflammatory biomarker 
 The lipopolysaccharide (LPS) induced model of neuroinflammation in chapter 6 
indicated that RAGE is not a robust biomarker in this model. Moving forward, it is 
recommended to not use this model to evaluate RAGE ligand binding. It would be very valuable, 
however, to perform similar quantitative immunohistochemistry on human AD tissue sections. 
This was originally a goal of the project, and human AD brain sections (with age matched 
controls) were requested in July. To date, the Ann Arbor Brain Bank has not approved this 
request and this has delayed progress of this part of the project. If it were to be approved and 
fulfilled, the human antibodies would need to be purchased and the project could continue as 
planned. 
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APPENDIX A 
Complete data sets 
Table A.1 Complete list of inhibition data from LeadProfilingScreen for RAGER 
Assay Name Species % Inhibition 
Adenosine A1 Human 8 
Adenosine A2A Human 5 
Adenosine A3 Human 4 
Adrenergic α1A Rat -1 
Adrenergic α1B Rat 4 
Adrenergic α1D Human 7 
Adrenergic α2A Human 13 
Adrenergic β1 Human 4 
Adrenergic β2 Human 7 
Androgen (Testosterone) Human 59 
Bradykinin B1 Human -7 
Bradykinin B2 Human -3 
Calcium Channel L-Type, benzothiazepine Rat 13 
Calcium Channel L-Type, dihydropyridine Rat 25 
Calcium Channel N-Type Rat 5 
Cannabinoid CB1 Human 18 
Dopamine D1 Human 4 
Dopamine D2S Human -1 
Dopamine D3 Human 8 
Dopamine D4.2 Human 1 
Endothelin ETA Human 0 
Endothelin ETB Human 3 
Epidermal Growth Factor (EGF) Human -8 
Estrogen ERα Human 32 
GABAA, flunitrazepam, central Rat 55 
GABAA, muscimol, central Rat -6 
GABAB1A Human -5 
Glucocorticoid Human 9 
Glutamate, Kainate Rat 1 
Glutamate, NMDA, Agonism Rat 11 
Glutamate, NMDA, Glycine Rat 4 
Glutamate, NMDA, Phencyclidine Rat -5 
Histamine H1 Human 23 
Histamine H2 Human -3 
Histamine H3 Human 15 
Imidazole I2, central Rat 13 
Interleukin IL-1 Human 14 
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Leukotriene, Cysteinyl CysLT1 Human -7 
Melatonin MT1 Human 96 
Muscarinic M1 Human -1 
Muscarinic M2 Human 16 
Muscarinic M3 Human 17 
Neuropeptide Y Y1 Human -9 
Neuropeptide Y Y2 Human -14 
Nicotinic Acetylcholine Human -16 
Nicotinic Acetylcholine α1, bungarotoxin Human -3 
Opiate δ1 (OP1, DOP) Human 0 
Opiate κ(OP1, KOP) Human 33 
Opiate µ (OP1, MOP) Human 6 
Phorbol Ester Mouse 5 
Platelet Activating Factor Human 6 
Potassium Channel [KATP] Human 22 
Potassium Channel hERG Human 24 
Prostanoid EP4 Human 6 
Purinergic P2X Rabbit 24 
Purinergic P2Y Rat 2 
Rolipram Rat 8 
Serotonin (5-Hydroxytryptamine) 5-HT1A Human 2 
Serotonin (5-Hydroxytryptamine) 5-HT2B Human 20 
Serotonin (5-Hydroxytryptamine) 5-HT3 Human -1 
Sigma σ1 Human 9 
Sodium Channel, site 2 Rat 1 
Tachykinin NK1 Human 20 
Thyroid Hormone Rat 5 
Transporter, Dopamine (DAT) Human 52 
Transporter, GABA  Rat 4 
Transporter, Norepinephrine (NET) Human 24 
Transporter, Serotonin (5-Hydroxytryptamine) (SERT) Human 3 
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Table A.2. Complete list of inhibition data from LeadProfilingScreen for InRAGER 
Assay Name Species % Inhibition 
Adenosine A1 Human 46.5 
Adenosine A2A Human 75.7 
Adenosine A2B Human -11.9 
Adenosine A3 Human 98.8 
Adrenergic α1A Human 35.2 
Adrenergic α1B Human 16.4 
Adrenergic α2A Human -22.5 
Adrenergic α2B Human -29.7 
Adrenergic β1 Human -36.5 
Adrenergic β2 Human 4.0 
AT1 Human -7.2 
AT2 Human -5.6 
BZD (central) Rat -3.7 
BZD (peripheral) Rat 63.2 
B2 Human -68.2 
CGRP Human 3.0 
CB1 Human 5.9 
CB2 Human 35.3 
CCK1 (CCKA) Human 76.4 
Dopamine D1 Human 21.2 
Dopamine D2S Human -5.7 
Endothelin ETA Human -11.2 
Endothelin ETB Human -4.3 
GABAA1  Human -27.3 
NMDA Rat 4.5 
TNF-α Human -6.3 
H1 Human -19.9 
H2 Human -33.9 
MT2 Human 15.9 
MAO-A Human 14.4 
Motilin Human 6.5 
M1 Human -66 
M2 Human -43.3 
M3 Human -16.6 
M4 Human -2.9 
M5 Human -24.9 
NK1 Human 30.0 
NK2 Human 31.5 
Y1 Human -16.2 
δ (DOP) Human 46.7 
κ (KOP) Human 83.1 
µ (MOP) Human 14.2 
PPARγ  Human 86.5 
PCP Rat -0.4 
EP2 Human 73.6 
P2X Rat -8.2 
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5-HT1A Human 31.5 
5-HT1B Human -7.1 
5-HT2A Human 67.3 
5-HT2B Human 97.1 
5-HT2C Human 17.4 
5-HT3 Human 0.9 
5-HT4e Human 14.4 
5-HT7 Human -31.9 
sigma (non-selective) Human 20.8 
GR Human 21.6 
Estrogen ER alpha Human 11.2 
AR Human 26.5 
UT Human 77.7 
VPAC 1 (VIP1) Human -0.5 
V1 a  Human 1.2 
Ca2+ channel (L, dihydropyridine site) Rat 45.2 
Ca2+ channel (L, diltiazem site) Rat 21.4 
KATP channel Rat -15.6 
SKCa channel Rat 4.2 
Na+ channel (site 2) Rat 9.7 
Cl- channel (GABA gated Rat 21.3 
norepinephrine transporter Human 94.6 
dopamine transporter Human 49.8 
GABA transporter Rat -11.9 
5-HT transporter Human -7.7 
 
Table A3. Complete list of inhibition data from LeadProfilingScreen for InRAGER2 
Assay Name Species % Inhibition 
Adenosine A1 Human 25.2 
Adenosine A2A Human 39.7 
Adenosine A2B Human -34.6 
Adenosine A3 Human 74.6 
Adrenergic α1A Human 13.9 
Adrenergic α1B Human 4.3 
Adrenergic α2A Human -7.0 
Adrenergic α2B Human -12.7 
Adrenergic β1 Human 2.5 
Adrenergic β2 Human -8.3 
AT1 Human 4.5 
AT2 Human 2.7 
BZD (central) Rat 1.7 
BZD (peripheral) Rat 81.2 
B2 Human -21.3 
CGRP Human -1.3 
CB1 Human 11.8 
CB2 Human 25.0 
CCK1 (CCKA) Human -9.3 
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Dopamine D1 Human -7.2 
Dopamine D2S Human -2.3 
Endothelin ETA Human -1.4 
Endothelin ETB Human -13.1 
GABAA1  Human -34.8 
NMDA Rat -16.2 
TNF-α Human 2.7 
H1 Human -2.0 
H2 Human -21.7 
MT2 Human 28.8 
MAO-A Human 14.4 
Motilin Human 21.6 
M1 Human 2.6 
M2 Human -25.3 
M3 Human -22.1 
M4 Human 16.7 
M5 Human -6.1 
NK1 Human -2.9 
NK2 Human 20 
Y1 Human 6.0 
δ (DOP) Human 20.9 
κ (KOP) Human 42.5 
µ (MOP) Human -5.3 
PPARγ  Human 31.6 
PCP Rat -3.4 
EP2 Human 36.3 
P2X Rat -1.7 
5-HT1A Human 23.8 
5-HT1B Human -0.8 
5-HT2A Human 8.7 
5-HT2B Human 95.1 
5-HT2C Human 48.8 
5-HT3 Human 15.9 
5-HT4e Human 14.1 
5-HT7 Human -7.7 
sigma (non-selective) Human 11.1 
GR Human 11.0 
Estrogen ER alpha Human 1.4 
AR Human -19.5 
UT Human 84.9 
VPAC 1 (VIP1) Human -13.5 
V1 a  Human -0.8 
Ca2+ channel (L, dihydropyridine site) Rat -10.3 
Ca2+ channel (L, diltiazem site) Rat -20.5 
KATP channel Rat -1.6 
SKCa channel Rat -3.7 
Na+ channel (site 2) Rat 24.9 
Cl- channel (GABA gated Rat 18.2 
norepinephrine transporter Human 1.8 
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dopamine transporter Human 5.5 
GABA transporter Rat 3.0 
5-HT transporter Human -12.3 
 
 
Figure A.1. Details from AV-1451 Autoradiography Optimization 
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APPENDIX B 
Protocols 
 
1. Generic Immunohistochemistry Protocol- Fixed Tissue 
Stock Solutions: 
 Davidson’s Fixative 
 Vectastain elite ABC kit (be sure to match species of 1° antibody) 
 70% Ethanol (in water) 
 70% Methanol (in water) 
 30% Peroxide (H2O2 in water) 
 Phosphate buffered saline, pH 7.4, 0.4% Triton-X-100, 1% BSA, 0.025% NaN3 (PBS-
TBA) 
 Phosphate buffered saline, pH 7.4, 0.4% Triton-X-100 (PBS-T) 
 Phosphate buffered saline, pH 7.4, 1 mM EDTA (PBS-EDTA) 
 Diaminobenzidine 0.05% + 0.01% H2O2 in PBS-T (DAB) 
 100% n-Butanol 
 Xylene 
 Permount 
 
Procedure: 
Fixing the fresh-frozen, thaw-mounted slides 
(use ~10 mL volumes in cytomailers) 
1. Rehydration  PBS-EDTA, pH 7.4, 30 s 
2. Fixation  Davidson’s fixative, 24 hr @ RT 
3. Rinse   70% EtOH (to remove formaldehyde) 
Primary Antibody 
4. 1% SDS/PBS  5 minutes 
5. PBS   3 x 5 min at RT (to remove SDS) 
6. Quenching  10 mL (70% MeOH, 100 µl 30% H2O2), 15 min, RT 
7. Wash PBS-T  3 x 5 min at RT 
8. Blocking  PBS-TBA, 30 min, RT 
9. 1° Antibody  (specific dilution) in PBS-TBA overnight at RT 
10. Wash PBS-T  3 x 5 min, RT 
Secondary Antibody 
11. 2° Antibody  50 µL in 10 mL PBS-TBA, 2+ hr, RT 
12. Wash PBS-T  3 x 5 min, RT 
Visualization 
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13. ABC Solution  ABC reagent diluted per Vectastain instructions in PBS-T, 30 min, 
RT 
14. Wash PBS-T  3 x 5 min, RT 
15. DAB Solution  ~4 min, RT (5 mg DAB + 10 mL PBS-T, dissolve, filter, then add 
3.33 
   µL 30% H2O2) 
16. Rinse   dH2O, 1 min, RT 
Counterstain- Giemsa 
17. Wash   dH2O, 5 min, RT 
18. Giemsa   1:50 (Giemsa in dH2O), overnight, RT 
19. Rinse   dH2O, 30 s, RT 
20. Rinse   2 x 4 min, 100% n-Butanol 
21. Fix   Xylene, 1 min 
22. Coverslip  Permount (let set for ~45 min before using microscope) 
 
 
2. Example Hot Metabolism Protocol  
 
Materials: 
glass culture tubes, Eppendorf tubes, HPLC vials, filters 
 
#1. Monkey liver microsome w/o UDPA, incubation time: (20, 45, 90, 150 min) 
 
Glycine/NaOH, pH 9.2  1M (2X)   125 ul 
(mw. 75.07. Glycine 15.01 g/ 200 ml) 
MgCl2. 6H2O    50mM (10X)   50 ul 
(mw 203.30. 2.33g/ 200 ml) 
DTT     30mM (10X)   50 ul 
(Dithiothreitol, mw 154.25. 2.32g/0.5ml) 
Microsome    0.5 mg(20 ug/ul)  25 ul 
_________________________________________________________________ 
½ final volume        250 ul 
 
#2. Monkey liver microsome w/o UDPA, incubation time: (20, 45, 90, 150 min) 
 
Glycine/NaOH, pH 9.2  1M (2X)   75 ul 
(mw. 75.07. Glycine 15.01 g/ 200 ml) 
MgCl2. 6H2O    50mM (10X)   50 ul 
(mw 203.30. 2.33g/ 200 ml) 
DTT     30mM (10X)   50 ul 
(Dithiothreitol, mw 154.25. 2.32g/0.5ml) 
UDP-glucuronic acid   20mM (10X)   50 ul 
(UDPGA, mw 631.38. 6.32 mg/ 0.5 ml) 
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Microsome    0.5 mg(20 ug/ul)  25 ul 
_________________________________________________________________ 
½ final volume        250 ul 
 
Add Substrate to each tube: 
RAGER     2.5mM (10X)   50 ul 
(mw 311.4004. 0.7785/ml) 
ddH2O         200 ul 
_________________________________________________________________ 
Total volume        500 ul 
 
Sample Preparation: 
Reaction was terminated by removing 250 ul aliquot (of 1000 ul total) and addition of ice cold 
methanol 500 ul. Vortex for 1 min, centrifuge 5 mins. Supernatant was filtered for HPLC. 
Conditions: 10 mM ammonium acetate 60% Acetonitrile pH 9. 
 
3. Example MAO-B Supersome Assay 
 
Monaomine Oxidase Activity Assays
February 19th, 2016 [enzyme] 80 ug/ml *edit protocol to be 100 minutes long (20 reads)
addition 10 uL
Name MW (Da) stock enzyme 1.2 mg/ml
7-hydroxy-4-methyl-coumarin 115.08 make stock 247 ul buffer
Coumarin-D3 274.14 78 uL aliquot in -80! A and B
Coumarin 271.31
Fluorescent Standard total vol (uL) 150 DF 5 10 mM 0.00002 mol 2.3016 mg
ROWS stock volume (uL) Stock (uM) buffer (uL) Final (uM) 2 mL
Make dilutions outside of well. A 50 ----- 200 300
Add 150uL to well. B 50 300 200 60 Making first stock:
C 50 60 200 12
D 50 12 200 2.4 10 mM stock
*Duplicate E 50 2.4 200 0.48 30 uL stock
F 50 0.48 200 0.096 970 uL buffer
G 50 0.096 200 0.0192 1000 uL total vol
H 50 0.0192 200 0.00384
LRD.II.60B total vol (ul) 150 DF 1.5 10 mM 0.00002 mol 5.4828 mg
D3 Compound range ROWS stock volume (uL) Stock (uM) enzyme (uL) buffer (uL) Final (uM) 2 mL
A 20 1500 10 120 200
MAO-A B 20 1000 10 120 133.33 Making first stock:
C 20 667 10 120 88.89 1 ml each 300 ul buffer
*Duplicate D 20 444 10 120 59.26 10 mM stock 600 ul stock
E 20 296 10 120 39.51 60 uL stock
F 20 198 10 120 26.34 340 uL buffer
G 20 132 10 120 17.56 400 uL total vol
H 20 88 10 120 11.71
AFB. VII.99 total vol (ul) 150 DF 1.5 10 mM 0.00002 mol 5.4262 mg
Compound range ROWS stock volume (uL) Stock (uM) enzyme (uL) buffer (uL) Final (uM) 2 mL
A 20 1500 10 120 200
MAO-A B 20 1000 10 120 133.33 Making first stock:
C 20 667 10 120 88.89 1 ml each 300 ul buffer
*Duplicate D 20 444 10 120 59.26 10 mM stock 600 ul stock
E 20 296 10 120 39.51 60 uL stock
F 20 198 10 120 26.34 340 uL buffer
G 20 132 10 120 17.56 400 uL total vol
H 20 88 10 120 11.71
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Prepping the assay: 
1. Make standard curve dilutions from fresh powder stock (10mm in DMSO) using borate 
buffer 
2. Make MAO-A substrate dilutions (denote vials as: AA, AB, AC…). Keep in separate 
bag! 
3. Make MAO-B substrate dilutions (denote vials as: BA, BB, BC…). Keep in separate bag! 
4. Transport supersomes in dry ice.  
5. Bring a new plate and buffer! 
 
Prepping the plate: 
1. Fill columns 2-3 with fluorescent standard                                           (140 ul) 
2. Fill columns 4-5 with MAO-A D3 substrate                                            (20 ul) 
3. Fill columns 6-7 with MAO-B D3 substrate                                            (20 ul) 
4. Fill columns 8-9 with MAO-A coumarin substrate                                  (20 ul) 
5. Fill columns 10-11 with MAO-B coumarin substrate                              (20 ul) 
6. Use multichannel to fill columns 1 + 12 with buffer                              (150 ul) 
LRD.II.60B total vol (ul) 150 DF 5 10 mM 0.00002 mol 0 mg
D3 Compound range ROWS stock volume (uL) Stock (uM) enzyme (uL) buffer (uL) Final (uM) 2 mL
A 20 375 10 120 50
MAO-B B 20 75 10 120 10.00 Making first stock:
C 20 15 10 120 2.00 1 ml each 200 ul buffer
*Duplicate D 20 3 10 120 0.40000 10 mM stock 50 ul stock
E 20 1 10 120 0.08000 37.5 uL stock
F 20 0 10 120 0.01600 962.5 uL buffer
G 20 0 10 120 0.00320 1000 uL total vol
H 0 0 10 140 0.00064
AFB. VII.99 total vol (ul) 150 DF 5 10 mM 0.00002 mol 0 mg
Compound range ROWS stock volume (uL) Stock (uM) enzyme (uL) buffer (uL) Final (uM) 2 mL
A 20 375 10 120 50
MAO-B B 20 75 10 120 10.00 Making first stock:
C 20 15 10 120 2.00 1 ml each 200 ul buffer
*Duplicate D 20 3 10 120 0.40000 10 mM stock 50 ul stock
E 20 1 10 120 0.08000 37.5 uL stock
F 20 0 10 120 0.01600 962.5 uL buffer
G 20 0 10 120 0.00320 1000 uL total vol
H 0 0 10 140 0.00064
1 2 3 4 5 6 7 8 9 10 11 12
A F E A A B B A A B B
B L N A A B B A A B B
C U T A A B B A A B B
D O A A B B A A B B
E R S A A B B A A B B
F E T A A B B A A B B
G S D A A B B A A B B
H C A A B B A A B B
BORATE D-3 COU
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7. Use multichannel to fill columns 4-11 with buffer                                 (120 ul) 
8. Check to see if plate reader is at 37! 
9. Thaw supersomes in 37 water bath (~3 min) 
10. Dilute supersomes by addition of 247 ul borate buffer 
11. Initiate reaction by addition of enzyme 4-5 A, 6-7 B, 8-9 A, 10-11, B    (10 ul) 
12. READ PLATE. 
 
4. Drake & Desmond Autoradiography Protocol 
Follow basic flowchart with experiment-specific changes 
 
1) Thaw tissues at room temperature for 5 minutes; rehydrate in experiment buffer for ~15 minutes 
(approximately, no more than 30 minutes). 
2a)  Use spreadsheet to calculate the volume to be added for the experiment: (example) 
 
2b) Add the requisite concentration of radioligand to your buffer; similarly for competitive or nonspecific 
binding add that ligand as well. In the “total binding” well add the same volume of vehicle. 
Calculating autoradiography dose
Tracer [18F] AV1451
Specific Activity 1178 Ci/ mmol
Dose Activity 0.104 Ci
Dose Volume 10 mL
Final conc 0.0000004 mmol
Add 0.045307692 ml
45.30769231 ul
200 
 
2c) Incubate/ co-incubate, recommended between 30-45 minutes. TIME SENSITIVE 
3) Wash tissues. 2 minutes (experimental buffer x 2), 30 s of water. TIME SENSITIVE 
4) Dry completely before exposing to plate, recommended 5 minutes of drying and 10 min exposure. 
Don’t forget to add your TLC plate with “experimental activity” spotted on it. 
5) Fix the slides if you are going to move onto step 6, which for some reason is not on this flowchart. 
 
5.  Buffer Recipes 
Phosphate Buffered Saline (PBS: 1X) 
NaCl 32.03g 
KCl 0.89 g 
Na2HPO4 4.54 g 
KH2PO4 1.22 g 
Total Volume: 4 L 
Adjust pH to: 7.4 
 
Phosphate Buffered Saline + EDTA (PBS- EDTA) 
NaCl 32.03g 
KCl 0.89 g 
Na2HPO4 4.54 g 
KH2PO4 1.22 g 
EDTA 1.17 g 
Total Volume: 4 L 
Adjust pH to: 7.4 
 
Borate Buffer (100 mM) 
Boric Acid 6.185 g 
NaCl 4.385 g 
Sodium Tetraborate 9.535 g 
Total Volume: 1 L 
Adjust pH to: 8.4 
 *This does not go into solution easily and will need to be heated while stirring. 
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6. Code for the RAGER Analogues in the freezer 
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Table B.1. Inventory of freezer boxes. 
Box # Cut Date Species Brain Tissue Disease State Notes 
1 Sept 2018 Human substantia nigra/ 
cerebellum 
AD/ DLB  
2 Oct 2018 Mouse sagittal half LPS – 1 day male animals 1 +2 
3 Oct 2018 Mouse sagittal half LPS – 1 day male animals 3 + 4 
4 Aug 2018 Mouse sagittal half normal male and female 
5 Oct 2018 Mouse sagittal half LPS – 1 day female animals 1 +2 
6 Oct 2018 Mouse sagittal half LPS – 1 day female animals 3 + 
4 
7 Aug 2018 Rat sagittal half normal  
8 Oct 2018 Human cerebellum Normal  
9 Nov 2018 Mouse sagittal half Normal male + female 
10 Nov 2018 Mouse sagittal half Normal 14 day vehicles 
11 Nov 2018 Mouse sagittal half LPS- 14 day male animals 1 -4 
12 Nov 2018 Mouse sagittal half LPS- 14 day female animals 1- 4 
 
 
